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Venous thromboembolism, risk factors and 
prophylaxis
Venous thrombosis, encompassing the clinical spectrum of deep vein thrombosis 
(DVT) and pulmonary embolism (PE), poses a significant clinical and economic 
burden on Western societies. It occurs annually in 1 to 2 per 1000 inhabitants, 
and has a steep age gradient, with an incidence of up to 1 per 100 in individuals 
older than 80 years. 1. Individuals with venous thrombosis constitute 0.64% of all 
hospital admissions 2, and  two-thirds have DVT as their primary manifestation, 
while the remaining one-third has PE. The overall mortality rate within 30 days of 
an event is nearly 6%. 3  A recurrence occurs in 7 to 14% of patients within the first 
year after the initial event. 4 The recurrence rate is even as high as 30% in the first 
10 years, and remains high lifelong. 4 Other long-term complications include post-
thrombotic syndrome in nearly one-third to half of DVT patients 5, and pulmonary 
hypertension, which has been reported to occur in nearly 4% of patients within the 
first two years after the first PE.6 These epidemiological characteristics of DVT 
and PE underline the importance of understanding the etiology of these events, as 
such understanding would promote our ability to predict and prevent risk. 
Venous thrombosis is a multi-factorial disease that is influenced by genetic 
determinants as well as acquired risk factors such as major trauma, prolonged 
immobilization, surgery, oral contraceptive use, hormone replacement therapy, 
pregnancy and puerperium. Thrombophilia, a term coined by Nygaard and 
Brown7,  is used to describe the inherited tendency toward venous thrombosis. 
Mutations underlying thrombophilia vary from rare ‘loss-of-function’ mutations 
in natural anticoagulants to common ‘gain-of-function’ mutations such as factor 
V Leiden and prothrombin G20210A. 8 Twenty-five to 35% of individuals 
experiencing a first episode of DVT or PE are heterozygous or homozygous for at 
least one of these mutations. Classifying the risk factors as ‘genetic’ or ‘acquired’ 
is not always straightforward. Examples are elevated factor VIII levels and 
hyperhomocysteinemia that are known to increase the risk of both venous and 
arterial thrombosis, and that are genetically and environmentally determined. 9 
The risk factors underlying thrombophilia have a varying clinical penetrance, 
and the presence of a thrombophilic defect per se does not always result in a 
thrombosis. Moreover, it is well documented that individuals carrying more than 
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one thrombophilic defect are at higher risk than those with a single inherited risk 
factor. 10 However, approximately one-third of familial venous thromboembolic 
events remain unexplained.11 
Appropriate prophylaxis can significantly reduce venous thrombosis related 
mortality and morbidity.12 Without prophylaxis, the incidence of hospital-
acquired DVT is 10 to 40% among medical or general surgical patients and 40 
to 60% following major orthopedic surgery.13;14 Certain issues remain unresolved 
surrounding appropriate prophylaxis, including optimal dosing in specific 
patient populations with respect to efficacy, safety and patient compliance. 15 For 
instance, the presumed lower risk of significant bleeding by low dose prophylaxis 
with low-molecular-weight heparin during pregnancy may be outweighed by an 
unacceptable high risk of venous thrombosis recurrence. 16;17
Arterial and venous thrombosis association
Arterial thrombotic events, i.e. myocardial infarction, stroke and peripheral artery 
disease have long been considered an entity separate from venous thrombosis. 
This distinction was supported by differences in the blood clot composition, 
underlying risk factors, and prophylactic as well as therapeutic measures. More 
recent evidence indicates that these two types of thrombosis might share at least 
some common risk factors 18;19, and experiencing one type of thrombotic event 
appears to predispose to the development of the other.20 For example, a consistent 
finding in several cohort studies 21-23 was that patients with a previous venous 
thrombotic episode had an about 50% higher risk to develop arterial thrombotic 
events in subsequent years than individuals without prior venous thrombosis. 
However, the underlying mechanisms, particularly the role of multiple 
thrombophilic defects and classical cardiovascular risk factors in this association 
have not been elucidated.
In this thesis, we address several unresolved questions. First, can we identify new 
hereditary thrombophilic defects in a large family with an unexplained thrombotic 
tendency? What are the potential clinical implications of thrombophilia testing? 
Is our strategy of thrombosis prophylaxis in pregnant women with thrombophilia 
adequate? Second, are there common risk factors that may explain the association 
of arterial and venous thrombosis?
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Study populations
The investigations described in this thesis were performed in three previously 
described studies with exception of those in chapter 5 and 8. The earlier studies 
were the Beethoven study (chapter 6 and 9), the GENES study (chapter 2 and 3) 
and the Leiden Thrombophilia Study (LETS) (chapter 7, 2 and 3).
The Beethoven study
The Beethoven study consists of three prospective cohorts of thrombophilic 
families which were identified by probands with documented DVT, PE, or 
premature arterial cardiovascular diseases (any arterial thrombotic event before 
50 years of age), and either hyperhomocysteinemia, prothrombin G20210A, 
or persistently elevated levels of factor VIII. Subjects were recruited between 
August 1997 and May 2004 from three academic hospitals: Academic Medical 
Center, Amsterdam, University Medical Center, Groningen and Academic 
Hospital Maastricht. Details of these studies have been published previously. 24-26 
Various other thrombophilic defects were tested in all participants. Information on 
previous episodes of venous thrombosis, arterial cardiovascular disease, exposure 
to exogenous risk factors for thrombosis, anticoagulant treatment, and the 
presence of cardiovascular risk factors was collected by validated questionnaire 
and by reviewing medical records at baseline. Also, every 6 months until April 
2006, all participants provided a detailed questionnaire focusing on new episodes 
of venous thrombosis, arterial cardiovascular diseases, exposure to risk factors, 
and medication use.
The GENES study
The pedigree studied for this thesis was drawn from the GENES study 27 in which 
Dutch thrombophilic families were included with the purpose of discovering 
new genetic risk factors of venous thrombosis. The probands had at least one 
first-degree or two second-degree family members with the same diagnosis 
and did not carry one of the known thrombophilic defects, i.e. factor V Leiden, 
prothrombin G20210A and deficiencies of antithrombin, protein C and protein S. 
One pedigree was selected for further investigation because it showed the highest 
heritability of ‘endogenous thrombin potential’ (ETP) levels (68%). Subsequently, 
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a genome wide linkage analysis was performed in the selected pedigree for 
several coagulation factor levels and global coagulation determinants using the 
‘Sequential Oligogenic Linkage Analysis Routines’ (SOLAR) program. 
The Leiden Thrombophilia Study (LETS) 
LETS is a population based case-control study, originally meant to investigate 
new risk factors of venous thrombosis. Between January 1988 and December 
1992, 474 patients younger than 70 years from anticoagulation clinics in Leiden, 
Amsterdam and Rotterdam with a first DVT of the leg or arm were included in 
LETS. An unrelated control for each case was selected matched on age and sex. 
Participants did not have overt malignancy. All participants filled out a standard 
questionnaire regarding risk factors of venous thrombosis. 
The follow-up part of the LETS was performed to investigate the risk factors 
for recurrent venous thrombosis. Cases were followed as described previously 
28 after anticoagulation cessation until January 2000. Information during follow-
up on the occurrence of risk situations, use of anticoagulation treatment, and 
recurrent events was collected by repeated mailed questionnaires. Patients were 
interviewed by telephone when they responded positively to any item of the 
questionnaire or when they did not return it. 
Outline of the thesis
The studies presented in this thesis follow two objectives, each presented in a 
separate section. The first section focuses on investigations performed in a selected 
pedigree from GENES that were aimed at discovering a genetic explanation for 
the significant quantitative trait loci that were found in a genome wide linkage 
study. In the other section, we examined the implications of thrombophilia testing, 
and safety of high doses of low-molecular-weight heparins as prophylaxis during 
pregnancy.
Part I
Chapter 2: We studied the linkage observed in the selected pedigree on 
chromosome 20 for the levels of protein C by evaluating the association 
between protein C levels and polymorphisms of three candidate genes encoding 
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thrombomodulin, endothelial protein C receptor and forkhead-box A2. In 
addition we assessed the association of the levels of protein C with the levels of 
soluble endothelial protein C receptor. To investigate the external validity of our 
observations, we confirmed the results in the control population of LETS. 
Chapter 3: We scrutinized the linkage signals for the levels of factor (F) V and 
prothrombin on chromosome 16 by studying the association of haplotypes of 
NQO1 (candidate gene) with the levels of FV and prothrombin in the pedigree 
from GENES. We performed similar analyses in the control population of the 
LETS. Furthermore, the associated risk of venous thrombosis with each NQO1 
haplotype was calculated in the LETS. In chapter 4, we studied the risk of 
venous thrombosis and the levels of vitamin K dependent coagulation factors for 
different haplotypes of the enzymes (VKORC1, GGCX and NQO1) involved in 
the vitamine K cycle.
Chapter 5: The current knowledge of hereditary and acquired thrombophilic 
defects and the associated risk of venous thrombosis are reviewed in this chapter 
and the clinical implications for thrombophilia testing are addressed.
Chapter 6: We discussed the risk of major bleeding around the delivery, known as 
post-partum hemorrhage, in women who received high doses of low-molecular-
weight heparin to prevent venous thrombosis. 
Part II of this thesis deals with the association between arterial and venous 
thrombosis.
Chapter 7: We intended to confirm the increased risk of arterial cardiovascular 
diseases after an episode of venous thrombosis in the Beethoven study. More 
importantly, we investigated whether the presence of multiple cardiovascular risk 
factors and thrombophilic defects could explain this increased risk.
Chapter 8: In this chapter the risk of venous thrombosis recurrence, in the LETS 
follow-up study, in patients with low and elevated levels of cytokines as compared 
with patients with undetectable levels of cytokines, are presented. In addition, we 
investigated the influence of high D-dimer (>250 ng/ml) and CRP (>3 mg/L) on 
recurrence risk of venous thrombosis.
Chapter 9: Here we report the role of established thrombophilic defects, 
fibrinolysis markers, and polymorphisms in genes encoding platelet receptors 
in the pathogenesis of idiopathic retinal vein thrombosis (RVO) by studying a 
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large number of patients without known risk factors for RVO and a sex and age 
matched control group.
Chapter 10: The risk of arterial thrombosis in double heterozygous or 
homozygous carriers of factor V Leiden or prothrombin G20210A is compared 
with single heterozygous carriers of one of these mutations. This analysis was 
done in the relatives on the Beethoven study and was recalculated by excluding 
all relatives who had another co-inherited thrombophilic defect.  
Chapter 1
14
References
 1.  Engbers MJ, van H, V, Rosendaal FR. Venous thrombosis in the elderly: 
incidence, risk factors, and risk groups. J Thromb Haemost 2010.
 2.  Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and 
subsequent hospital readmission rates: an administrative claims analysis from 
30 managed care organizations. J Manag Care Pharm 2007;13:475-486.
 3.  Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, 
Hammerstrom J. Incidence and mortality of venous thrombosis: a population-
based study. J Thromb Haemost 2007;5:692-699.
 4.  Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after 
deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-
774.
 5.  Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ. Risk factors for 
post-thrombotic syndrome in patients with a first deep venous thrombosis. J 
Thromb Haemost 2008;6:2075-2081.
 6.  Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic 
pulmonary hypertension after pulmonary embolism. N Engl J Med 
2004;350:2257-2264.
 7.  Nygaard KK, Brown GE. Essential thrombophilia: report van five cases. Arch 
Intern Med 1937;59:82-106.
 8.  Middeldorp S, Levi M. Thrombophilia: an update. Semin Thromb Hemost 
2007;33:563-572.
 9.  Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous 
thromboembolism: implications for testing. Semin Thromb Hemost 2007;33:573-
581.
 10.  Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous 
thrombosis - current understanding from an epidemiological point of view. Br J 
Haematol 2010;149:824-833.
General introduction and outline of the thesis
1
15
 11.  Reitsma PH, Rosendaal FR. Past and future of genetic research in thrombosis. J 
Thromb Haemost 2007;5 Suppl 1:264-269.
 12.  Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: 
American College of Chest Physicians Evidence-Based Clinical Practice 
Guidelines (8th Edition). Chest 2008;133:381S-453S.
 13.  Anderson FA, Jr., Wheeler HB, Goldberg RJ et al. A population-based 
perspective of the hospital incidence and case-fatality rates of deep vein 
thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern 
Med 1991;151:933-938.
 14.  Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. 
Chest 2001;119:132S-175S.
 15.  Huo MH, Spyropoulos AC. The eighth American college of chest physicians 
guidelines on venous thromboembolism prevention: implications for hospital 
prophylaxis strategies. J Thromb Thrombolysis 2010.
 16.  Sanson BJ, Lensing AW, Prins MH et al. Safety of low-molecular-weight heparin 
in pregnancy: a systematic review. Thromb Haemost 1999;81:668-672.
 17.  Roeters van Lennep JE, Meijer E, Klumper FJCM, Middeldorp JM, Bloemenkamp 
KWM, Middeldorp S. Prophylaxis with low-dose low-molecular-heparin during 
pregnancy and postpartum: is it effective? Submitted to JTH. 
 18.  Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular 
risk factors and venous thromboembolism: a meta-analysis. Circulation 
2008;117:93-102.
 19.  Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which 
hemostatic markers add to the predictive value of conventional risk factors for 
coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 
2005;112:3080-3087.
 20.  Prandoni P, Bilora F, Marchiori A et al. An association between atherosclerosis 
and venous thrombosis. N Engl J Med 2003;348:1435-1441.
Chapter 1
16
 21.  Bova C, Marchiori A, Noto A et al. Incidence of arterial cardiovascular events in 
patients with idiopathic venous thromboembolism. A retrospective cohort study. 
Thromb Haemost 2006;96:132-136.
 22.  Klok FA, Mos IC, Broek L et al. Risk of arterial cardiovascular events in patients 
after pulmonary embolism. Blood 2009;114:1484-1488.
 23.  Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous 
thromboembolism and subsequent hospitalisation due to acute arterial 
cardiovascular events: a 20-year cohort study. Lancet 2007;370:1773-1779.
 24.  Lijfering WM, Coppens M, van de Poel MH et al. The risk of venous and 
arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on 
concomitant thrombophilic defects. Thromb Haemost 2007;98:457-463.
 25.  Coppens M, van de Poel MH, Bank I et al. A prospective cohort study on the 
absolute incidence of venous thromboembolism and arterial cardiovascular 
disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood 
2006;108:2604-2607.
 26.  Bank I, van de Poel MH, Coppens M et al. Absolute annual incidences of first 
events of venous thromboembolism and arterial vascular events in individuals 
with elevated FVIII:c. A prospective family cohort study. Thromb Haemost 
2007;98:1040-1044.
 27.  Wichers IM, Tanck MW, Meijers JC et al. Assessment of coagulation and 
fibrinolysis in families with unexplained thrombophilia. Thromb Haemost 
2009;101:465-470.
 28.  Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. 
Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 
2005;293:2352-2361.
17
Part I

High levels of protein C are determined by PROCR haplotype 3
2
19
High levels of protein C are determined by 
PROCR haplotype 3
Sara Roshani, Maria Carolina Pintao, Marieke C.H. de Visser, Chris 
Tieken, Michael W.T. Tanck, Iris M. Wichers, Joost C.M. Meijers, Frits R. 
Rosendaal, Saskia Middeldorp and Pieter H. Reitsma
J Thromb Haemost. 2011 
Chapter 2
20
Abstract
Background 
Genetic determinants of plasma levels of protein C (PC) are poorly understood. 
Recently, we identified a locus on chromosome 20 determining high PC levels in 
a large Dutch pedigree with unexplained thrombophilia. Candidate genes in the 
LOD-1 support interval included FOXA2, THBD and PROCR. 
Objectives 
To examine these candidate genes and their influence on plasma levels of PC. 
Patients/Methods 
Exons, promoter and 3’UTR of the candidate genes were sequenced in twelve 
family members with normal to high PC levels. Four haplotypes of PROCR, 
common in the European population, were examined in the family, and critical 
SNPs encountered during resequencing were genotyped in the family and in a large 
group of healthy individuals (the Leiden Thrombophilia Study (LETS) controls). 
Soluble endothelial protein C receptor (sEPCR) and soluble thrombomodulin 
(sTM) plasma levels were measured in the family. 
Results
PROCR haplotype 3 (H3) and FOXA2 rs1055080 were associated with PC levels 
in the family but only PROCR H3 was also associated with plasma levels in the 
healthy individuals. Carriers of both variants had higher PC levels than carriers 
of only PROCR H3 in the family but not in healthy individuals, suggesting that a 
second determinant is present between FOXA2 and PROCR. Plasma levels of PC 
and sEPCR were associated in both studies, contrasting to sTM which was not 
associated with variations of THBD or with PC levels.
Conclusion
Chromosome 20 harbors a locus influencing PC and sEPCR plasma levels 
and a detailed analysis of candidate genes suggests that PROCR H3 is 
responsible.
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Introduction 
Protein C (PC) is a vitamin K-dependent plasma glycoprotein that circulates 
at a concentration of ~40-80 nM and plays a major role in the control of the 
coagulation cascade. Upon activation by the thrombin-thrombomodulin complex, 
activated PC (APC) inactivates FVa and FVIIIa, consequently reducing thrombin 
formation1. Binding of PC to the endothelial protein C receptor (EPCR) increases 
the activation rate of PC 20-fold 2. Individuals with abnormalities in components 
of the PC pathway (such as PC or protein S deficiency) have an increased risk of 
venous thrombosis3.
Determinants of variation in PC levels are poorly known but, given the high 
heritability of about 50%, genetic determinants are likely to be important 4,5. The 
PC gene (PROC) is located on chromosome 2 and around 6% of the variability 
in PC levels has been attributed to polymorphisms in the promoter region of 
the gene 6,7. The GAIT (Genetic Analysis of Idiopathic Thrombosis) study 
estimated that additive effects of genes outside of the PROC structural locus 
cause approximately half of the phenotypic variation in PC levels 4. The authors 
identified a major quantitative trait locus (QTL) for PC levels on chromosome 16, 
where NQO1, a gene encoding a quinone reductase involved in the metabolism of 
vitamin K, is located. Subsequently they found that variations in this gene were 
associated with PC levels 5.
Variations in the PROCR gene (encoding the EPCR) were associated with a 
moderate increase in levels of PC in the Leiden Thrombophilia Study (LETS) 
8 and in the Cardiovascular Health Study (CHS) 9. While this work was in 
progress, a genome-wide association scan (GWAS) in the Atherosclerosis Risk 
in Communities (ARIC) study claimed four loci associated with PC levels, that 
included PROC, PROCR and three other genes (EDEM2, GCKR and BAZ1B) 10. 
The GENES study was designed to search for novel hereditary risk factors for 
venous thrombosis in families with unexplained thrombophilia 11. Previously, a 
genome-wide linkage analysis was performed. In one particular family, a QTL 
influencing PC levels was found on chromosome 20 (chr 20), with a log-odds 
(LOD) score of 4.8 at 51cM 12. In the 1-LOD support interval (38-64cM), three 
candidate genes encoding components potentially influencing PC levels are 
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present, namely forkhead box A2 (FOXA2, previously known as hepatic nuclear 
factor 3ß), thrombomodulin (THBD), and the endothelial protein C receptor 
(PROCR). 
FOXA2 is part of the forkhead box family and encodes a transcription factor 
(FOXA2) for a large number of genes, including PROC. Two binding sites for 
FOXA2 in the promoter region of PROC have been described and mutations in 
this region were associated with type I PC deficiency 13.  
THBD encodes thrombomodulin (TM), a transmembrane protein that, in complex 
with thrombin, enhances thrombin-mediated PC activation by more than 1000-
fold 1. 
PROCR encodes the already mentioned EPCR. Besides the membrane-anchored 
form, a soluble form of EPCR (sEPCR) lacking the transmembrane and cytoplasmic 
domain is present in human plasma. Like EPCR, sEPCR binds PC and APC with 
similar affinity 14. Binding of sEPCR to APC inhibits its anticoagulant activity 
by impairing the inactivation of FVa, and binding to PC prevents PC activation 
by thrombin-TM complexes 15. Four haplotypes of PROCR are present in the 
European population 8. Haplotype 3 (H3) is tagged by a missense variation that 
leads to the Ser219Gly variant (rs867186). The Gly219 variant is associated with 
increased levels of sEPCR which can be explained by an increased sensitivity 
of the protein to sheddases such as metalloprotease ADAM17 16 and by the 
expression of an alternatively spliced mRNA that lacks the sequence encoding 
the transmembrane domain 17.
In this study, we investigated whether genetic variations in the three candidate 
genes on chr 20 influence the plasma level of PC.
Patients and methods
Subjects 
GENES. The pedigree analyzed in the present study is one of the 22 families 
originally included in GENES, a study of Dutch families with unexplained 
thrombophilia 11. Probands with personal and/or family history of venous 
thrombosis (defined as at least one first degree or two second degree relatives with 
venous thrombosis) but with none of the known inherited thrombophilic defects 
(i.e. PC-, protein S-, antithrombin deficiency, factor V Leiden or prothrombin 
High levels of protein C are determined by PROCR haplotype 3
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G20210A variation) were recruited together with their extended pedigree, 
including spouses. A standardized history was taken and for most individuals, 
plasma and DNA samples were obtained for coagulation tests and genotyping 
12. This analysis focuses on the largest pedigree in GENES, consisting of 185 
individuals distributed over five generations. In this family, four individuals 
had a history of thrombosis of whom two had experienced more than one event. 
Detailed information about these individuals is given in table 1. 
Leiden Thrombophilia Study (LETS). For replication of the results obtained in the 
family, relevant DNA variations were genotyped in healthy (i.e., non-thrombotic) 
individuals, who were the controls in a population-based case-control study for 
venous thrombosis (LETS). The design of this study has been described before 
18. Briefly, 474 consecutive patients with a first episode of deep vein thrombosis 
and 474 sex- and age-matched healthy controls were included. All patients were 
younger than 70 years and had no overt malignancy. Controls were healthy 
acquaintances and partners brought by the patients, accordingly to pre-established 
criteria. Mean age for patients and controls was 45 years (range 15-69 for patients 
and 15-72 for controls). Standardized questionnaire, DNA and plasma samples 
were obtained from all the participants. GENES and LETS were approved by 
the Central Committee on Research Involving Human Subjects (CCMO) and all 
participants have provided informed consent.
Table 1. Characteristics of family members with venous thrombosis. 
First episode of VT Second episode of VT PC PROCR FOXA2
Sex Type
Age
(y)
Risk factor Type
Age
(y)
Risk factor (%) genotype rs1055080
Female PE 32 Pregnancy - - - - H1H2 CC
Male DVT 41 Trauma - - - 82 H2H2 CC
Male DVT 4 Trauma DVT 28 Idiopathic 114 H2H3 CT
Female DVT 40 Idiopathic DVT 44 Idiopathic 178 H3H3 CT
Abbreviations - VT: venous thrombosis; PE: pulmonary embolism; DVT: deep vein thrombosis. 
PC levels are presented as percentage of reference pooled plasma. FOXA2 rs1055080: 
NM_021784.4:c.*50C>T or NM_153675.2:c.*50C>T.
    
Resequencing of candidate genes
Three genes in the linkage region (LOD-1 support interval) on chr 20 were 
selected for further analysis. 
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FOXA2 has two known mRNA splicing variants. The first variant (NM_021784) 
contains 2 exons and covers 2422 bases. Alternative splicing at the 5’-end results 
in a second mRNA variant (NM_153675) in which translation initiation starts 6 
amino acids later than in variant 1. Variant 2 also has an additional (untranslated) 
5’-exon, leading to a total mRNA length of 2410 bases. THBD is transcribed from 
an intron-less gene as a 4109 bases long mRNA (NM_000361). PROCR has four 
exons with transcription length of 1449 bases (NM_006404).  
To investigate genetic variations associated with PC levels in the family, we 
selected twelve family members based on their PC levels: (a) three with normal 
levels (72, 75 and 82%); (b) three with intermediate high levels (114, 116 and 
128%); and (c) six with the highest levels (range: 166 – 212%). Three out of four 
patients with thrombosis were included in this panel (table 2). PC plasma level 
was not available for the fourth individual.
Exons and their flanking regions, 5’ and 3’ UTRs, and 1000 bp upstream to the 
initiation codon were resequenced. For FOXA2, the DNA sequence covering both 
splicing variants and 1000 bp upstream to exon 1 of both isoforms was analyzed. 
Primers and PCR conditions are available on request. 
After amplification, the PCR product was sequenced using an ABI Prism® 3730 
DNA Analyzer (Applied Biosystems, Carlsbad, California, USA). The results 
were analyzed using vector NTI® software version 10 (Invitrogen, Paisle, 
UK). Potentially interesting variations found by sequencing were investigated 
in all family members and in the healthy individuals using single nucleotide 
polymorphism (SNP) genotyping assays. 
SNP genotyping assays 
All SNPs were determined using TaqMan SNP genotyping assays (Applied 
Biosystems, California, USA). PCR reactions were performed in 384-well plates 
using the GeneAmp PCR System 9700 (Applied Biosystems, California, USA) 
and fluorescent endpoints were read on a 7900 HT Real-Time PCR System 
(Applied Biosystems, California, USA). 
Common haplotypes of PROCR were tested in all family members with DNA 
available. Three haplotype tagging SNPs were chosen: rs2069952 (H1, pre-
designed assay), rs867186 (H3, pre-designed assay) and rs2069951 (H4, custom 
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assay). The presence of the rare allele determines the mentioned haplotype and 
the presence of three common genotypes determines H2 8. 
Two common variations in FOXA2 (rs1055080 and rs2277764) that were 
identified during sequencing analysis in individuals with high levels of PC were 
investigated in all family members and/or in healthy individuals using a custom 
TaqMan genotyping SNP assay.
Plasma assays
Protein C. In both the family and healthy individuals, blood was collected in tubes 
containing 0.106 mol L-1 trisodium citrate. Plasma was prepared by centrifugation 
at 2000 g for 10 min at room temperature and stored at -70°C 12,18. PC levels 
were determined using a chromogenic assay (Chromogenix, Mölndal, Sweden). 
Levels were expressed as percentage of the level in a reference pooled plasma. 
Measurements in GENES and LETS were performed in different laboratories, 
several years apart, using different reference pooled plasmas. 
Plasma soluble EPCR (sEPCR) levels were determined in the family using the 
Asserachrom sEPCR ELISA kit (Diagnostica Stago, Asnières, France) according 
to the manufacturer’s instructions. Samples were tested in duplicate and plasmas 
were diluted 1/26 prior to the assay. 
Plasma soluble TM (sTM) levels were measured in the family using the CD141 
ELISA kit (Diaclone, Besançon, France) according to the manufacturer’s 
instructions. Samples were tested in triplicate in non-diluted plasmas. 
Linkage analysis
To assess the influence of the investigated genetic variations and plasma 
measurements of sEPCR and sTM on the QTL on chr 20 for PC levels, linkage 
analyses were performed using SOLAR 12. The effects of the genetic variations 
were assessed by adding them to the marker set or by adding them as covariate 
to the linkage model (conditional analyses). Effects of sEPCR and sTM levels 
were assessed by adding them as covariates to the linkage model. In addition, 
LOD scores for sEPCR and sTM levels were determined on chromosome 20. 
Following Lander and Kruglyak 19, and correcting for two phenotypes, we used 
thresholds of 3.6 for genome wide significance and 2.2 for suggestive linkage.
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Statistical analysis
Mean and 95% confidence interval (CI95) were used to compare continuous 
variables with normal distribution (i.e., PC and sEPCR). Patients using vitamin 
K antagonists at the time of venapuncture were excluded. Median and range were 
used to describe sTM because of the skewed distribution in the family. Linear 
regression analysis was used to analyze the correlation between sEPCR and 
PC levels. All calculations were performed using PASW Statistics 17.0 (IBM 
Corporation, Somers, USA).
Results
Genetic analysis of candidate genes PROCR, FOXA2 and THBD 
Resequencing of candidate genes yielded five variations in FOXA2, four variations 
in THBD and five variations in PROCR. All non-synonymous variations are 
summarized in table 2. For PROCR, variations were within the expected for the 
haplotypes and only the haplotypes are shown. All SNPs have been previously 
reported. One variation in PROCR (rs867186, a tagging SNP for H3) and two 
variations in FOXA2 (rs1055080, in the 3’- UTR and rs2277764, in the 5’-UTR) 
were associated with higher levels of PC. Other SNPs found in FOXA2 were 
rs1800847, rs1203910 and rs1212275, all leading to synonymous amino acid 
substitutions (not shown). Relevant variations found in THBD were: rs1042579 
(p.Val473Ala), rs1042580, rs3176123 and rs1962 (last three in the 3’-UTR) but 
none of these was associated with PC plasma levels. This excludes THBD as a 
likely determinant of PC levels.
The co-inheritance of the rare variations of PROCR (rs817186) and FOXA2 
(rs1055080 and rs2277764) in individuals with high PC plasma levels suggests 
that PROCR and FOXA2 SNPs are inherited as a single haplotype in these 
individuals. In an attempt to distinguish which gene is actually responsible, 
we genotyped all members of the family for FOXA2 rs1055080 and for the 
tagging SNPs of common PROCR haplotypes (table 3). Genotyping of PROCR 
showed 52 heterozygotes and two homozygotes for rs817186 minor allele, 
whereas for FOXA2 rs1055080, thirty four individuals were heterozygotes and 
no homozygote for the minor allele was present. Except for two individuals, all 
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carriers of the FOXA2 rs1055080 minor allele were also carriers of PROCR H3, 
again suggesting co-inheritance in the family. 
To answer the question whether PROCR H3 or FOXA2 rs1055080 is responsible 
for PC levels variation, we investigated these SNPs in LETS controls. FOXA2 
rs1055080 was determined in 465 healthy individuals, out of whom thirty seven 
carried the minor allele, two in homozygous state (table 3). Only eight carriers of 
the minor FOXA2 rs1055080 allele also carried PROCR H3, which suggests that, 
in this population-based study, PROCR and FOXA2 are not inherited together, 
reinforcing the idea that the co-inheritance of the rare variations is particular to 
this family. 
FOXA2 rs2277764 was also determined in LETS controls but because of its tight 
linkage with FOXA2 rs1055080 (r2=0.98), this variation was not analyzed further.
PROCR H3 is associated with high levels of PC in the family and in healthy 
individuals 
Table 2. Polymorphisms detected in twelve family members with normal, 
intermediate and high PC levels. Only non-synonymous variations are shown in 
the table. 
PROCR FOXA2 THBD
Sample PC (%) haplotype rs1055080 rs2277764 rs1962 rs3176123 rs1042580 rs1042579 
36049 72 H2H4 1 1 1 1 3 1
29640 75 H1H2 1 1 2 2 1 2
29448* 82 H2H2 1 1 1 1 2 1
29494* 114 H2H3 2 2 1 1 1 1
29599 116 H1H3 1 1 2 2 1 2
29495 128 H2H3 2 2 1 1 1 1
29600 166 H2H3 2 2 1 2 1 2
29680 166 H1H3 2 2 2 1 1 1
29552 169 H3H3 2 2 1 2 1 2
29678 170 H1H3 2 2 2 1 1 1
29529* 178 H3H3 2 2 1 2 1 2
29687 212 H2H3 2 2 2 1 1 1
*individuals with thrombosis; 1 homozygous for the common allele, 2 heterozygous and 3 
homozygous for the rare allele. PC levels are presented as percentages of the reference pooled 
plasma.
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Table 3 shows the mean plasma levels of PC and 95% confidence intervals (CI95) 
for the different genotype groups. Levels of PC cannot be compared directly 
between the family and healthy individuals because different pooled plasmas were 
used as a reference. In the healthy individuals, levels of PC were systematically 
lower than the levels in the family. In the family, mean PC level was higher in 
PROCR H3 carriers (mean: 131%; CI95: 123-138), than in non-carriers (mean: 
106%; CI95: 102-110). In two individuals from the family who were homozygous 
for H3, PC levels were 169% and 178%. In healthy individuals, mean PC level 
was higher in H3 heterozygotes (mean: 113%; CI95: 110-117) than in non-carriers 
of H3 (mean: 99%; CI95: 97-100). Mean PC level in homozygotes for H3 was 
127% (CI95: 109-144) which is somewhat higher than the levels in heterozygote 
carriers, but the confidence intervals overlap. 
Carriers of the FOXA2 rs1055080 minor allele in the family had increased levels 
of PC (mean: 139%; CI95: 128-150) in comparison with non-carriers (mean: 
109%; CI95: 105-113). This was not seen for heterozygous carriers and non-
carriers in the healthy individuals (mean: 100% (CI95: 93-106) and 103% (CI95: 
101-104), respectively). Two individuals were homozygous for the minor allele 
and PC levels were 92 and 123%. This indicates that the minor allele of FOXA2 
rs1055080 is not associated with plasma level of PC in the population. 
We further examined whether family members carrying both rare variants in 
PROCR and FOXA2 had increased levels of PC in comparison to carriers of only 
one rare variant (table 3). Mean level of PC was higher in carriers of both PROCR 
H3 and FOXA2 rs1055080 rare variants (mean: 142%; CI95: 131-153) than in 
carriers of PROCR H3 only (mean: 120%; CI95: 111-129). This indicates that, 
in this family, a second gene variation (other than PROCR H3) may determine 
protein C levels. Since in the healthy individuals no effect of FOXA2 rs1055080 
on PC levels was found, this second gene variation is not FOXA2 rs1055080.  
PROCR H3 is associated with elevated sEPCR levels in the family and in the 
healthy individuals
In the family, sEPCR was increased in carriers of PROCR H3 (mean: 261 ng/
ml; CI95: 240-281) in comparison to non-carriers (mean: 103 ng/ml; CI95: 97-
108). Carriers of the FOXA2 rs1055080 minor allele also had increased sEPCR 
in the family but not in healthy individuals (table 3). No difference in the level 
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of sEPCR was observed between carriers of the rare allele for both variations 
and carriers of PROCR H3 only, either in the family or in the health individuals. 
sEPCR and PC levels were correlated in both the family (r2=0.18) and healthy 
individuals (r2=0.15). 
sTM concentration is not different between PROCR H3 carriers and non-carriers
Median sTM plasma level was 1.2 ng/ml (range: 0.1 to 4.0) in the family. Median 
levels were not different between PROCR H3 carriers (median: 1.3 ng/ml; range: 
0.3 to 4.0) and non-carriers (median: 1.2 ng/ml; range: 0.1 to 4.0). sTM was not 
measured in LETS.
Linkage analysis
Finally, we (re)examined linkage between PC, sEPCR and sTM levels and genetic 
markers on chr 20, now including PROCR H3 and FOXA2 rs1055080. For PC 
levels, the addition of new genetic markers did not change the LOD-score (Fig. 
1a). When the analysis was performed conditional on PROCR H3 and FOXA2, 
the LOD score for PC went down to <2.0, suggesting that most of the variation of 
PC levels can be attributed to these genetic markers (Fig. 1b). 
For sEPCR, the linkage analysis performed with the initial genetic markers 
yielded a LOD score of 6.2. Adding FOXA2 rs1055080 to the analysis increased 
the LOD score to 7.7 and addition of PROCR H3 increased it further to 9.3, 
reinforcing the idea that this haplotype is largely responsible for sEPCR plasma 
level variation (Fig. 1c). For sTM, the LOD score remained <1.0 for any model 
(Fig. 1d). 
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Table 3. PC and sEPCR plasma levels for PROCR H3 and FOXA2 rs1055080 
carriers and non-carriers in the family and in the healthy individuals from LETS. 
Abbreviations - (n): number of individuals per group; PC levels are presented as percentages 
of the reference pooled plasma and sEPCR as ng/ml. *only one or two measurements were 
available and therefore, mean and CI95 were not calculated. Genotype for FOXA2 rs1055080 
(NM_021784.4:c.*50C>T or NM_153675.2:c.*50C>T) was performed in 465 controls from LETS 
with DNA available. PC measurement was not available for 26 individuals from the family and 
sEPCR measurement was not available for 16 individuals from the family and for 1 control from 
LETS. 
Protein C Soluble EPCR
Genotype Family (n) LETS (n) Family (n) Mean (CI95) LETS (n) Mean (CI95) Family (n) Mean (CI95) LETS (n) Mean (CI95)
PROCR H3
HxHx 106 360 85 106 (102-110) 360 99 (97-100) 96 103 (97-108) 360 94 (91-96)
H3Hx 52 100 47 131 (123-138) 100 113 (110-117) 47 261 (240-281) 99 258 (248-269)
H3H3 2 10 2 169; 178* 10 127 (109-144) 1 337* 10 439 (399-478)
Total 160 470 134 - 470 - 144 469 -
FOXA2
CC 126 428 104 109 (105-113) 428 103 (101-104) 114 131 (118-144) 427 138 (129-146)
CT 34 35 30 139 (128-150) 35 100 (93-106) 30 249 (216-282) 35 117 (96-139)
TT - 2 - - 2 92;123* - - 2 54;176*
Total 160 465 134 - 465 - 144 - 464 -
PROCR H3 + FOXA2 
HxHx +CC 104 326 83 106 (102-110) 326 99 (97-100) 94 103 (98-109) 326 94 (92-96)
HxHx +CT/TT 2 29 2 87;117* 29 97 (90-104) 2 66;81* 29 90 (81-98)
H3Hx/H3H3+CC 22 102 21 120 (111-129) 102 115 (111-119) 20 263 (235-291) 101 279 (265-294)
H3Hx/H3H3+CT/TT 32 8 28 142 (131-153) 8 111 (101-121) 28 262 (232-292) 8 217 (168-265)
Total 160 465 134 - 465 - 144 - 464 -
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Discussion 
In this study, we provide evidence for the association of a common haplotype 
(H3) of PROCR with high plasma levels of PC. Resequencing of PROCR did 
not provide proof for additional determinants of plasma PC levels. Furthermore, 
we excluded that two other genes involved in the PC anticoagulant pathway, i.e. 
FOXA2 and THBD, both located on chr 20 close to the PROCR gene, determined 
the plasma level of PC, both at the level of common variations as well as on the 
level of rare sequence variations. Finally, variations in THBD did not influence 
the levels of sTM (data not shown) nor were these levels associated with the 
level of PC. This contrasted with the clear relationship between levels of PC and 
sEPCR.
Our results regarding the role of chr 20 in determining PC levels are in agreement 
with previous reports 8-10,20. Most notably, a recent study by Tang et al. that was 
published while this work was in progress, came to very similar findings using a 
radically different approach 10. In that study, two neighboring genes, i.e. PROCR 
and EDEM2, were found as determinants of variations in PC levels. In the family, 
carriers of PROCR H3 who also carried the rare allele of FOXA2 rs1055080 had 
higher PC levels than carriers of H3 alone. The fact that this effect was absent in 
the healthy individuals from LETS indicates that a second determinant is present 
between the FOXA2 and PROCR genes, which could well be EDEM2. 
When we genotyped the family and the healthy individuals from LETS for 
EDEM2 rs6120846 and rs3746429 and analyzed the association to PC plasma 
levels, PC levels were lower in carriers of one or two minor alleles in both the 
family and healthy controls (unpublished observations), which is in accordance 
with the data from Tang et al 10. In addition, we observed that sEPCR levels were 
also lower in carriers of the minor alleles of EDEM2 which suggests that, also in 
this case, PC levels are influenced through EPCR. This is supported by the fact 
that we could not see any relationship between the minor alleles and levels of 
other coagulation proteins (FII, FV, FVII, FVIII, FIX, FX or FXI). 
The precise mechanisms underlying the association of PROCR and PC levels are 
not known, and there might be an important role for sEPCR. It is known that PC 
(and APC) has a comparable affinity (Kd»30nM) for membrane bound EPCR 
and sEPCR 14. Therefore, complex formation between PC and sEPCR in plasma 
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is to be expected and thus, high levels of sEPCR might drive high levels of PC. 
The problem with this explanation is that, in general, PC levels are much higher 
than sEPCR levels, even in the presence of PROCR H3. PC levels in carriers 
of H3 in the family is estimated to range from 63 to 163 nM whereas sEPCR 
levels in the same individuals is estimated to range from 4 to 18 nM. Based on 
these estimations it is difficult to simply explain the relationship between PC 
and sEPCR levels. Perhaps, higher sEPCR levels are associated with low levels 
of EPCR on the endothelial membrane, thus leading to a redistribution of PC 
between the membrane-bound compartment and a soluble compartment. There 
is indeed evidence that the H3 haplotype associated Gly219 involves increased 
EPCR shedding from the endothelium 16, but evidence that this leads to lower 
density on the endothelial membrane is not available. In preliminary studies we 
have analyzed blood-originated endothelial cells (BOECs) from carriers and non-
carriers of PROCR H3 (three individuals of each) by flow cytometry, but the data 
suggests that the expression of EPCR on the membrane is not different between 
the groups (unpublished data). It has also been hypothesized that the local 
concentration of sEPCR at the endothelial surface is higher than the concentrations 
measured in the plasma, possibly exceeding the Kd of PC interaction 20, but this 
also does not readily explain the increased plasma PC levels. Future research 
might solve this problem. 
There are claims that H3 not only influences PC levels but also the level of other 
coagulation proteins, e.g. FVII 21,22. In the present GENES study or in the healthy 
individuals from LETS, this association was not confirmed (data not shown), 
neither was H3 associated with levels of FII, FV, FVIII, FIX or FXI 8.
Since low levels of PC, as in individuals with inherited PC deficiency, are a risk 
factor for venous thrombosis, it is tempting to assume that high levels of PC 
are protective, but there is no evidence that the latter is indeed the case. Thus, 
it is also reasonable to assume that the H3 haplotype, from the perspective of 
PC levels, would protect against venous thrombosis. This does not seem to 
be the case: in the family, two of the H3 carriers who had high levels of PC 
experienced recurrent venous thrombosis, but this family study obviously does 
not have sufficient power to determine the relationship between H3 and venous 
thrombosis. Population-based case-control studies have not been conclusive. 
Some authors report increased risk of venous 20,23 and arterial thrombosis 24 in H3 
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carriers, and others claim no association 8,9,25,26. It seems fair to conclude though, 
that the markedly elevated levels of PC associated with H3 do not protect against 
thrombotic disease. 
In conclusion, our data provide new evidence for the association of PROCR H3 
and sEPCR with plasma levels of PC and suggest that FOXA2 and THBD, two 
other genes on chr 20, are not involved. Further studies are necessary to elucidate 
the mechanisms underlying this association.
Figure 1. LOD-scores for Protein C levels using additional markers (a) or 
additional covariates (b), and for sEPCR (c) and sTM (d) levels using additional 
markers. The horizontal line indicates the genome-wide significance threshold. 
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Abstract
Background 
Earlier genome-wide linkage analyses of  coagulation factor levels in a large Dutch 
pedigree (GENES Family 8) yielded suggestive linkage signals on chromosome 
(chr) 16 for Factor (F) V (LOD score: 3.9 at 110 cM) and FII levels (LOD score: 
3.4 at 97 cM). 
Objectives
NQO1, which encodes an enzyme involved in vitamin K metabolism, is a 
candidate gene in the LOD-1 region of the linkage signals on chr16 and therefore 
we evaluated the influence of five NQO1 haplotypes on coagulation factor 
levels (i.e. protein C, protein S, FII, FV, FVII, FVIII and FIX) in the pedigree 
and in controls of a population-based case-control study on venous thrombosis, 
the Leiden Thrombophilia Study (LETS). We also assessed the risk of venous 
thrombosis for each haplotype in the LETS. 
Results
NQO1 haplotype 4 (H4) carriers in Family 8 had lower FV levels than non-
carriers while H4 had no effect on FV levels in the LETS controls. Each H4 copy 
was associated with 11.8 U/dl decrease in FV level (95% CI: -21.4, -2.3) in the 
family. In the LETS controls, H4 was associated with lower levels of vitamin 
K-dependent coagulation factors. The strongest association was observed with 
the levels of FII (-2.6; 95% CI: -5.2, -0.1) and total protein S (-4.3; 95% CI: -7.6, 
-1.0). We did not observe a similar pattern in the Family 8. NQO1 haplotypes do 
not influence the risk of thrombosis in the LETS. 
Conclusions
Haplotype 4 carriers of NQO1 have lower levels of vitamin K-dependent 
coagulation factors especially lower FII and total protein S. None of the haplotypes 
affect the risk of venous thrombosis. 
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Introduction
The levels of many coagulation factors are in part genetically determined 1. 
However, the genes influencing the levels are not all known. 
Previously, we conducted genome-wide linkage analyses of coagulation factor 
levels and of the outcome of global coagulation assays in a large Dutch pedigree 
(Family 8) from the GENES study 2. Four statistically significant linkage signals 
were observed: on chromosome (chr) 20 for protein C levels (LOD score: 4.8), on 
chr 17 for prothrombin time (LOD score: 3.8) and on chr 16 for factor (F) V (LOD 
score: 3.9) and FII (LOD score: 3.4) levels. The protein C linkage signal and the 
signal on chr 17 will be presented elsewhere (in preparation). In the current study, 
we set out to explore explanations for the positive linkage signal for factor V and 
prothrombin (FII) on chr 16 (figure 1). 
Candidate genes were searched in the LOD-1 region using Biomart (www.
biomart.org). Only one gene, NQO1, was identified with a plausible role in blood 
coagulation factor synthesis. NQO1 is a cytosolic enzyme, which is expressed in 
the liver and converts vitamin K to hydroquinone vitamin K, the co-enzyme of 
gamma-glutamyl carboxylase (GGCX) (figure 2). Gamma-carboxyl modification 
enables proteins such as blood coagulation factors (i.e. protein C, S and Z, FII, 
FVII, FIX and FX), proteins involved in calcium homeostasis (osteocalcin and 
matrix Gla protein), cell growth (Gas6) and signal transduction (RPGP1 and 
RPGP2) to bind to calcium and thereby to be physiologically active 3. Although 
factor V is not itself carboxylated, one can not exclude an indirect influence of 
NQO1. The precedent for this, is protein S that influences the level of tissue 
factor pathway inhibitor and the level of C4BP 4;5.
In the present study we investigated the association between haplotypes of NQO1 
and the levels of FV and FII and various other factors in GENES Family 8. To 
verify our findings we performed similar analyses in the control population of the 
Leiden Thrombophilia Study (LETS), a population based case-control study on 
venous thrombosis. Furthermore, we evaluated the risk of venous thrombosis for 
each NQO1 haplotype in the LETS.
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Figure 1: linkage results for FV and FII on chromosome 16
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Figure 2: vitamin K cycle: NQO1 converts vitamin K to hydroquinone vitamin 
K, the co-enzyme of gamma-glutamyl carboxylase (GGCX). After gamma 
carboxylation vitamin K transforms to vitamin K epoxide which then by vitamin 
K epoxide reductase complex subunit 1 (VKORC1), the rate limiting enzyme in 
the vitamin K cycle, is reduced to vitamin K
 16 
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Subjects and methods
Family 8 and the GENES study
Family 8 is one of the thrombophilic families included in a larger study called 
the GENES study. GENES is described in a previous publication 2. In short, 43 
families which were ascertained through probands with venous thromboembolism 
(VTE) and a strong family history of VTE participated in this study. Family 
history of VTE was defined as at least one first degree or two second degree 
family members affected by VTE. As the purpose of GENES was to identify 
new genetic risk factors for VTE, none of the probands should have any of the 
known thrombophilic defects: factor V Leiden (FVL), prothrombin G20210A 
or deficiencies of antithrombin, protein C and protein S. The diagnosis of VTE 
was established based on a standardized questionnaire or on documented medical 
records. Blood and DNA samples were available for the participants of GENES. 
The GENES study was approved by the Central Committee on Research Involving 
Human Subjects (CCMO) and all subjects provided an informed consent.
Leiden Thrombophilia Study 
Details of the Leiden Thrombophilia Study (LETS) have been published 
previously 6. Briefly, 474 patients younger than 70 years of age with a first deep 
vein thrombosis were recruited from anticoagulation clinics in Leiden, Amsterdam 
and Rotterdam (the Netherlands) between January 1988 and December 1992. 
None of the participants had overt malignancy. As controls, partners or friends 
of the patients who did not have venous thrombosis were included. Levels of FII 
7, FV 8, FVII 9, FIX 10, FVIII 11, protein C and protein S 12 have been determined 
before and were expressed in U/dl.
Linkage analysis in Family 8
Using the Sequential Oligogenic Linkage Analysis Routines (SOLAR) program 
probability of identity by descent and variance components linkage analysis in 
Family 8 members were previously  performed for several intermediate phenotypes 
such as prothrombin F1+2, thrombin generation time, endogenous thrombin 
potential, clot lysis time, activated protein C sensitivity ratio, prothrombin time, 
activated partial thromboplastin time, activity of FII, FVII, FVIII, FIX, FXI and 
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antithrombin, and antigen concentrations of total and free protein S, protein 
C, FV and tissue factor pathway inhibitor 2. Genotyping was conducted by the 
NHLBI Mammalian Genotyping Service at the Marshfield Medical Foundation 
(Marshfield, WI, USA, Weber and Broman, 2001) using the 10 cM spaced short 
tandem repeat polymorphism screening set 16 2. In the current study, linkage 
analyses for FV and FII levels were performed adjusted for NQO1 haplotypes 
to investigate whether these haplotypes influenced the linkage signals on chr 16.
SNP genotyping in Family 8 and LETS
We searched for haplotype tagging (ht) SNPs in NQO1 in the European Hapmap 
population (CEU) using the Genome Variation Server (http://gvs.gs.washington.
edu/GVS). A htSNP is a polymorphism whose minor allele is specific to one 
haplotype (H). Four htSNPs (rs689453, rs10517, rs1800566 and rs2965753) 
were identified, which together tag five haplotypes (figure 3). We used TaqMan® 
SNP genotyping assays to determine the htSNPs. Fluorescent allele-specific 
oligonucleotide probes (Applied Biosystems, CA, USA) were used for PCR 
amplification and fluorescence endpoint reading for allelic discrimination was 
done on an ABI 7900 HT (Applied Biosystems). 
Statistical analysis
We used linear regression analysis in Family 8 as well as in the LETS control 
population to investigate the association between the haplotypes of NQO1 and 
vitamin K-dependent (protein C and S, FII, FVII and FIX) and independent (FV 
and FVIII) coagulation factor levels. The regression coefficient (β) represents 
the mean difference of the levels related to each haplotype copy. Furthermore, to 
investigate whether carrying a certain haplotype increases the risk of deep venous 
thrombosis, we computed the odds ratios (OR) and 95% confidence intervals 
(CI), as an estimate of relative risk of thrombosis for subjects heterozygous or 
homozygous for each NQO1 haplotype compared with non-carriers (reference 
group). The latter analyses were also performed in the LETS.
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Figure 3: Five haplotypes of NQO1 and their frequencies in Family 8 and controls 
of the Leiden Thrombophilia Study
Results 
Family 8 characteristics
Family 8 comprises 218 individuals in 5 generations. Plasma and DNA samples 
are available for 161 members. The mean (range) age of the members is 46 (15-
87) years and 80 (50%) of them are men. Four members experienced thrombosis 
of whom two had a recurrent event. The linkage signals for FV and FII levels 
were located at chromosomal regions 16q23 (location maximum LOD score: 110 
cM; LOD-1 support interval: 98-114 cM) and 16q22 (location 97 cM; LOD-1 
support interval: 89-113 cM), respectively (figure 1). 
NQO1 haplotype tagging SNPs
Four htSNPs identified five haplotypes of NQO1 (figure 3). Haplotypes could not 
be assigned to three members of Family 8 and 14 controls and 15 patients of the 
LETS because of missing genotypes due to technical failure in SNP genotyping. 
Haplotypes and their frequencies in Family 8 and in LETS controls are shown 
in figure 3. Haplotype 5 (H5) was tagged by two SNPs and H2 consisted of the 
common alleles of all htSNPs. 
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Association of NQO1 haplotypes with coagulation factor levels in Family 8 and 
LETS controls
The regression coefficients (β) for the association of each NQO1 haplotype with 
coagulation factor levels are summarized in table 1. Members of Family 8 who 
inherited H4 had lower FV levels than H4 non-carriers while H4 had no effect 
on FV levels in the LETS controls. Each H4 copy was associated with 11.8 
U/dl decrease in FV level (95% CI: -21.4, -2.3). No other haplotypes showed 
significant association with FV level, neither in Family 8 nor in LETS controls. In 
the LETS controls, H4 was consistently associated with lower levels of vitamin 
K-dependent coagulation factors. The strongest association of H4 was with the 
levels of factor II (95% CI: -5.2, -0.1) and total protein S (95% CI: -7.6, -1.0). We 
did not observe similar pattern in the Family 8.
Association of NQO1 haplotypes with thrombosis risk
Table 2 shows the thrombosis risks for homozygous and heterozygous carriers of 
each NQO1 haplotype as compared with non-carriers of that particular haplotype 
in the LETS. H1 carriers (homozygotes and heterozygotes) had a 30% lower risk 
of thrombosis (95% CI: 0.5-1.1) than non-carriers of H1. Contrarily, H4 carriers 
(homozygotes and heterozygotes) had a 1.3 times higher thrombosis risk than 
non-carriers (95% CI: 0.96-1.7). Other haplotypes of NQO1 were not associated 
with thrombosis risk. 
Linkage analysis with adjustment for NQO1 haplotypes
Adjusting the linkage analyses of FV and FII levels for NQO1 haplotypes did not 
reduce the linkage signal on chr16 noticeably. The LOD score after adjustment 
was reduced mildly.
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Table 1: Association of NQO1 haplotypes with levels of coagulation factors in 
Family 8 and in controls of the Leiden Thrombophilia Study 
NQO1 
haplotype
FII FVII FIX FV FVIII PC tPS
LETS Family LETS Family LETS Family LETS Family LETS Family LETS Family LETS Family
H1 0.5 -2.9 0.4 1.6 -4.3 -1.9 -1.8 1.8 -5.8 -0.8 -1.0 -0.0 1.1 -6.7
H2 0.7 2.7 2.2 -1.3 7.4 1.1 -1.2 2.1 -1.6 3.8 1.2 -0.02 1.9 1.9
H3 0.2 2.9 -3.9 18.7 29.8 8.5 -4.6 16.5 -28.4 13.6 -1.1 4.1 2.5 -12.7
H4 -2.6 -3.7 -2.6 2.1 -15.8 0.9 2.7 -11.8 6.1 -3.6 -0.7 4.4 -4.3 -1.1
H5 1.7 0.05 -1.1 -3.2 3.9 -2.8 1.0 4.5 2.1 -4.5 -0.7 -4.6 0.7 2.9
Regression coefficients β are shown. The direction of the regression coefficient represents the effect 
of each extra copy of the haplotype (i.e. a positive regression coefficient means that the haplotype 
increases phenotype mean). 
The bold typed ciphers are statistically significant.
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 Table 2: The risk of thrombosis for NQO1 haplotypes in the Leiden Thrombophilia 
Study
Haplotype Patients (%)
N=459
Controls (%)
N=460
OR 95% CI
H1 (rs689453)
     HxHx 399 (87) 382 (83) 1*
     H1Hx 55 (12) 76 (16) 0.7 0.5-1.0
     H1H1 5 (1) 2 (0.4) 2.4 0.5-12.4
     H1Hx/ H1H1 60 (13) 78 (17) 0.7 0.5-1.1
     Frequency H1 7 9
H2 (all common) 
     HxHx 61 (13) 68 (15) 1
     H2Hx 239 (52) 216 (47) 1.2 0.8-1.8
     H2H2 159 (35) 176 (38) 1.0 0.7-1.5
     H2Hx/ H2H2 398 (87) 392 (85) 1.1 0.8-1.6
     Frequency H2 61 62
H3 (rs10517)
     HxHx 447 (97) 447 (97) 1
     H3Hx 12 (3) 12 (3) 1.0 0.4-2.3
     H3H3 - 1 (0.2) 0.9 0.4-2.0
     H3Hx/ H3H3 12 (3) 13 (3)
     Frequency H3 1 2
H4 (rs1800566)
     HxHx 293 (64) 318 (69) 1
     H4Hx 155 (34) 126 (27) 1.3 1.0-1.8
     H4H4 11 (2) 16 (4) 0.7 0.3-1.6
     H4Hx/ H4H4 166 (36) 142 (31) 1.3 1.0-1.7
     Frequency H4 19 17
H5 (rs10517 and rs2965753)
     HxHx 361 (79) 368 (80) 1
     H5Hx 89 (19) 84 (18) 1.1 0.8-1.5
     H5H5 9 (2) 8 (2) 1.1 0.4-3.0
     H5Hx/ H5H5 98 (21) 92 (20) 1.1 0.8-1.5
     Frequency H5 12 11
* Reference category; Hx: all haplotypes but the one given.
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Discussion
We studied the effect of NQO1 haplotypes on the levels of several coagulation 
factors in a large family and in a population based case-control study on venous 
thrombosis, the Leiden Thrombophilia Study. We observed that H4 carriers had 
lower levels of FV in the family but were unable to confirm this difference in 
LETS controls. In the LETS controls, H4 appears to be associated with lower 
levels of vitamin K-dependent coagulation factors. It is worth mentioning that 
coagulation factor levels can not easily be compared between Family 8 and LETS 
because assays were performed in different laboratories at different time points 
and sometimes other assays were used (e.g. for FV levels).
The effect of NQO1 polymorphisms on the levels of coagulation factors is 
poorly studied and the results remain controversial. Rs1800566, which tags the 
haplotype 4, results in a proline to serine substitution. This amino acid change 
was reported to cause rapid degradation of the enzyme 13 and thereby lower 
or undetectable enzymatic activity in heterozygous and homozygous carriers 
respectively 14.  This postulates that H4 carriers have lower levels of vitamin 
K-dependent coagulation factors. Similar to our observation in the LETS, a 
significant correlation between rs1437135 in NQO1 (a SNP in complete linkage 
disequilibrium with rs1800566) and the levels of protein C, protein S and FII but 
not FVII, FIX and FX is reported in a genome-wide linkage study of Spanish 
families (Genetic Analysis of Idiopathic Thrombophilia (GAIT)) 15. However, no 
relation was evident between the levels of protein C and S and rs1800566 (the 
htSNP of H4) in a study in the Japanese population 16. Unfortunately, the Spanish 
authors did not consider FV levels in their analysis, probably because vitamin K 
is not deemed essential for FV biosynthesis. In both genome-wide linkage studies 
(GAIT and Family 8), adjusting for NQO1 polymorphisms did not attenuate the 
linkage signal suggesting the presence of other genetic variation on chr 16 that 
is responsible for the linkage peaks. Since identity by descent probabilities are 
already quite accurate in Family 8, the possibility to narrow down the linkage 
signal by fine mapping is limited. We assessed the risk of venous thrombosis in 
the LETS for each NQO1 haplotype. Heterozygous carriers of haplotype 4 were 
at almost significantly 30% higher risk of venous thrombosis as compared with 
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non-carriers. However, as the effect was not dose-dependent we presume it would 
lose its significance by enlarging the sample size.  
In conclusion, we observed that haplotype 4 carriers of NQO1 gene have lower 
levels of vitamin K-dependent coagulation factors especially lower FII and total 
protein S, in the control population of the Leiden Thrombophilia Study. None 
of the haplotypes seem to affect the risk of venous thrombosis. One NQO1 
haplotype was associated with FV levels in Family 8. However, linkage analyses 
adjusted for NQO1 haplotypes showed that variations in NQO1 could not explain 
the linkage peaks on chromosome 16 for the levels of FV and FII. 
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Dear Sirs,
Vitamin K antagonists, e.g. warfarin, acenocoumarol, and phenprocoumon, are 
widely used as treatment for individuals with increased thrombosis risk. The 
target of these drugs is the vitamin K epoxide reductase complex subunit 1 
(VKORC1), a key enzyme in the vitamin K cycle. A reduced form of vitamin K 
(vitamin K hydroquinone) serves as a cofactor for gamma-carboxylase (GGCX) 
in the posttranslational carboxylation of vitamin K-dependent proteins, such as 
the coagulation proteins factor II, VII, IX and X, protein C, protein S, and protein 
Z. This carboxylation of glutamate residues is essential for full activation of these 
proteins. During gamma-carboxylation vitamin K epoxide is generated, which 
must be rapidly reduced again because of limited availability of reduced vitamin 
K. Via VKORC1 and NAD(P)H dehydrogenase [quinone] 1 (NQO1), vitamin 
K epoxide is recycled to its active form vitamin K hydroquinone. Binding of 
vitamin K antagonists to VKORC1 inhibits recycling of vitamin K, resulting in 
the formation of inactive, non-carboxylated proteins.
Whereas data on NQO1 and GGCX are scarce, genetic variation (single nucleotide 
polymorphisms, SNPs) in the VKORC1 gene was repeatedly reported to influence 
the individual response of patients to vitamin K antagonists. Carriers of a 
specific VKORC1 haplotype (A), consisting of several SNPs in complete linkage 
disequilibrium, were found to require a lower maintenance dose of vitamin K 
antagonists compared with haplotype B carriers 1.
Elevated plasma levels of vitamin K-dependent coagulation factors II, VII, IX, 
and X were previously found to be associated with an increased risk of venous 
thrombosis and they seem to have a significant genetic component 2. However, 
only a few genetic determinants of these plasma levels have been identified. 
Furthermore, clustering of the levels of vitamin K-dependent proteins has been 
reported 3, suggesting that a common modifier gene exists. Genetic variation 
in VKORC1, NQO1, and GGCX might affect plasma activity levels of vitamin 
K-dependent proteins, and thereby thrombosis risk.
Several studies investigated the association between VKORC1 variation and 
venous thrombosis risk 4-7, mainly by genotyping a SNP distinguishing haplotypes 
A and B. Lacut et al. 5 reported that haplotype A protected against thrombosis, 
whereas the other studies did not show any association. In a recent German study 
no association between SNPs in VKORC1, NQO1, and GGCX and activity levels 
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of vitamin K-dependent coagulation factors was found 8, whereas a Spanish study 
reported an association between an NQO1 SNP with protein C levels 9.
Until now the association between genetic variation in NQO1 and GGCX and 
venous thrombosis risk has not been studied. Furthermore, most previous studies 
only studied one SNP per gene, thereby not taking into account all common 
haplotypic variation. In the present study we investigated VKORC1, NQO1, 
and GGCX haplotypes and their association with activity levels of vitamin 
K-dependent coagulation proteins and venous thrombosis risk. 
For our investigation we used the Leiden Thrombophilia Study (LETS), a population-
based case-control study on venous thrombosis, including 474 consecutive patients 
aged 18-70 years with a first deep-vein thrombosis and 474 age- and sex-matched 
healthy controls 10. Venous blood was collected into tubes containing 0.1 volume 
0.106 mol/L trisodium citrate. Plasma was prepared by centrifugation for 10 
minutes at 2000 g at room temperature and stored at -70°C. High molecular weight 
DNA was isolated from leukocytes and stored at 4°C. Measurements of factor II 11, 
factor VII 12, and protein C activity 13 have been described before.
Haplotype tagging SNPs in the VKORC1 (n=4), NQO1 (n=4), and GGCX (n=6) 
genes were identified in either the Caucasian Seattle PGA panel (NQO1, GGCX) 
or the Caucasian (CEU) Hapmap panel (VKORC1) using the Genome Variation 
Server (GVS, http://gvs.gs.washington.edu/GVS). Minor allele frequencies 
(MAF) were above 3%. All SNPs were genotyped using a 5’-nuclease/TaqMan 
assay (Applied Biosystems, Foster City, CA, USA). For all fourteen SNPs, 
the distribution of genotypes among control subjects was in Hardy-Weinberg 
equilibrium (tested using the χ2-statistic). Tagging SNPs and haplotypes are 
shown in Table 1A. For VKORC1 haplotypes, Geisen’s nomenclature was used 
14. Analyses were performed with PLINK v1.06 software (http://pngu.mgh.harvard.
edu/purcell/plink/) 15. Haplotypes for the three genes were inferred in subjects 
without missing genotypes and haplotype allele frequencies were compared 
between patients and controls (Table 1A).
None of the haplotypes of the three genes affected venous thrombosis risk. Our 
results on VKORC1 are in agreement with most previous findings. We could not 
confirm the finding that homozygous carriers of VKORC1 haplotype A (tagged 
by rs2359612) are protected against thrombosis 5. Individual SNPs were also not 
associated with the risk of venous thrombosis.
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Linear regression analysis was used to test for an association between haplotypes 
and activity levels of vitamin K-dependent coagulation proteins in the LETS 
control population. Table 1B shows the regression coefficients β. Only two 
regression coefficients were significantly different from zero (p<0.05). NQO1 
H4 was associated with reduced factor II activity. Each copy of NQO1 H4 was 
associated with a reduction in factor II activity of 2.68 % (i.e., linear regression 
coefficient β= -2.68; p=0.04). This reduction was consistent as also factor VII 
and protein C activity were reduced in NQO1 H4 carriers. NQO1 H4 is tagged 
by rs1800566 (p.Pro187Ser). The proline to serine substitution was found to be 
associated with loss of NQO1 protein and NQO1 activity 16, which may explain 
the observed reduction in levels. The rs1800566 SNP is in complete linkage 
disequilibrium with rs1437135 (http://www.hapmap.org) which was previously 
reported to be associated with protein C levels in the GAIT study 9. Individual 
analysis of all fourteen SNPs also showed an association between rs1800566 
and factor II activity. This finding was the only significant result in the single 
SNP analysis. The second significant result in the haplotype analysis was the 
association between GGCX H1 and reduced factor II activity (β= -1.90; p=0.048), 
but this result may be spurious. The reduction was not consistent as factor VII 
activity was not reduced. Rieder et al. previously showed that VKORC1 haplotype 
A (combination of VKORC1*2A and VKORC1*2B) is associated with a reduced 
expression of VKORC1 in the liver 1. In LETS controls a trend towards lower 
activity of factor II, factor VII and protein C was observed in haplotype A carriers, 
which is in accordance with Rieder’s report. 
 In conclusion, we did not find an association between haplotypes of VKORC1, 
NQO1 and GGCX and venous thrombosis risk. NQO1 H4 does possibly have 
a small influence on activity levels of vitamin K-dependent proteins. However, 
these changes are too subtle to noticeably change thrombosis risk.
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Table 1A. Haplotypes and tagging SNPs of VKORC1, NQO1 and GGCX
Minor alleles in bold and underlined 1 http://pga.mbt.washington.edu/, 2According to Geisen et al 
(14), 3According to Rieder et al (1), 4Not determined in SeattleSNPs panels, 5in Hapmap CEU 
population A is minor allele
 
Tagging SNPs rs number (SeattleSNPs numbering1) Frequency LETS
VKORC1 haplotypes2 (clusters)3
rs2884737
(5808)
rs17708472
(6009)
rs2359612
(7566)
rs7294
(9041)
Patients
n=469
Controls
n=466
VKORC1*2A (A) T C T G 13.2 14.5
VKORC1*2B (A) G C T G 26.9 26.3
VKORC1*4 (B) T T C G 22.0 21.7
VKORC1*3 (B) T C C A 36.8 36.2
VKORC1*1 (B) T C C G 1.2 1.3
NQO1 haplotypes
rs689453
(1910)
rs2965753
(2898)
rs1800566
(9144)
rs10517 4 Patients
n=461
Controls
n=462
NQO1 H1 A A C C 7.1 8.7
NQO1 H2 G A C C 60.7 61.8
NQO1 H3 G A C T 1.2 1.4
NQO1 H4 G A T C 19.2 17.1
NQO1 H5 G G C T 11.9 11.0
GGCX haplotypes
rs6738645
(7475) 5
rs699664
(10067)
rs10179904
(10496)
rs11676382
(12970)
rs17026447
(13031)
rs2028898
(13333)
Patients
n=465
Controls
n=461
GGCX H1 A G C G T C 43.6 41.6
GGCX H2 A G C C T C 9.8 11.5
GGCX H3 C A C G G C 2.9 2.7
GGCX H4 C A C G T T 30.6 30.2
GGCX H5 C G T G T C 10.9 10.5
GGCX H6 C G C G T C 2.2 3.4
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Table 1B. Association of VKORC1, NQO1 and GGCX haplotypes with activity of 
vitamin K-dependent coagulation proteins in controls
Factor II (%) Factor VII (%) Protein C (%)
VKORC1 haplotypes
VKORC1*2A 1.57 0.81 1.60
VKORC1*2B -1.11 -1.46 -1.17
VKORC1*4 0.02 2.36 -0.96
VKORC1*3 0.07 -0.36 0.98
VKORC1*1 -1.63 -5.67 -4.12
VKORC1 haplotype A1 -0.07 -0.73 -0.16
NQO1 haplotypes
NQO1 H1 1.18 1.21 -0.31
NQO1 H2 0.75 2.28 1.35
NQO1 H3 0.85 -4.31 -2.05
NQO1 H4 -2.68* -2.85 -1.03
NQO1 H5 1.47 -1.21 -0.92
GGCX haplotypes
GGCX H1 -1.90* 0.94 -2.02
GGCX H2 1.76 -2.71 -1.40
GGCX H3 2.32 -0.16 -0.18
GGCX H4 1.21 0.95 2.29
GGCX H5 -0.95 -2.09 -0.59
GGCX H6 -0.70 4.15 2.78
Regression coefficients β are shown. The direction of the regression coefficient represents the effect 
of each extra copy of the haplotype (i.e. a positive regression coefficient means that the haplotype 
increases phenotype mean). Activity in pooled normal plasma is 100%.
1According to Rieder et al (1)
* p<0.05
Haplotypes of VKORC1, NQO1 and GGCX, their effect on activity levels of vitamin 
K-dependent coagulation factors, and the risk of venous thrombosis
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Abstract
In the last decades, the knowledge on the etiology of venous thromboembolism 
(VTE) has increased tremendously. In approximately half of patients presenting 
with VTE, one or more thrombophilic defects can be identified. This has led to 
widespread testing for thrombophilia, despite the fact that, at present, it is unclear 
whether this should have therapeutic consequences. Here we review the currently 
established hereditary and acquired thrombophilic defects, and focus on the pros 
and cons of testing in the setting of VTE. Thrombophilia is defined as a disorder 
associated with an increased tendency to venous thromboembolism (VTE). 
Thrombophilia can be acquired, such as in patients with cancer, or congenital, in 
which case a defect in the coagulation system is hereditary. Egeberg was the first 
to use the term thrombophilia in 1965, when he described a Norwegian family 
that had a remarkable tendency to VTE, based on a deficiency of antithrombin.1 
Since then, various laboratory abnormalities, both hereditary and acquired, have 
been discovered that increase the risk of VTE. This article reviews the currently 
established thrombophilic abnormalities and discusses the potential usefulness 
and implications of testing for thrombophilia.
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Coagulation cascade and regulatory mechanisms
Well-established hereditary thrombophilia can be categorized into abnormalities 
of the natural anticoagulant system, elevation of plasma levels of coagulation 
factors, abnormalities in the fibrinolytic system, and miscellaneous hereditary 
conditions.
Fig. 1 depicts the current, simplified insight into the regulation of the coagulation 
system. Coagulation is initiated by a tissue factor (TF)/factor (F) VIIa complex 
that can activate FIX or FX. At high TF concentrations, FX is activated primarily 
by the TF/FVIIa complex, whereas at low TF concentrations, the contribution 
of the FIXa/FVIIIa complex to the activation of FX becomes more pronounced. 
Coagulation is maintained through the activation of FXI by thrombin. The 
coagulation system is regulated by the protein C pathway. Thrombin activates 
protein C. With protein S as a cofactor, activated protein C (APC) inactivates 
FVa and FVIIIa, which results in a downregulation of thrombin generation and 
consequently in an upregulation of the fibrinolytic system. Antithrombin is the 
other important natural anticoagulant that inhibits not only thrombin but also FXa 
and other coagulation factors by forming irreversible complexes. Furthermore, 
tissue factor pathway inhibitor (TFPI) inhibits the initiation of coagulation. 
Thrombin-activatable fibrinolysis inhibitor (TAFI) inhibits fibrinolysis, thereby 
protecting a formed thrombus from lysis in the presence of large amounts of 
thrombin.
Abnormalities of the anticoagulant system
Most defects in the natural anticoagulant systems increase the tendency toward 
thrombosis. In the following paragraphs, deficiencies of the well-established 
thrombophilic abnormalities (i.e., deficiencies of protein C, protein S, and 
antithrombin) are discussed, as well as the evidence on less well-known candidates. 
Figure 1. Regulation of blood coagulation. Coagulation is initiated by a tissue 
factor (TF)/factor (F) VIIa complex that can activate FIX or FX. At high TF 
concentrations, FX is activated primarily by the TF/FVIIa complex, whereas at 
low tissue factor concentrations the contribution of the FIXa/FVIIIa complex 
to the activation of FX becomes more pronounced. Coagulation is maintained 
Chapter 5
64
through the activation by thrombin of FXI. The coagulation system is regulated 
by the protein C pathway. Thrombin activates protein C. Together with protein 
S (PS), activated protein C (APC) is capable of inactivating FVa and FVIIIa, 
which results in a downregulation of thrombin generation and consequently in an 
upregulation of the fibrinolytic system. The activity of thrombin is controlled by 
the inhibitor antithrombin. The solid arrows indicate activation and the dashed 
arrows indicate inhibition.
Figure 1. Regulation of blood coagulation. Coagulation is initiated by a tissue 
factor (TF)/factor (F) VIIa complex that can activate FIX or FX. At high TF 
concentrations, FX is activated primarily by the TF/FVIIa complex, whereas at 
low tissue factor concentrations the contribution of the FIXa/FVIIIa complex 
to the activation of FX becomes more pronounced. Coagulation is maintained 
through the activation by thrombin of FXI. The coagulation system is regulated 
by the protein C pathway. Thrombin activates protein C. Together with protein 
S (PS), activated protein C (APC) is capable of inactivating FVa and FVIIIa, 
which results in a downregulation of thrombin generation and consequently in an 
upregulation of the fibrinolytic system. The activity of thrombin is controlled by 
the inhibitor antithrombin. The solid arrows indicate activation and the dashed 
arrows indicate inhibition.
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Protein C Deficiency
Protein C deficiency appears to be quite rare, with a prevalence of 0.2% in 
the general population and 2.5 to 6% in patients with first VTE.2,3 Numerous 
mutations in the gene coding for protein C lead to several types of protein C 
deficiency and are summarized in a published database.4 In type I deficiency, 
levels of both antigen and activity are reduced, whereas in type II deficiency, 
antigen levels are normal but one or more functional defects lead to a decreased 
activity. Abnormalities in type II protein C deficiency can occur on sites of 
substrate binding, thrombomodulin interaction, or calcium binding. Most 
patients have heterozygous protein C deficiency with a protein C level  50% 
of normal. Homozygous protein C–deficient patients who completely lack the 
natural anticoagulant protein are extremely rare. These patients will develop a 
syndrome characterized by diffuse VTE with accompanying skin necrosis shortly 
after birth, known as neonatal purpura fulminans, which is fatal unless protein 
C is given in the form of protein C concentrate, fresh frozen plasma,5 or FIX 
concentrate (which contains a large amount of protein C and S) together with 
heparin.6 Homozygous or compound heterozygous patients with mutations 
leading to severely reduced but not absent levels of protein C do not have this 
clinical syndrome but may present with VTE in adulthood or will develop skin 
necrosis when exposed to vitamin K antagonists (VKA). These patients have 
protein C levels less than 20% of normal.7 
Protein S Deficiency
The prevalence of protein S deficiency in the general population is estimated 
between 0.026% and 0.13% in a Scottish study among healthy blood donors, 
and at 1 to 2% patients with first VTE episode8,9 . Protein S, in addition to being 
a cofactor to protein C, independently inhibits the prothrombinase and tenase 
complexes.10 The pattern of inheritance is autosomal dominant. One third 
of patients with protein S deficiencies will have VTE by the age of 60 years. 
Homozygosity is associated with neonatal purpura fulminans.5 Warfarin skin 
necrosis has been reported in protein S–deficient patients.11 
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Antithrombin Deficiency
Antithrombin directly inhibits thrombin and activated FIX, FX, and FXI by 
forming a covalent complex, a process that is accelerated 1000-fold by heparin and 
endogenous heparin-like substances. Antithrombin deficiency occurs in  0.02% 
of the general population and in 0.5 to 7.5% of patients presenting with a first 
VTE.12 Traditionally, antithrombin-deficient patients are considered at higher risk 
for thrombosis than patients with other congenital thrombophilic states, although 
this observation may be caused by selection of severely thrombophilic families 
in the early days of thrombophilia testing, when only antithrombin deficiency 
was known. However, the rarity of the deficiency may point to a more severe 
clinical expression. The inheritance pattern is autosomal dominant, and almost 
all patients are heterozygous. 
Activated Protein C Resistance and FV Leiden
FV Leiden (FVL) is responsible for at least 90% of APCresistant conditions. 
It is the most prevalent thrombophilic defect that occurs in 5 to 12% of the 
general population, with variations throughout the world.13 APC, together 
with its cofactor protein S, regulates the coagulation cascade by inactivating 
FVa and FVIIIa. APC cleaves FVa in three sites, but cleaving the first site at 
amino acid position 506 is necessary for better access to the other two sites. 
The mutation in the first site is known as FVL, and in the other site is described 
as FV Cambridge (at position 306)14 and FV Hong Kong.15 In carriers of FVL, 
FVa is inactivated approximately 10 times more slowly than normal,16 whereas 
the implications of the other mutations on APC resistance are not as strong.17 
No mutations at cleavage sites in FVIII were found that cause APC resistance.18 
Recently, through genome-wide scans in family studies, a locus on chromosome 
18 was described that appeared to influence normal variation in APC resistance 
and FVIII levels, as well as susceptibility to thrombosis.19 However, to date, this 
has not been confirmed by other groups. Other mechanisms for APC resistance 
are antiphospholipid antibody syndrome (APS),16 high concentration of FVIII,20 
and reduced levels of protein S.21 
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Prothrombin G20210A Mutation 
The second most prevalent form of thrombophilia is prothrombin G20210A. 
This mutation is found in 1% of the population, in 4 to 8% of patients with a 
first VTE.22 The proposed mechanism for thrombosis is elevation in the levels of 
normal prothrombin.23 A prothrombin level higher than 115% (90th percentile) 
results in a 2.1-fold increased VTE risk also in the absence of the prothrombin 
20210A mutation.23,24 However, carriers and noncarriers cannot be distinguished 
using the prothrombin level because there is a high degree of overlap between 
the groups.24 
Elevated Levels of Coagulation Factors 
As is the case for prothrombin (FII), increased levels of coagulation FVIII, FIX, 
FXI, and fibrinogen increase the risk of VTE.25–28 In several studies, elevated 
FVIII levels were shown to be quite prothrombotic, with a dose-dependent 5- to 
10-fold relative risk increase.25,29,30 For each 10% increase of FVIII, the VTE risk 
increases by 10% (95% confidence interval, 0.9 to 21.0),30 and this is independent 
of an acute-phase role of FVIII.29,31 Although the etiology of persistently elevated 
FVIII is not clear, it appears to be determined in part genetically in some 
patients,30,32 but not all studies confirm this.33 Elevated FIX was also shown to 
increase the risk of VTE 2.5-fold, independent of several potential confounders 
and other genetic defects.26 Elevated FXI is associated with a 2-fold risk increase 
for VTE.27 The likely mechanism for an elevation of FXI is excessive thrombin 
generation, which in turn leads to more thrombin deposition and downregulation 
of fibrinolysis by activation of TAFI.34 Finally, fibrinogen levels >500 mg/dL 
are associated with approximately a 4-fold risk increase of VTE,28 which was 
not explained by acute-phase reactions as measured by C-reactive protein.31 
Elevated levels of FV,35 FVII,28 and FX,36 have not shown to increase the risk for 
thrombosis. 
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Miscellaneous (candidate) Risk Factors
Hyperhomocysteinemia
Severe hyperhomocysteinemia or homocystinuria is a rare condition that is 
associated with strongly elevated levels of homocysteine (>100 mmol/L), premature 
arterial and VTE, mental retardation, and a Marfan-like stature.37 It is caused by 
homozygosity or compound heterozygosity of mutations in cystathionine-b-
synthase, whereas heterozygosity results in mild to moderate homocysteinemia. 
More than 90 mutations in this gene are known to cause homocystinuria.38 
The second gene that may be involved is methylenetetrahydrofolate reductase 
(MTHFR). Several mutations are known to increase the levels of homocysteine; 
homozygosity leading to MTHFR deficiency, however, is rare. Contrary to 
homocystinuria, mild hyperhomocysteinemia is common and, depending 
on chosen cutoff values, occurs in 5 to 10% of the population. A common 
thermolabile C677T polymorphism results in mild hyperhomocysteinemia in 
homozygotes who are low in folate, vitamin B12, or vitamin B6.39 It has remained 
a matter of debate whether mild homocysteinemia is a cause or consequence of 
VTE. The current opinion is that the association is mild; a 5 mmol/L increase in 
plasma level increases the risk for VTE by 1.27 in prospective studies, and by 
1.60 in retrospective studies.40 The presence of the homozygous TT677 MTHFR 
polymorphism increases the risk 1.20-fold, with no observed effect in studies in 
North America. It was hypothesized that this differential effect is explained by 
the higher folate intake in this part of the world.
Other natural anticoagulants
TFPI inhibits the coagulation process during its earliest phase. Levels below the 
10th percentile of values in control subjects were associated with a 1.7-fold risk 
increase for VTE in one study.41 
Fibrinolytic system 
Generally, impaired overall fibrinolysis appears to be associated with an increased 
risk for VTE, although the role of the individual components is not very clear.42 
No relationship has been found between deficiencies of plasminogen, levels of 
polymorphisms in the gene, and levels of polymorphisms in the gene coding for 
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tissuetype plasminogen activator, whereas increased levels of tissue plasminogen 
activator inhibitor type 1 have shown conflicting results.42 High levels of TAFI 
have been shown consistently to increase the risk for VTE.43–45
Miscellaneous
Although it has been hypothesized that deficiencies in the contact coagulation 
pathway, in particular FXII, may increase the risk of thrombosis because of a 
reduced fibrinolytic capacity, several studies have indicated that FXII deficiency 
does not increase the risk of VTE.46,47 
Acquired Thrombophilia 
Antiphospholipid antibody syndrome 
APS is an autoimmune disorder defined as venous and/ or arterial thrombosis 
or recurrent pregnancy loss in the presence of persistent antibodies against 
phospholipids or phospholipid-binding proteins, and is categorized into primary 
and secondary status based on presence of autoimmune diseases such as systemic 
lupus erythematosus.48 The syndrome is not common in consecutive patients with 
VTE, although the prevalence of isolated antiphospholipid antibodies measured 
on a single occasion in healthy subjects is not uncommon, and is only a weak 
risk factor for VTE.46 The presence of lupus anticoagulant, however, is associated 
with a 5- to 16- fold increased risk for VTE.49 
Implications of testing for thrombophilia
Given that, at present, a thrombophilic defect can be demonstrated in more 
than 50% of the patients who present with a VTE, the tendency to test patients 
for thrombophilia has increased tremendously. However, the usefulness and 
cost effectiveness of testing is a matter of debate.51,52 The (dis)advantages and 
implications of thrombophilia testing are discussed in the following section. 
Reasons for testing for thrombophilia might be clarification of the cause, the 
possibility to adjust therapeutic regimes of VTE in thrombophilic patients for 
the optimal prevention of recurrence, and the possibility to track asymptomatic 
family members (and subsequently take preventive measures). Conversely, testing 
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for thrombophilia might lead to needless expenses, anxiety, and social problems. 
Reasons to Test for Thrombophilia 
It is often argued that patients and their doctors would like to have an explanation 
for the episode of VTE, although this has never been explicitly studied. It should 
be realized however, that the existence of a thrombophilic defect does not 
exclude other reasons for a prothrombotic state. For example, a 60-year-old male 
presenting with an idiopathic deep VTE of the leg might have an occult cancer 
as well as a thrombophilic defect. An important argument in favor of testing 
for thrombophilia would be the possibility to adjust therapeutic measures for 
treatment of a VTE (by means of intensity or duration of treatment). The optimal 
therapy for VTE depends on the risk of recurrence, the (dis)- comfort of the 
therapy and the risk of side effects, such as (major) bleeding. The estimated risk 
of recurrence for VTE, in general, is 5% per year,52,53 although idiopathic episodes 
tend to recur more frequently (20% in the first 2 years) compared with provoked 
episodes.54 Standard therapy for patients with a first VTE includes anticoagulant 
treatment with VKAs for 3 to 6 months, with international normalized ratios 
between 2 and 3.55 This therapy ensues an annual bleeding risk of 0.25% for 
fatal bleeding and 1.0% for life-threatening bleeding.56,57 A different approach to 
thrombophilic patients, compared with nonthrombophilic patients, is only justified 
if the former have a different risk of recurrence. Even though thrombophilia has 
shown to increase the risk of a first VTE, it is to date still controversial whether 
thrombophilia also increases the risk of recurrent VTE. The estimated relative 
risk of recurrence in patients with thrombophilia is small, compared with patients 
without thrombophilia (Table 1). The estimated odds ratios (ORs) for the natural 
anticoagulant deficiencies, as described mainly in retrospective analyses, were 
2.5.58–60 In one prospective study, the follow- up of the Leiden Thrombophilia 
Study (LETS), the risk of recurrence appeared even more moderate, with an OR 
of 1.8.61 Two meta-analyses studied the risks of recurrence in patients with the 
common thrombophilias: FVL and the prothrombin G20210A mutation. The risk 
of recurrence was found consistently to be 1.3- to 1.4-fold higher in patients 
with FVL and 1.4- to 1.7-fold higher in patients with the prothrombin mutation. 
62,63 For the other thrombophilic defects, less data are available. Three studies 
assessed the risk of recurrence in patients with high levels of FVIII coagulant 
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activity (FVIII:c) compared with patients with normal levels. One case-control 
study showed that elevated levels of FVIII:c above 150% were associated with an 
approximate 2-fold increased risk of recurrent VTE, compared with patients with 
a single episode.30 In two cohort studies, the estimated relative risk of recurrent 
VTE was 6-fold increased in those with FVIII:c levels above the 90th percentile, 
corresponding to 234% and 294%, respectively.64,65 These results could not be 
reproduced in the LETS follow-up study, in which an OR of only 1.3 was found.61 
The data on estimated risk of recurrence for elevated levels of FIX and FXI are 
scarce, but their impact on recurrence seems negligible.61 The attribution of mild 
hyperhomocysteinemia in terms of risk of recurrence appears low (1.8 to 2.7),66–
68 and treating hyperhomocysteinemia did not show a decrease in the number 
of recurrences. 67 The risk of recurrence in antiphospholipid or anticardiolipin 
antibodies was investigated in four studies. 69–72 The outcomes regarding relative 
risk for recurrence range between 2- and 6-fold. These results are difficult to 
interpret, given that in these studies the antiphospholipid and anticardiolipin 
antibodies or lupus anticoagulant were not tested repetitively (as suggested by 
international guidelines48). Moreover, duration of anticoagulant treatment differed 
substantially. Adjustment of anticoagulant treatment in thrombophilic patients 
after a first VTE has only been addressed for a difference in intensity. This has 
not shown to be beneficial in patients with VTE, regardless of thrombophilia. 
Reducing the intensity of VKAs below 2.0 led to an increase of recurrence 
risk (1.9 versus 0.6%),73,74 whereas major bleeding complications did not differ 
between a low-intensity and regular-intensity treatment (0.96 versus 0.93%).73 A 
higher intensity of VKA in patients with antiphospholipid antibodies showed no 
reduction in the risk of recurrence, but led to an increase in the bleeding risk.75,76 
Whether clinical outcome of patients with VTE and thrombophilia improves 
with prolongation of anticoagulant has never been investigated. Current trials 
focus on whether such an intervention outweighs the bleeding risk, given that it 
is known that oral anticoagulant medication prevents VTE by more than 90%, 
as long as it is used.77 Finally, a potential advantage of testing patients with VTE 
for thrombophilia may be the identification of asymptomatic family members. 
These individuals have a 2- to 10-fold increased risk for VTE as compared with 
noncarriers.78–81 Regardless of this increased relative risk, the overall absolute risk 
remains low (Table 2). It is often argued that asymptomatic family members with 
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thrombophilia may benefit from targeted prevention in high-risk situations (e.g., 
pregnancy, puerperium, surgery,immobilization, and trauma), and the avoidance 
of acquired risk factors, most notably oral contraceptives. It is clear from Table 2 
that bleeding risk associated with continuous anticoagulant treatment outweighs 
the risk of VTE. It is notable that the figures considering surgery, trauma, and 
immobilization, as shown in Table 2, have been collected for the larger part 
in times before standard prophylaxis was routine patient care. For pregnancy, 
80% of the episodes occur in the postpartum period. Whether this should lead to 
administration of prophylaxis in the postpartum period is a matter of physician 
and patient preference, given that the number needed to treat is 25 in case of 
a deficiency in the natural anticoagulants and approximately twice as high in 
patients with the common thrombophilias. Finally, it is clear from data in Table 
2 that the use of oral contraceptives should be weighed against the disadvantages 
of other contraceptive methods. 
Table 1. Estimated Relative Risk of VTE Recurrence in Patients with 
Thrombophilia
Type of Thrombophilia Relative Risk
Natural anticoagulant deficiencies 1.8-2.558-61
FVL 1.3-1.462,63
Prothrombin 20210A 1.4-1.762,63
Elevated FVIII:c 1.3-661,64,65
Elevated levels of FIX 1.261
Elevated levels of FXI 0.661
Mild hyperhomocysteinemia 1.8-2.766-68
Antiphospholipid antibodies 2-669-72
VTE, venous thromboembolism; FVL, factor V Leiden; FVIII:c, factor VIII coagulation activity; 
F, factor.
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Table 2.  Absolute Risk of VTE in Asymptomatic Carriers of Thrombophilia
Type of Thrombophilia Overall Risk (%/
year)
Surgery, Trauma, 
or Immobilization 
(%/episode)
Pregnancy (%/
pregnancy)
Oral Contraceptive 
Use (%/year of use)
Natural anticoagulant 
deficiencies
0.4-4.078,87-91 8.178 4.178 4.378
FVL 0.1-
0.778,80,81,87,90,92,94
1.8-2.481 1.9-2.178,81 0.5-2.078,81
Prothrombin 20210A 0.1-0.494-97 2.095 2.895 0.295
Elevated FVIII:c 0.397 1.297 1.397 0.697
Mild hyperhomocysteinemia 0.298 0.998 0.598 0.198
VTE, venous thromboembolism; FVL, factor V Leiden; FVIII:c, factor VIII coagulant activity; 
F,factor.
Reasons Not to Test for Thrombophilia 
Disadvantages of testing patients with a VTE for thrombophilia might be the cost 
of testing, which is approximately s500.51 Several sophisticated studies focused 
on the cost effectiveness of testing for thrombophilia. 82,83 These studies focused 
on selected patient groups, because universal testing was considered less cost 
effective. It is of note that the external validity of the results may be distorted 
by the fact that the findings were based on a range of various assumptions. One 
study, by Marchetti et al,82 assessed the cost effectiveness of testing for double 
heterozygosity of FVL and the prothrombin mutation, and subsequently prolonging 
anticoagulant therapy in those tested positive for both common thrombophilias. 
This strategy was considered cost effective, given that testing all patients with 
VTE provided one additional day of life at the cost of $13.624/quality-adjusted 
life-years.82 The Thrombosis: Risk and Economic Assessment of Thrombophilia 
Screening study assumed that testing for thrombophilia might be efficacious in 
high-risk situations.83 The cost effectiveness of four different testing scenarios 
was calculated: (1) testing all women prior to prescription of oral contraceptives 
and restricting prescription only to those tested negative for thrombophilia; 
(2) testing all women prior to prescribing hormone replacement therapy and 
restricting prescription only to those tested negative for thrombophilia; (3) testing 
women at the onset of pregnancy and prescribing prophylaxis to those tested 
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positive for thrombophilia; and (4) testing all patients prior to major elective 
orthopedic surgery and prescribing extended thromboprophylaxis to those tested 
positive for thrombophilia. It was concluded in this study that the second scenario 
would be most cost effective, compared with the other scenarios. Nevertheless, 
selective screening based on the presence of previous personal or family history 
of VTE was considered to be more cost effective than universal testing in the four 
different scenarios.
Furthermore, the psychological impact and consequences of knowing that one is 
a carrier of a (genetic) thrombophilic defect could be regarded as a drawback of 
testing. Most studies that focused on impact of testing for thrombophilia showed 
that patients had experienced low psychological distress following thrombophilia 
testing. 84,85 Nevertheless, qualitative studies described several negative effects. 
In the study by Bank et al,86 it is mentioned that parents were worried that their 
children ‘‘would be negatively influenced by factor V Leiden’’ and that some 
carriers ‘‘felt stigmatized.’’ Finally, a disadvantage of testing for thrombophilia 
could be its potential social consequences (for instance, problems with health 
insurance or life insurance), although little data are available on this issue. 
Conclusions
The discovery of newer thrombophilic defects has led to a deeper insight in the 
development of VTE during the last decades. However, testing patients with 
VTE, with respect to its advantages and disadvantages, has so far no direct 
consequences in terms of different treatment strategies. Given the absence of 
clear benefits, thrombophilia testing should be performed with restraint.
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Abstract 
Background
Low-molecular-weight heparin (LMWH) is the drug of choice to prevent venous 
thrombosis in pregnancy, but the optimal dose for prevention while avoiding 
bleeding is unclear. We investigated whether therapeutic doses of LMWH 
increase the incidence of postpartum hemorrhage in a retrospective controlled 
cohort study.
Methods
We identified all pregnant women who received therapeutic doses of LMWH 
between 1995 and 2008 in the Academic Medical Center, Amsterdam, The 
Netherlands. The controls were women registered for antenatal care in the same 
hospital who did not use LMWH during pregnancy, matched by random electronic 
selection for age, parity and delivery date to LMWH users. We compared the 
incidence of PPH (blood loss> 500 mL), incidence of severe PPH (blood loss> 
1000 mL) and the median blood loss in two cohorts of LMWH users and non-
users. 
Results
The incidence of PPH was 18% in LMWH users (N=95) and 22% in non-users 
(N=524) (RR 0.8; 95%CI 0.5 to 1.4). The incidence of severe PPH was 6% in 
both groups (RR 1.2; 0.5 to 2.9). Median amount of blood loss differed only in 
normal vaginal deliveries. It was 200 mL in LMWH users and 300 mL in non-
users (difference -100 mL; 95%CI -156 to -44). 
Conclusion
We observed that therapeutic doses of LMWH in pregnancy was not associated 
with clinically meaningful increase in the incidence of PPH or severe PPH in 
women delivered in our hospital although this observation may be confounded 
by differential use of strategies to prevent bleeding. A randomized controlled trial 
is necessary to provide a definite answer about the optimal dose of LMWH in 
pregnancy.
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Introduction
Low-molecular-weight heparin (LMWH) is the drug of choice in pregnant 
women requiring prophylaxis or treatment for venous thrombosis. However, the 
optimal dose with respect to efficacy and safety is uncertain.1 LMWH has the 
disadvantage that its anticoagulant effect can only be partially antagonized. This 
is of particular importance with respect to its use in high doses and raises concerns 
about an increased risk of bleeding, most notably postpartum hemorrhage (PPH), 
when used in pregnant women. 
PPH is defined by the World Health Organization (WHO) as postpartum blood 
loss in excess of 500 mL.2 However, since other definitions have been suggested,3 
we classified blood loss more than 1000 mL as severe PPH.  PPH has an incidence 
of 19% in nulliparous deliveries in the Netherlands.4 The diagnosis encompasses 
excessive blood loss from uterus, cervix, vagina and perineum. The commonest 
cause of primary PPH (PPH < 24 hours following delivery) is uterine atony.5 In 
order to limit the risk of PPH, current guidelines recommend discontinuation of 
LMWH 12 to 24 hours prior to delivery.1;6 However, as labour can commence 
spontaneously, timely discontinuation cannot be guaranteed. The risk of PPH 
associated with use of LMWH has been assessed in several studies.3;7-13 These 
studies either included a small or an unknown number of women treated with 
therapeutic doses of LMWH 3;7-10 or they lacked a control group of women who 
did not use LMWH.7;9-11;13 Only two studies report the bleeding risk associated 
with antepartum therapeutic doses of LMWH: a prospective multicenter survey 
in the UK and Ireland and a systematic review of studies about LMWH use in 
pregnancy.11;13  Blood loss more than 500 mL was observed in 6/126 (4.8%) and 
3/174 (1.7%) of women who were treated with therapeutic doses of LMWH in 
these two studies respectively. On the other hand, significant failure rates have 
been observed despite prophylaxis with low-dose LMWH in pregnancy.14-16 In our 
hospital, pregnant women whom we judge to require anticoagulant prophylaxis 
are treated with therapeutic doses of LMWH. This protocol was based on a 
systematic review that we performed in 1998.14 In this review of several cohorts 
of women, recurrent venous thromboembolism (VTE) occurred in 2.0% (3/149) 
of pregnant women, all of whom were treated with prophylactic or intermediate 
doses of LMWH. Similar findings were reported in another large cohort study in 
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which 7 of 8 recurrent episodes of VTE occurred in women on prophylactic or 
intermediate doses of enoxaparin.15
We performed a controlled cohort study in our hospital to assess the risk of PPH 
associated with therapeutic doses of LMWH in pregnant women.
Material and methods
Identification of study cohorts
By hospital protocol, anti-Xa levels were measured at one-month intervals in 
women who were treated with therapeutic doses of LMWH or heparinoid during 
pregnancy. Thus, our study cohort was identified by collection of hospital ID 
numbers in whom anti-Xa measurements were performed between mid-August 
1995 and mid-February 2008. We reviewed charts to assess whether the anti-
Xa measurements were performed during pregnancy. Inclusion criteria were: 
therapeutic doses of LMWH, pregnancy duration of at least 25 weeks gestation, 
and delivery in the Academic Medical Center (AMC).
The control cohort consisted of women who had been registered for antenatal 
care in the AMC before 24 weeks gestational age, delivered in the AMC and 
did not use LMWH during their pregnancy. Women treated with LMWH and 
controls were matched by random electronic selection for age (±2 years), parity 
(nulliparous or multiparous) and date of delivery (±1 year) in a 1:6 ratio. This 
study was approved by the Medical Ethics Committee of the Academic Medical 
Center in Amsterdam.
Intervention
The hospital protocol was to base LMWH doses on body weight prior to 
pregnancy, in which the therapeutic dose of LMWH was prescribed according to 
the manufacturer (Table 1).   
All women were seen at the outpatient clinic of the Department of Vascular 
Medicine with regular intervals in which measurements of anti-Xa levels 
were performed. Dose-adjustments were only done if peak anti-Xa activity 
was lower than 0.4 or higher than 1.2 anti-Xa units on repeated occasions. A 
multidisciplinary team of obstetricians and vascular medicine experts discussed 
patients at regular intervals. Women were advised to discontinue LMWH as soon 
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as either contractions started, membranes ruptured or administer the last injection 
the morning prior to the day that induction of labour or a cesarean section was 
planned. Also women were informed that epidural or spinal anesthesia was 
contraindicated within 24 hours after the last dose of LMWH. Management of 
postpartum hemorrhage was performed at the attending obstetrician’s discretion.
Table 1. Types of LMWH administered and the median and range of the doses 
per day
LMWH type N Median* Range Weight range
Enoxaparin, mg 16 120 60 to 200 53 to 116
Dalteparin, IU anti-Xa 9 15000 10000 to 20000 64 to 115
Nadroparin, IU anti-Xa 64
   <75 kg 33 11400 11400 to 15200 48 to 74
   ≥75 kg 31 15200 11400 to 20900 75 to 117
Danaparoid, IU anti-Xa 3 4000 3000 to 4500 55 to 66
Tinzaparin, IU anti-Xa 3 18000 14000 to 28000 75 to 82
* Doses are presented in mg for enoxaparin and IU for other LMWHs
Outcomes
The primary outcomes were PPH and severe PPH defined as the amount of blood 
loss estimated by the attending obstetrician or midwife of more than 500 mL 
and more than 1000 mL respectively, within 24 hours of delivery. Secondary 
outcomes were the estimated amount of blood loss in mL, blood transfusions in 
the first week postpartum, and recurrent VTE.
Statistical analysis
We calculated the incidence of PPH and severe PPH for LMWH users and non-
users. Relative risks (RR) of PPH and severe PPH and their 95%CI in pregnant 
women treated with therapeutic doses of LMWH compared to non-users 
were calculated. Non-normally distributed data are presented as medians. We 
calculated the median blood loss difference between two cohorts of women and 
its 95%CI. Furthermore, we compared the median blood loss of both groups in 
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strata of a priori defined other risk factors, if kwn (i.e. type of vaginal delivery 
[normal versus assisted] or cesarean section [elective versus emergency], perineal 
laceration degree and ethnicity) to investigate their interaction with LMWH on 
the incidence of PPH. Blood transfusion in the first 24 hours of delivery was 
compared between two groups of the study using the X2 test.
Results 
We identified 95 women who used therapeutic doses of LMWH during pregnancy 
for various indications (see Figure 1 for case selection) and 524 women as control 
cohort who did not use LMWH in their pregnancy. Baseline characteristics of the 
study groups are shown in Table 2. Median gestational age (range) was 39 (26-44) 
weeks in LMWH users and 39 (25-43) in non-users. In both cohorts, almost 93% 
of vaginal deliveries proceeded spontaneously (normal vaginal delivery) and 7% 
needed assistance. Almost one-quarter (23 %) of the women treated with LMWH 
delivered by cesarean sections; half of these were elective, i.e. planned before 
onset of labour. In the control cohort 10% of the women underwent cesarean 
sections, most were emergency cesarean sections (90%). 
Table 3 demonstrates the outcomes of the study, some stratified for types and 
subtypes of delivery. PPH occurred in 18% of women who used therapeutic 
doses of LMWH and in 22% of controls (RR for PPH: 0.8; 95%CI: 0.5 to 1.4). 
The incidence of severe PPH (6%) was the same in two groups of LMWH users 
and non-users (RR for severe PPH: 1.2; 95%CI: 0.5 to 2.9). The risk of PPH 
and severe PPH after vaginal or cesarean section delivery was not statistically 
significant different between two groups of women.
Median blood loss after vaginal delivery was 250 (range, 50 to 4000) and 300 
(20 to 3600) mL in LMWH users and non-users respectively (median difference 
-50; 95%CI: -102 to 2). After cesarean section, it was 425 (200 to 2000) mL in 
LMWH users and 400 (100 to 2000) mL in non-users (25; -153 to 203). Median 
blood loss stratified for subtypes of delivery differed between LMWH users and 
non-users only after normal vaginal deliveries (200 (range, 50 to 4000) and 300 
(20 to 3600) mL in LMWH users and non-users respectively. 
Median blood loss did not differ between groups after stratification for ethnicity 
and perineal laceration degree (data not shown).
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Blood transfusion was given, at the discretion of the attending obstetrician, in 5% 
of LMWH users and 3% of non-users after delivery (OR 1.6; 95%CI: 0.6 to 4.3).
In terms of efficacy, recurrent VTE was suspected in one woman (1.2%, 95%CI 
0.6-5.8) despite the use of therapeutic doses of LMWH. However, a recurrent 
episode was not confirmed as ventilation/perfusion scintigraphy revealed a 
perfusion defect on the same localization as the previous PE. 
Figure 1. inclusion flowchart of women treated with LMWH.
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Table 2. Baseline characteristics of the two study groups 
Women who used 
therapeutic dose of 
LMWH (N=95)
Women who did 
not use LMWH 
(N=524)
Age, years Median (range) 32 (21-43) 31 (18-44)
Ethnicity N (% ) 
Caucasian 67 (70) 264 (50)
African 14 (15) 167 (32)
Others/unknown* 14 (15) 93 (18)
Gestational age, weeks Median (range) 39 (26-44) 39 (25-43)
Delivery route 
Vaginal N (% of all women) 73 (77) 472 (90)
Normal delivery, (% of vaginal deliveries) 67 (92) 437 (93)
Assisted delivery, (% of vaginal deliveries) 6 (8) 35 (7)
Cesarean section N (% of all women) 22 (23) 52 (10)
Primary cesarean section, (% of cesarean sections) 11 (50) 5 (10)
Emergency cesarean section, (% of cesarean sections) 11 (50) 47 (90)
Perineal laceration degree N (% of vaginal deliveries) 
1st degree 7 (10) 43 (9)
2nd degree, Episiotomy 12 (16) 59 (12)
2nd degree, Spontaneous rupture 24 (33) 100 (22)
3rd degree 0 (0) 7 (1)
No laceration 29 (40) 263 (56)
Unknown 1 (1) -
Birth weight, grams Median (range) 3150 (365-4290) 3235 (555-5035)
Indication for LMWH administration N (% of all women)
History of VTE 15 (16)
History of VTE and thrombophilia 52 (55)
Current VTE† 11 (12)
Current VTE† and  thrombophilia 2 (2)
Recurrent thrombophlebitis and thrombophilia 1 (1)
Antiphospholipid syndrome 4 (4)
Pre-eclampsia 1 (1)
Prosthetic heart valve 7 (7)
Prosthetic heart valve+ current heart thrombosis 1 (1)
Current CVA 1 (1)
*Data on ethnicity for 2 cases was missing, †VTE during current pregnancy
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Table 3. Incidence of PPH, severe PPH and median (range) of blood loss stratified 
for types of deliveries and blood transfusion rate in two groups of the study 
Discussion 
We observed that the incidence of severe bleeding during delivery was not 
increased by using therapeutic doses of LMWH during pregnancy, though a non-
statistically significant increase in the risk of severe PPH was noticed. 
Similar to our finding, a previous study reported no difference in the risk of PPH 
(5.7%)  in women who delivered vaginally and used LMWH (doses not specified) 
and those who did not use LMWH (OR 1.0; 95%CI: 0.2 to 4.7).3 However, the 
absolute risk of PPH in our study cohorts (12% in LMWH users and 21% in non-
LMWH users) was relatively higher. Although the incidence of PPH in our control 
group appears to be higher as compared to other studies that assessed PPH in the 
general population,17-19 a previously performed population-based cohort study 
in the Netherlands also observed an incidence of PPH of 19%.4 An explanation 
could be the difference in blood loss estimation and in treatment regimens. In 
the Netherlands, an active management in the third stage of delivery (such as 
prophylactic administration of oxytocics, immediate cord clamping or controlled 
cord traction) is not routinely performed, although oxytocics administered in the 
Women who used therapeutic 
doses of LMWH (N=95)
Women who did not use 
LMWH (N=524)
RR Median 
difference
95%CI of RR or 
median difference
PPH events N (%) 17 (18) 113 (22) 0.8 0.5 to 1.4
   Vaginal delivery 9 (12) 100 (21) 0.5 0.3 to 1.1
   Cesarean section 8 (36) 13 (25) 1.7 0.6 to 5.0
Severe PPH events N (%) 6 (6) 29 (6) 1.2 - 0.5 to 2.9
   Vaginal delivery 4 (5) 27 (6) 0.9 0.3 to 2.8
   Cesarean section 2 (9) 2 (4) 2.5 0.3 to 18.9
Blood loss Median (range)
   Vaginal delivery 250 (50 to 4000) 300 (20 to 3600) - -50 -102 to 2
        Normal vaginal delivery 200 (50 to 4000) 300 (20 to 3600) - -100 -156 to -44
        Assisted vaginal delivery 350 (250 to 550) 400 (100 to 2500) - -50 -217 to 117
   Cesarean section 425 (200 to 2000) 400 (100 to 2000) - 25 -153 to 203
        Primary cesarean section 450 (200 to 1200) 200 (100 to 400) - 250 -15 to 515
        Emergency cesarean section  400 (200 to 2000) 400 (100 to 2000) - 0 -225 to 225
Blood transfusion N (%) 5 (5) 18 (3) 1.6 - 0. 6 to 4.3 
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third stage of delivery have been shown to reduce the amount of blood loss.20 
Therefore we hypothesize that withholding oxytocics might have led to a higher 
incidence of PPH in our control cohort, whereas this was not observed in the 
treated women since LMWH use warranted an active management of the third 
stage of delivery according to the hospital protocol. Furthermore, as our hospital 
is a tertiary referral center, the observed high incidence of blood loss more than 
500 mL in the control cohort may be explained by comorbidities that increase the 
risk of a complicated delivery. 
For cesarian section, the incidence of severe PPH may be more relevant to evaluate 
since blood loss between 500 and 1000 mL is not considered uncommon during 
surgery. Severe PPH risk was 2.5 times higher (95%CI: 0.3 to 18.9) in women 
who used LMWH as compared to those who did not, although the certainty of this 
estimate is limited by the small number of individuals in this stratum. In another 
study where the doses of the administered LMWH was not specified, the risk of 
severe PPH for LMWH users (5%) in cesarean sections was surprisingly stated 
half of the controls (12.5%) (OR 0.4; 95%CI: 0.04 to 3.4).3
Although this is the largest cohort of pregnancies treated with high doses of 
LMWH, its power to calculate the risk of PPH is limited and is at most 44% 
in calculating the relative risk of PPH in vaginal deliveries. Therefore we 
compared the median of blood loss between cohorts of LMWH users and non-
users considering that median is less sensitive to outliers. The only difference in 
median blood loss was found in the subgroup of normal vaginal deliveries where 
it was lower in the LMWH users.
Some issues warrant comment. First, although this was a controlled cohort study, 
it is likely that strategies to decrease the risk of PPH differed between women 
who were treated with LMWH and controls. Given the observational study 
design, our study does not exclude an increased risk of PPH by use of therapeutic 
LMWH if similar obstetric measures are taken. Second, we have not measured 
anti-Xa
 
levels shortly prior to delivery, since this was not part of the hospital 
protocol. However, the advice given to all women reflects a real life situation 
(i.e. to discontinue LMWH when contractions started, membranes ruptured 
or the evening before the planned induction of labour or cesarean section). 
Furthermore, evidence about the association between this duration and the risk 
of PPH is conflicting.8;9;21 Third, blood loss was estimated rather than measured 
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which may have led to higher estimates.22 This was done similarly in women 
treated and untreated with LMWH. If any, it is more likely that blood loss would 
be overestimated rather than underestimated in women who used LMWH than in 
women without LMWH. 
In conclusion, we observed that therapeutic doses of LMWH administered in 
pregnancy was not associated with clinically meaningful increase in the incidence 
of PPH or severe PPH in women who delivered in our hospital. Although this 
observation may be confounded by differential use of strategies to prevent 
bleeding, it is unlikely that LMWH levels in blood at the time of delivery can cause 
PPH knowing the routine recommendations to stop the injections when signs of 
labor start.  A randomized controlled trial to assess the safety of therapeutic doses 
of LMWH to prevent venous thromboembolism in pregnant women is necessary 
to provide a definite answer about the optimal dose of LMWH in this population.
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Abstract
Background
The effect of cardiovascular risk factors (CVRs) and thrombophilic defects on 
the risk of arterial cardiovascular complications in patients with prior venous 
thromboembolism (VTE) is unclear. 
Objective
We investigated whether the risk of arterial cardiovascular complication is 
increased after VTE and whether CVRs and thrombophilic defects influence this 
risk.
Methods
Subjects were selected from 3 family cohorts of probands with VTE or arterial 
cardiovascular complication before the age of 50 and thrombophilic defects 
(i.e. hyperhomocysteinemia, prothrombin G20210A or elevated FVIII). For this 
analysis, probands with arterial cardiovascular complications before inclusion 
and their relatives as well as relatives without the studied thrombophilic 
defects were excluded. We calculated the incidence of arterial cardiovascular 
complications (e.g. myocardial infarction, ischemic stroke, transient ischemic 
attack or peripheral arterial disease) in subjects with and without VTE and 
adjusted the relative risk for at least one CVR, two or more thrombophilic defects 
and quintiles of a propensity score (considering risk factors conditional to VTE 
history). 
Results
861 subjects were included, of whom 399 had experienced VTE before inclusion. 
12 arterial cardiovascular complications occurred in subjects with and 9 in subjects 
without VTE history. Hence the annual incidence was 1.0 (95%CI, 0.5-1.7) and 
0.7 (0.3-1.2) in subjects with and without VTE (RR 1.5, 0.6-3.6). Adjusting for 
possible confounders did not change this relative risk.
Conclusion
The mildly elevated risk of arterial cardiovascular complications in patients 
with prior VTE appears to be independent of cardiovascular risk factors and 
thrombophilic defects.
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Introduction
Following the observation of higher prevalence of subclinical atherosclerosis 
in patients with previous idiopathic venous thromboembolism (VTE) in 2003,1 
several studies have investigated the association between venous and arterial 
thrombosis. A mildly increased risk of arterial cardiovascular complications in 
patients with previous VTE has been demonstrated consistently2-6. A plausible 
explanation of such an association might be the presence of shared risk factors 
between VTE and arterial cardiovascular complication7-9. However, two large 
cohort studies were unable to establish a link between atherosclerosis at baseline 
and venous thrombosis during follow-up.10;11 As the study populations in various 
published cohorts differ, we intended to confirm the increased risk of arterial 
cardiovascular complications after an episode of VTE in three prospective cohorts 
of thrombophilic families. More important, we aimed to investigate whether the 
presence of multiple conventional cardiovascular risk factors and thrombophilic 
defects are able to explain the risk increase.  
Materials and methods
Study population
The study subjects were selected from three cohorts of thrombophilic families 
which were identified by probands with documented VTE or premature arterial 
cardiovascular complications (any event before 50 years of age) and either 
hyperhomocysteinemia, prothrombin G20210A or persistently elevated levels of 
factor VIII. Subjects were recruited between August 1997 and May 2004 from 
three academic hospitals: Academic Medical Center, Amsterdam, University 
Medical Center, Groningen and Academic Hospital Maastricht. Details of these 
studies have been published previously.12-14 The study was approved by the 
institutional review boards of the participating hospitals. Additional thrombophilia 
tests for factor V Leiden and deficiencies of antithrombin, protein S and protein C 
were performed in all participants. Detailed information about previous episodes 
of VTE and arterial cardiovascular complication, exposure to exogenous risk 
factors for thrombosis and anticoagulant treatment was collected by validated 
questionnaire and by reviewing medical records at baseline. Also, cardiovascular 
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risk factors namely smoking, diabetes mellitus, hyperlipidemia and hypertension 
were recorded at inclusion.
Outcome
The outcome of this analysis was the first arterial cardiovascular complication 
as myocardial infarction (MI), ischemic stroke, transient ischemic attack (TIA) 
or peripheral arterial disease. Coronary and peripheral arterial disease had to be 
symptomatically and angiographically proven while MI was diagnosed according 
to clinical, enzymatic and electrocardiographic criteria. Ischemic stroke was 
defined as the onset of rapidly developing symptoms and signs of cerebral 
function loss which lasted at least 24 hours and had an apparent vascular cause, 
as demonstrated by computed tomography scan or magnetic resonance imaging. 
If a cerebral event completely resolved within 24 hours without cerebral lesions 
at scanning, it was classified as TIA.12 We contacted subjects every 6 months until 
April 2006, with a detailed questionnaire to identify new episodes of VTE and 
arterial cardiovascular complication, exposure to risk factors and medication use. 
Statistical analysis
To evaluate whether the risk of arterial cardiovascular complication is higher in 
subjects with history of VTE than those without, we excluded probands who had 
had arterial cardiovascular complication prior to the enrollment, as well as their 
relatives, because of higher risk of a recurrent event or the possible hereditary 
inclination to develop an event. Similarly, relatives with arterial cardiovascular 
complication before baseline were excluded. Furthermore, in order to compare 
subjects with comparable genetic background regarding thrombophilic defects, 
we excluded relatives with none of the three thrombophilic defects originally 
qualifying for inclusion.
The annual incidence (95% confidence interval [95%CI]) of the outcome was 
computed for two groups of subjects, with and without history of VTE. The follow-
up period was defined as years between the inclusion date and the date of death, 
last contact visit or when an arterial cardiovascular complication occurred. The 
relative risk of arterial cardiovascular complication was computed by dividing 
the incidences of two groups. Potential confounders for the observed relative 
risk were considered as the presence of conventional cardiovascular risk factors 
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(i.e. smoking, diabetes mellitus, hyperlipidemia and hypertension and obesity 
(BMI≥25 kg/m2)) and thrombophilic defects. We computed the Mantel-Haenszel 
adjusted relative risk for the presence of at least one cardiovascular risk factor and 
two or more thrombophilic defects. We also developed a propensity score which 
is the probability of experiencing VTE, based on individual characteristics (i.e. 
age, cardiovascular risk factors and thrombophilic defects) using binary logistic 
regression model and subsequently computed the Mantel-Haenszel adjusted 
relative risk for the quintals of the propensity score.15 Finally, to exclude the 
protective effect of anticoagulation on the development of arterial thrombosis, 
we subtracted periods of anticoagulation treatment from the follow-up period. 
Results 
A total of 861 subjects met the inclusion criteria for this analysis (Figure 1): 
399 subjects (317 probands and 82 relatives) had experienced VTE prior to 
enrollment and 462 subjects (all relatives) had not. During follow-up, 21 subjects 
experienced an arterial cardiovascular event, of whom 12 had a history of VTE 
and 9 did not. The median follow-up duration was 3 years (range: 0.1-7) and 
did not differ between subjects with and without VTE. The annual incidence 
rate of arterial cardiovascular events was 1.0 (95%CI 0.5-1.7) in subjects with 
previous VTE, and 0.7 (0.3-1.2) in those without past VTE (RR 1.5; 95%CI 0.6-
3.6). Table 1 shows the baseline characteristics of the two groups. Sex and age 
were balanced between both groups as were classical cardiovascular risk factors 
except for obesity which was more prevalent in subjects with a history of VTE 
(22% versus 16%). The thrombophilic defects that were qualified for inclusion, 
i.e. hyperhomocysteinemia, prothrombin G20210A mutation and elevated levels 
of FVIII, were present in 30%, 33% and 58% of subjects with a history of VTE, 
and in 39%, 35% and 49% in the subjects without previous VTE. Overall, the 
prevalences of co-inherited thrombophilic defects were somewhat higher in the 
group with a history of VTE, i.e. 24% versus 15% for the FV Leiden mutation, 
3% versus 1% for protein S deficiency, 2% versus 1% for protein C deficiency 
and 2% versus 0.2% for antithrombin deficiency.
Table 2 shows the distribution of cardiovascular risk factors and thrombophilic 
defects of the subjects who experienced arterial cardiovascular events during 
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follow-up, stratified for history of VTE. Adjusting the observed relative risk 
for arterial cardiovascular events in subjects with a history of VTE versus 
those without previous VTE for the presence of at least one cardiovascular risk 
factor and for two or more thrombophilic defects did not changes the relative 
risk estimate (1.5 ; 95%CI 0.7-3.3 and 1.5; 0.7-3.3 respectively). Likewise, the 
adjusted relative risk for quintiles of the propensity score was 1.4 (95%CI 0.5-
3.5). The relative risk of arterial cardiovascular events adjusted for quintiles of 
propensity score after subtracting periods of anticoagulation use from the follow-
up was 1.7 (0.7-4.1).
Figure1: Applied selection for current analysis
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Figure1: Applied selection for current analysis 
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27 probands, 80 relatives 
399 subjects with VTE history (317 
probands, 82 relatives) 
462 subjects without VTE 
history 
Relatives without either 
hyperhomocysteinemia, prothrombin 
G20210A or elevated FVIII (N= 461) 
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Table1: Baseline characteristics and number of arterial cardiovascular outcome 
stratified for history of venous thromboembolism
Subjects without VTE 
history (N=462)
Subjects with 
VTE history (N=399)
Sex, M/ F (%) 40/ 60 36/ 64
Age, year (Mean± SD) 47±17 49±16
Hypertension (%) 82 (18) 82 (21)
Hyperlipidemia (%) 47 (10) 45 (11)
Diabetes mellitus (%) 16 (4) 15 (4)
Obesity BMI≥30 (%) 72 (16) 86 (22)
Smoking (%) 177 (38) 132 (33)
Hyperhomocysteinemia (%) 178 (39) 120 (30)
Prothrombin G20210A (%) 160 (35) 131 (33)
Factor VIII elevation (%) 225 (49) 232 (58)
FVL (%) 68 (15) 97 (24)
Protein S deficiency (%) 6 (1) 13 (3)
Protein C deficiency (%) 4 (1) 6 (2)
Antithrombin deficiency (%) 1 (0.2) 8 (2)
Number of arterial
cardiovascular events N
9 12
Number of person-years of follow-up year 1367 1199
Annual incidence of arterial cardiovascular  
events
(%) (95%CI)
0.7 (0.3-1.2) 1.0 (0.5-1.7)
Relative risk of arterial thrombotic events 
in subjects with VTE compared with those 
without
(95%CI)
Ref 1.5 (0.6-3.6)
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Table 2: Cardiovascular risk factor and thrombophilic defect distributions in 
subjects who developed arterial cardiovascular events stratified for VTE history
Subjects without VTE history 
(N=9)
Subjects with VTE history 
(N=12)
Sex M/ F (%) 67/ 33 67/ 33
Age year (Mean± SD) 53±18 68±11
Hypertension (%) 1 (11) 4 (33)
Hyperlipidemia (%) 1 (11) 0 (0)
Diabetes mellitus (%) 0 (0) 1 (8)
Obesity BMI≥30 (%) 1 (11) 0 (0)
Smoking (%) 4 (44) 3 (25)
Hyperhomocysteinemia (%) 3 (33) 3 (25)
Prothrombin G20210A (%) 4 (44) 5 (42)
Factor VIII elevation (%) 3 (33) 8 (67)
FVL (%) 2 (22) 4 (33)
Protein S deficiency (%) 0 (0) 0 (0)
Protein C deficiency (%) 0 (0) 0 (0)
Antithrombin deficiency (%) 0 (0) 0 (0)
Discussion
In this prospective analysis of subjects from three prospective family cohort 
studies we observed that patients with previous VTE have a 1.5 times higher 
risk of developing arterial cardiovascular complications than their first degree 
relatives who do not have a history of VTE. The estimated relative risk did not 
alter by adjusting for cardiovascular risk factors or the presence of thrombophilic 
defects. To our knowledge, this analysis is the first that evaluated simultaneously 
the effect of cardiovascular risk factors and thrombophilic defects on the risk of 
arterial cardiovascular complications in patients with previous VTE.
Three other cohort studies of patients with either unprovoked and provoked 
venous thrombosis or pulmonary embolism also have confirmed the increased 
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risk of arterial cardiovascular complications after VTE.6;16;17 Among which, one 
study adjusted the risk for age and cardiovascular risk factors where they did not 
notice a difference by adjustment.16
Our study is different from the previous ones because we included first-degree 
relatives of the patients with a history of VTE as the control cohort, implicitly 
expressing the highest possible similarity between the exposed (probands and 
relatives with VTE) and the control cohort for the environmental variables such as 
lifestyle and known and unknown genetic variables that are burdensome to adjust 
for and can produce residual confounding in any association under study. On the 
other hand, having strict inclusion criteria resulted in a small number of arterial 
cardiovascular complications. Hence, we could not investigate whether type of 
VTE (unprovoked versus provoked) modulates the risk of arterial cardiovascular 
complications. This may have led to underestimation of the observed increased 
risk as some but not all studies have shown that only subjects with unprovoked 
VTE had an increased risk of subsequent arterial cardiovascular complications. 
2;3;6;17 Furthermore our results are only applicable in a highly selected cohort of 
thrombophilic families.
In conclusion, conventional cardiovascular risk factors and multiple thrombophilic 
defects do not seem to explain the mildly increased risk for arterial cardiovascular 
complication in subjects with a history of VTE. 
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Abstract
Several studies have suggested an association between inflammation and 
coagulation. Whether the risk of recurrent venous thrombosis is increased with 
high levels of cytokines is not fully elucidated. We investigated the associations 
of cytokine levels (TNF-a, IL-1b, IL-6, IL-8, IL-12p70 and IL-10), CRP and 
D-dimer with recurrent venous thrombosis in the Leiden Thrombophilia Study 
(LETS). We included 399 LETS participants who were followed for a mean of 8 
years after cessation of treatment for their first venous thrombosis. We compared 
the recurrence risk for low or high cytokine levels (>10 pg/ml for TNF-a, IL-6 
and IL-10, >20 pg/ml for IL-1b and IL-8 and >50 pg/ml for IL-12p70) versus 
undetectable cytokine levels, for CRP >3 versus ≤3 mg/L and D-dimer >250 
versus ≤250 ng/ml. The blood draw took place 19 (range 6-68) months after the 
initial event. Sixty patients experienced a recurrence (19 per 1000 person years, 
95% CI 14-24).  Recurrence rates were not higher in individuals with low or high 
levels of cytokines compared to those with undetectable levels.  The adjusted 
risk for age, sex and BMI was 2.2 (95% CI 1.3-3.8) for elevated CRP and 1.7 
(0.9-3.4) for elevated D-dimer.  Individuals with either elevated D-dimer or CRP 
and those with both elevated CRP and D-dimer had higher risk as compared to 
patients with low CRP and D-dimer levels (HR 1.9; 95% CI 1.1-3.5 and 3.1; 1.4-
7.2 respectively).
In conclusion, high levels of CRP and D-dimer are associated with thrombosis 
recurrence while high levels of pro-inflammatory cytokines are not. 
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Introduction
Venous thrombosis is an important morbidity and mortality cause in Western 
society. Each year about 2 per 1000 individuals in Western populations develop 
venous thrombosis 1;2, 7% (range 3-13%) experience a recurrence in the first year 
and 12-25% recur over 5 years 3;4. The risk profile for recurrent venous thrombosis 
appears to be different from that for a first event 5. In contrast to the first events, 
age and most prothrombotic abnormalities do not appear to play an important 
role in provoking a recurrence in the general population 6;7 while male sex is a 
risk factor for recurrence but not for the first event 5. Rare deficiencies of natural 
anticoagulants and antiphospholipid syndrome at most have a moderate effect on 
the risk of recurrent venous thrombosis 8-11. In line with the first event, cancer, 
continued oestrogen use and obesity are known as determinants of recurrence 
risk 6;7;12-15. Hemostatic activation, assessed by D-dimer level, appears to be an 
important determinant of the risk of recurrent venous thrombosis, although not 
all studies agree 16-20. The effect of elevated levels of FVIII and FIX on the risk of 
recurrent event are either controversial or little discussed 7;21-23.  
Several, mainly laboratory studies have suggested a link between coagulation and 
inflammation 24-26. Studies evaluating the relation of the risk of first VTE with a 
promoter polymorphism (-174, G>C) of IL-6, known to influence IL-6 levels 27, 
or haplotypes of IL1RN failed to prove an association 28;29. Further, a population-
based study in which cytokine levels were measured prior to the first thrombosis 
showed no association between cytokine levels and the risk of first thrombosis 
30. These findings challenge earlier results that suggested an association between 
cytokines and the development of a first VTE 31;32. Data on association of 
cytokine levels with risk of recurrent venous thrombosis are scarce. One study 
observed associations of IL-8, IL-6 and MCP-1 levels and recurrent events of 
venous thrombosis, however it is not mentioned whether the blood was drawn 
before or after the recurrences 33. In contrast, the Prevention of Recurrent Venous 
Thromboembolism trial (PREVENT) study reported no association between 
genetic variants in 86 candidate genes involved in the inflammatory process 
and recurrent venous thrombosis 34. Results of studies investigating the relation 
between CRP (C-reactive protein) and venous thrombosis are contradictory 35-41. 
Altogether, the role of cytokines and CRP in the recurrence of venous thrombosis 
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is not yet clarified. In this study we aimed to evaluate the risk of recurrent venous 
thrombosis associated with plasma levels of the inflammatory markers, tumor 
necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6, IL-8, IL-10, IL-12p70, CRP 
and D-dimer. 
Materials and methods
Study population
This study is comprised of all patients who participated as cases in a population-
based case-control study; the Leiden Thrombophilia Study (LETS). Details of 
this study have been published previously 42. Briefly, 474 patients younger than 70 
years of age with a first deep vein thrombosis were recruited from anticoagulation 
clinics in Leiden, Amsterdam and Rotterdam (the Netherlands) between January 
1988 and December 1992. Participants had no overt malignancy. Blood was 
drawn at least 3 months after discontinuation of oral anticoagulant treatment 
unless treatment was prescribed indefinitely and could not be stopped (n=48). 
The median time interval between the first venous thrombosis and the blood draw 
was 19 (range 6-68) months.  
Patients were followed as described previously 7 from the end of initial 
anticoagulation treatment period until January 1st 2000. Information during 
follow-up on the occurrence of risk situations, use of anticoagulation treatment, 
and recurrent events was gathered by repeated mailed screening questionnaires. 
Patients were interviewed by telephone when they responded positively to any 
item of the questionnaire or when they did not return it. Information on recurrent 
events and risk situations was confirmed by contacting patients’ physicians. 
Recurrent events were confirmed by objective diagnostic tests, i.e. ultrasound, 
venography or impedance plethysmography for deep vein thrombosis and positive 
perfusion lung scan (at least one segmental perfusion defect), ventilation-perfusion 
lung scan (intermediate or high probability) or computerized tomography scan 
for pulmonary thrombosis. Venous events occurring within 90 days of the first 
event were considered a progression of the initial event. A provoked event was 
defined as occurring during pregnanacy or puerperium (period of 6 weeks after 
delivery), during (or within 30 days after the cessation of) oral contraceptive 
use, during immobilization (period of less than 3 month being immobilized due 
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to hospitalization or due to being bedridden at home) or within a period of 30 
days after major trauma or surgery. The initial and follow-up phases of the LETS 
were approved by the medical ethics committee of the Leiden University Medical 
Center and all patients signed an informed consent for the participation in the 
follow-up phase.
Cytokines, CRP and D-dimer measurement 
Blood (0.9 vol) was collected into Sarstedt Monovette tubes containing 0.106 M 
of trisodium citrate (0.1 vol), prepared by centrifugation for 10 minutes at 2000xg 
and stored in aliquots at –70 °C until assayed. Plasma was available for 470 
patients with a first venous thrombosis. TNF-a, IL-1b, IL-6, IL-8, IL-10 and IL-
12p70 were measured simultaneously using a commercially available multiplex 
cytometric bead assay (BD Biosciences, Alphen aan den Rijn, The Netherlands), 
as described earlier 31. The detection limit of each of the cytokines was 2.5 pg/ml. 
CRP was measured by a sandwich enzyme immunoassay (Kordia, Leiden, The 
Netherlands) based on two polyclonal rabbit antibodies against CRP. D-dimer 
was measured using ELISA, as described earlier 43. 
Statistical Analysis
To evaluate the association between cytokine levels CRP, D-dimer and the 
risk of thrombosis recurrence we excluded the individuals who experienced 
recurrent venous thrombosis before the blood draw (n=27), who were taking oral 
anticoagulation therapy at the time of the blood draw (n=27) and those for whom 
we did not have follow-up information (n=17) from the analysis. (Figure 1) 
We compared recurrence rates of thrombosis in patients with low (detectable but not 
high) or high levels of cytokines with patients with undetectable cytokine levels. 
We applied the same cut-off levels as used earlier in the LETS to discriminate 
low and high cytokine levels 31. These levels are approximately equivalent to the 
95th percentile in healthy individuals: above 10 pg/ml for TNF-a, IL-6 and IL-
10, above 20 pg/ml for IL-1b and IL-8 and above 50 pg/ml for IL-12p70. The 
95th percentile of D-dimer levels (250 ng/ml) in the LETS control population and 
the clinical cardiovascular risk cut-off level (3 mg/L) for CRP 44 were used as 
the cut-off points for high CRP and D-dimer levels. Follow-up time was defined 
from 90 days after the initial event until the recurrent event, death, or the last date 
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of follow-up, whichever occurred first. As cut-off points might be arbitrary, we 
also addressed other cut-off points for CRP and D-dimer; 50th, 67th, 80th and 90th 
percentiles of the control group distributions. Patients with CRP and D-dimer 
levels below the 50th percentile level in the LETS controls served as the reference 
group in this sensitivity analysis. Besides, we compared the risk of recurrence in 
patients with both elevated D-dimer and CRP or patients with either of them to 
patients whose D-dimer and CRP were below the cut-off.
Recurrence rates were calculated by dividing the number of recurrent events 
by the sum of the follow-up years. Ninety-five percent confidence intervals 
(95% CIs) were calculated according to Poisson distribution for the number of 
events 45. Hazard ratios (HR), as estimation of the relative risk, were calculated 
using Cox regression. We adjusted hazard ratios for possible confounders like 
age, sex and body mass index (BMI; kg/m2) and stratified the adjusted hazard 
ratios according to recurrence location (i.e. contralateral vs ipsilateral) and type 
of first or recurrent event (unprovoked vs provoked). To calculate the risk of 
unprovoked recurrences, we subtracted periods of exposure to risk factors (i.e. 
oral contraceptive use, pregnancy, trauma, surgery and immobilization) and the 
use of oral anticoagulants from the follow-up duration. Moreover, because of the 
broad range of time between the initial event and the blood draw, we computed 
the recurrence risks for high D-dimer or CRP stratifying by time elapsed between 
the first venous thrombosis and the blood draw (in tertiles)
Inflammation markers, D-dimer and the risk of recurrent venous thrombosis
8
119
Figure 1. Flow-chart of selection of patients for the analysis
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Patients with first venous 
thromboembolism N=474 
Exclusion criteria: 
1. Anticoagulant therapy at the time of blood draw 
N=27 
2. Recurrence before blood draw   N=27 
3. No follow-up data after blood draw  N=17 
4. Plasma not available   N=4   
Cytokine and CRP measurements N=399 
Men/ Women (%) 40/ 60 
Unprovoked/ Provoked 1st event (%) 53/ 47 
Recurrent events N=60 
D-dimer measurements N=392 
Men/ Women (%) 40/ 60 
Unprovoked/ Provoked 1st event (%) 53/ 47 
Recurrent events N=59 
Patients eligible for this analysis 
N=399 
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Results
A total of 399 LETS patients were eligible for this analysis (figure 1). The 
mean age of the patients was 45 (range 14-69) years at the start of follow-up 
and 160 (40%) of them were men. Approximately half (n=210, 53%) of the first 
thromboses occurred in the absence of known risk factors for venous thrombosis. 
The mean follow-up duration was 8 years (range 1-12). In the 399 patients 60 
(15%) recurrent events occurred with an incidence of 19 per 1000 person years 
(95% CI 14-24). The recurrences were located in the leg (n=47), arm (n=3), lung 
(n=7), leg and lung (n=2) and Budd-Chiari syndrome with extension into the 
vena cava (n=1). 
Table 1 shows the mean, median and range of cytokines, CRP and D-dimer 
levels for individuals with detectable levels. Few patients had high levels of the 
cytokines (1 to 4% for the various cytokines). Elevated CRP (>3 mg/l) was seen 
in 107 patients (27%) and high D-dimer (>250 ng/ml) in 49 patients (13%). 
The incidence rate of recurrent venous thrombosis was similar in individuals with 
high pro-inflammatory cytokines (i.e. all cytokines except IL-10) (n=38; 20 per 
1000 person years; 95% CI 7-47) and those with undetectable pro-inflammatory 
levels (n=301; 22 per 1000 person years; 95% CI 16-30). The recurrence rate 
in individuals with detectable but not high levels (n=60) of at least one pro-
inflammatory cytokine was 30 per 1000 person years (95% CI 15-54).  The 
adjusted relative risks of recurrent venous thrombosis for age, sex and BMI in 
individuals with high and detectable (but not high) levels of at least one pro-
inflammatory cytokine compared to those with undetectable levels were also not 
increased; hazard ratios were 1.0 (95% CI 0.6-1.5) for individuals with high levels 
and 1.3 (95% CI 0.7-2.4) for those with detectable but not high levels (Table 2). 
Similarly, no increased risks were found for each separate cytokine (Tables 3 and 
4). None of the four individuals with high or low levels of the anti-inflammatory 
cytokine IL-10 had recurrent events. 
 The incidence of recurrent event in patients with elevated CRP (n=107) was 37 
per 1000 person years (95% CI 24-55), which was higher than the incidence in 
patients with low CRP (n=292, 18 per 1000 person years; 95% CI 13-25).  The 
corresponding hazard ratio for recurrence with elevated CRP, adjusted for age, 
sex and BMI, was 2.2 (95% CI 1.3-3.8). Elevated CRP was most predictive when 
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blood was drawn within 14 months after the index event (i.e. the first tertile of 
the period between the first venous thrombosis and blood draw) (HR 2.5, 95% 
CI 1.1-5.8). The HRs in de second (blood draw between 14 and 24 month of the 
first event) and third tertile (blood draw after 24 month of the first event) were 1.8 
(95% CI 0.7-4.9) and 2.0 (95% CI 0.7-5.5). 
The recurrence rate for levels of D-dimer above 250 ng/ml was 38 per 1000 
person years (95% CI: 19-68), which was higher than the recurrence rate in 
patients with levels below 250 ng/ml (21 per 1000 person years; 95% CI 16-
28). The adjusted hazard ratio was 1.7 (95% CI 0.9-3.4) for patients with high 
D-dimer levels compared to those with low levels. Similar to CRP, high levels 
of D-dimer were only associated with higher risk of recurrence when blood was 
drawn within 14 months after the index event (HR 5.8, 95% CI 2.1-16.2). The 
HRs in de second (blood draw between 14 and 24 month of the first event) and 
third tertile (blood draw after 24 month of the first event) were 1.2 (95% CI 0.3-
4.1) and 0.7 (95% CI 0.1-3.1). Compared to patients with low levels of CRP and 
D-dimer, the recurrence risk was increased for individuals with either elevated 
D-dimer or CRP (HR 1.9; 95% CI 1.1-3.5) and for subjects with both elevated 
D-dimer and CRP (HR 3.1; 95% CI 1.4-7.2). 
The adjusted hazard ratios did not substantially change when stratifying for the 
location of the recurrent event (contralateral versus ipsilateral), except for D-dimer 
(Table 4). Patients with elevated D-dimer showed a higher risk for recurrence in 
the contralateral leg (HR 3.1; 95% CI: 1.2-8.3) than in the ipsilateral leg (HR 0.9; 
95% CI: 0.3-3.2). 
Hazard ratios for the cytokines and CRP did not differ when stratifying for the 
type of recurrent event, i.e. unprovoked vs. provoked (data not shown). High 
D-dimer and CRP levels seemed to increase the risk of recurrence especially in 
those with provoked first events (HR 3.5; 95% CI 1.3-9.6, HR 3.6; 95% CI 1.5-
8.7 respectively for D-dimer and CRP) compared to those with unprovoked first 
events (HR 1.2; 95% CI 0.5-2.9, HR 1.7; 95% CI 0.9-3.4). Evaluation of different 
cutpoints defining elevated CRP or D-dimer did not reveal a threshold that might 
perform better in identifying risk status. (Table 5)
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Table 1. Mean, median and range of inflammatory markers and D-dimer levels in 
individuals with detectable levels 
Analyte N (detectable) Mean Median Range 5th-95th percentile range
TNF-a* 26 28 14 5-212 5-160
IL-1b* 33 32 12 5-161 6-131
IL-6* 19 25 18 7-81 7-81
IL-8* 57 21 10 5-120 5-80
IL-10* 6 22 18 7-44 7-44
IL-12p70* 42 53 21 5-259 6-218
CRP# 399 3.8 1.4 0.0-142.3 0.2-15.8
D-dimer$ 392 168 109 11-1946 35-671
Abbreviations: TNF=tumor necrosis factor, IL=interleukin, CRP=C-reactive protein.
Unites: * pg/ml, # mg/l, $ ng/ml
Table 2. Incidence and risk of recurrent thrombosis in individuals with 
undetectable, low and high levels of at least one pro-inflammatory cytokines
Total N Number of 
recurrences (%)
Incidence of recurrent 
thrombosis per 1000 
person years (95% CI)
Adjusted 
HR** (95% 
CI)
Undetectable level of at least  
one pro-inflammatory 
cytokine
301 44 (15) 22 (16-30) Ref.
Low level of at least one pro-
inflammatory cytokine
60 11 (18) 30 (15-54) 1.3 (0.7-2.4)
High level of at least one pro-
inflammatory cytokine
38 5 (13) 20 (7-47) 1.0 (0.6-1.5)
**Adjusted for age, sex and BMI
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Table 3. Incidence of recurrent events associated with inflammatory markers and 
D-dimer
N Recurrent events N (%) Incidence per 1000 person-
year (95% CI)
TNF-a*
Non-detectable 373 57 (15) 23 (18-30)
0-10 9 1 (11) 17 (0.4-95)
>10 17 2 (18) 18 (2-66)
IL-1b*
Non-detectable 366 54 (15) 23 (17-29)
0-20 21 4 (19) 32 (9-81)
>20 12 2 (17) 25 (3-90)
IL-6*
Non-detectable 380 56 (15) 23 (17-29)
0-10 6 1 (17) 23 (0.6-127)
>10 13 3 (23) 40 (8-116)
IL-8*
Non-detectable 342 50 (15) 22 (16-29)
0-20 43 9 (21) 37 (17-70)
>20 14 1 (7) 10 (0.3-58)
IL-10*
Non-detectable 393 59 (15) 23 (18-30)
0-10 2 1 (50) 108 (3-599)
>10 4 0 (0) 0 (0.0-132)
IL-12p70*
Non-detectable 357 54 (15) 23 (17-30)
0-50 31 4 (13) 20 (5-50)
>50 11 2 (18) 30 (3-99)
CRP#
≤ 3 292 36 (12) 18 (13-25)
> 3 107 24 (22) 37 (24-55)
D-dimer$
≤ 250 343 48 (14) 21 (16-28)
> 250 49 11 (22) 38 (19-68)
Abbreviations: BD=blood draw, TNF=tumor necrosis factor, IL=interleukin, CRP=C-reactive 
protein. Unites: * pg/ml, # mg/l, $ ng/ml
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Table 4. Hazard ratios of recurrent events associated with inflammatory markers 
and D-dimer level
Marker Crude HR Adjusted HR**
All  
recurrences
N=60
Contralateral 
recurrences
N=21
Ipsilateral 
recurrences
N=27
Unprovoked 
1st event
N=210
Provoked 1st 
event
N=189
TNF-a*
0-10 0.8 (0.1-5.6) 0.8 (0.1-5.5) 0.8 (0.3-2.3) 1.0 (0.4-2.3) 0.9 (0.1-6.6) ***
>10 0.8 (0.2-3.4) 0.6 (0.2-2.6) 0.8 (0.1-5.7) 0.8 (0.1-5.7) 0.8 (0.2-3.3) ***
IL-1b*
0-20 1.4 (0.5-4.0) 1.4 (0.5-3.7) 1.4 (0.6-3.1) 1.2 (0.5-2.7) 1.4 (0.4-4.7) 1.2 (0.2-8.8)
>20 1.1 (0.3-4.6) 1.0 (0.2-4.2) 1.4 (0.2-10.5) 1.2 (0.2-8.7) 0.7 (0.1-4.8) 3.2 (0.4-27.5)
IL-6*
0-10 1.0 (0.1-7.0) 0.6 (0.1-4.6) 1.3 (0.5-3.2) 1.5 (0.7-3.3) 0.7 (0.1-5.3) ***
>10 1.9 (0.6-6.0) 1.8 (0.6-5.7) 1.6 (0.2-11.6) 3.2 (0.7-13.7) 1.5 (0.4-6.4) 3.1 (0.3-28)
IL-8*
0-20 1.7 (0.9-3.6) 1.7 (0.8-3.5) 0.9 (0.4-2.2) 1.2 (0.5-2.5) 1.8 (0.8-3.9) 1.2 (0.2-9.1)
>20 0.5 (0.1-3.6) 0.5 (0.1-3.4) *** 1.1 (0.1-8.5) 0.6 (0.1-4.5) ***
IL-10*
0-10 5.0 (0.7-36.0) 5.0 (0.7-37.1) *** 1.0 (0.2-4.0) 7.5 (0.9-58.1) ***
>10 *** *** *** *** *** ***
IL-12p70*
0-50 0.9 (0.3-2.4) 0.8 (0.3-2.3) 1.2 (0.5-2.8) 0.8 (0.3-2.1) 0.9 (0.3-3.1) 0.5 (0.1-4.1)
>50 1.2 (0.3-4.9) 1.0 (0.2-3.9) 1.4 (0.2-10.6) 1.0 (0.1-7.2) 0.6 (0.1-4.2) 5.4 (0.6-50.5)
CRP#
> 3 2.0 (1.2-3.4) 2.2 (1.3-3.8) 2.6 (1.1-6.3) 2.2 (0.9-4.8) 1.7 (0.9-3.4) 3.6 (1.5-8.7)
D-dimer$
> 250 1.8 (0.9-3.4) 1.7 (0.9-3.4) 3.1 (1.2-8.3) 0.9 (0.3-3.2) 1.2 (0.5-2.9) 3.5 (1.3-9.6)
The reference group was patients with non-detectable levels for cytokines, £3 mg/l for CRP and 
£250 ng/ml for D-dimer .***No recurrent events occurred
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Table 5. Hazard ratios of recurrent events for different cut-off levels of CRP and 
D-dimer
Cut-off level*# N Recurrent events N (%) Crude HR Adjusted HR**
CRP
< 50 % 169 21 (14) Ref Ref
> 50 % 1.1 230 39 (20) 1.5 (0.9-2.5) 1.6 (0.9-2.8)
> 67 % 2.0 148 27 (22) 1.6 (0.9-2.8) 1.7 (1.0-3.2)
> 75 % 2.5 117 25 (27) 1.9 (1.1-3.4) 2.2 (1.2-4.0)
> 80 % 3.0 105 24 (30) 2.1 (1.2-3.7) 2.3 (1.2-4.3)
> 90 % 5.1 64 13 (26) 1.9 (0.9-3.7) 2.0 (1.0-4.0.0)
> 95 % 9.7 42 9 (27) 1.9 (0.9-4.2) 1.9 (0.8-4.5)
D-dimer
< 50 % 128 17 (15) Ref Ref
> 50 % 74.0 264 42 (19) 1.3 (0.7-2.2) 1.4 (0.8-2.6)
> 67 % 103.0 204 31 (18) 1.2 (0.7-2.2) 1.4 (0.7-2.6)
> 75 % 121.4 171 27 (19) 1.3 (0.7-2.4) 1.5 (0.8-2.8)
> 80 % 136.3 145 24 (20) 1.4 (0.7-2.5) 1.6 (0.8-3.1)
> 90 %  185 91 16 (21) 1.5 (0.7-2.9) 1.7 (0.8-3.5)
> 95 %  250 49 11 (22) 1.8 (0.9-3.4) 1.7 (0.9-3.4)
* The cut-off levels are applied from the LET’s controls. 
# mg/l for CRP and ng/ml for D-dimer. **Adjusted for age, sex and BMI
Discussion
In this prospective study, we observed that “low detectable” or high levels of pro-
inflammatory cytokines (i.e. TNF-a, IL-1b, IL-6, IL-8, IL-10 and IL-12p70) do 
not increase the risk of a second thrombosis. Elevated levels of CRP (> 3 mg/d) 
were associated with an increased risk of recurrent venous thrombosis (adjusted 
HR 2.2; 95% CI 1.3-3.6), as well as D-dimer levels above 250 ng/ml (adjusted 
HR 1.7; 0.9-3.4). 
To our best knowledge this is the first study evaluating the association of 
inflammatory markers and the risk of thrombosis recurrence. Several studies have 
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suggested that increased levels of inflammatory factors might be a result and not a 
cause of venous thrombosis. 46-48 This may explain why we could not demonstrate 
an association between cytokines and recurrent disease. It may also explain the 
small percentage of patients showing elevated levels of the various cytokines in 
our study (range 1-4%), as blood from all patients was drawn at least six months 
after the initial event. We did find a 2-fold increased risk of recurrence though in 
patients with elevated CRP levels. The clinical implication of this finding needs 
further investigation. The association we observed between high D-dimer levels 
and thrombosis recurrence (HR 1.7, 95% CI: 0.9-3.4), confirms previous studies, 
which found a 2 to 3-fold higher risk of recurrence associated with D-dimer levels 
more than 250 ng/ml 49-51. 
A systemic increase in inflammatory markers in patients with venous thrombosis 
might reflect locally damaged veins and might therefore predict ipsilateral 
recurrent events. However, we did not find such an association, which is 
consistent with studies showing that residual vein thrombosis also correlates 
with contralateral recurrent events 50;52. It can, however, not be excluded that 
plasma concentrations of inflammatory markers do not reflect the situation at 
the thrombus site. Interestingly, we have observed that increased recurrence risk 
for elevated CRP and D-dimer was present only in patients who had their blood 
drawn within 14 months after the initial event. However, these results should be 
interpreted with caution because   few recurrent events happened in the second 
and third tertile of the time between the initial event and the blood draw especially 
for D-dimer risk estimation. 
Our study has several limitations. Firstly, the measurements were only done 
once which precluded the evaluation of the association of persistent elevation 
of cytokines on the risk of thrombosis recurrence. Also, since the average time 
interval between the blood draw and the index thrombotic event was 19 months, 
we were unable to calculate the recurrence risk within the first year of thrombotic 
events when the absolute risk of recurrence is the highest. 
In conclusion, elevated levels of CRP and D-dimer appear to increase the risk of 
venous thrombosis recurrence while high levels of pro-inflammatory cytokine do 
not. Furthermore, individuals with simultaneous elevated CRP and D-dimer have 
the most risk of recurrence compared to those with none of them elevated.
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Abstract  
Risk factors for idiopathic retinal vein occlusion (RVO) are not well defined. 
We investigated the role of thrombophilia, fibrinolysis and platelet receptors in 
idiopathic RVO in a case-control study. Cases were 101 patients (55% men) with 
angiographically confirmed RVO, recruited from four Dutch academic ophthalmic 
centers. None of them had ocular disease or systemic risk factor predisposing to 
RVO. Controls (n=94, 52% men) were either brought by cases or selected from 
hospital contact lens services. 
We compared the mean level of endogenous thrombin potential, antithrombin, 
protein C and S, Factor VIII and homocysteine as well as clot lysis time and 
thrombin activatable fibrinolysis inhibitor (TAFI) between the two groups. 
We calculated the odds ratio (OR) of RVO for antithrombin, protein C and S 
deficiency, hyperhomocysteinemia, factor V Leiden, prothrombin G20210A, 
lupus anticoagulant, anticardiolipin antibodies, TAFI and protein C receptor 
(PROCR) haplotypes (H) and platelet receptor polymorphisms. Increased ORs 
were observed for PROCR H1 (OR: 1.5, 95%CI: 0.8-2.8) and H4 (1.8, 0.6-5.5), 
elevated TAFI activity (1.5, 0.7-3.3), TAFI H1 (1.4, 0.8-2.7) and platelet receptor 
polymorphisms (rs5918; 1.8, 0.9-3.4 and in a recessive model rs1062535; 1.8, 
0.8-3.9 and rs1126643; 1.9, 0.9-4.1) but neither increase reached significance.
None of the established thrombophilia and clot lysis time showed an association 
with the risk of idiopathic RVO. These results should be interpreted with caution 
due to limited power to detect small effects.
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Introduction
Retinal vein occlusion (RVO) has a prevalence of 5.2 per 1000 individuals in 
the general population and constitutes the second most common retinal vascular 
disease after diabetic retinopathy 1. The four year recurrence rate in the opposite 
eye is estimated to be 7% 2. Despite the importance of RVO, the underlying 
etiology is not fully elucidated.
According to Virchow’s triad, a thrombus can be formed following a change in 
one or more of three elements of vessel wall integrity, hemodynamics or blood 
coagulability. Risk factors that are correlated with arterial thrombosis, such as 
hypertension, hyperlipidemia and diabetes, and which are known to affect vessel 
wall integrity, predispose to RVO 3-5. This is in line with studies reporting an 
increased risk of other manifestations of atherosclerosis such as stroke and 
myocardial infarction in patients with previous RVO 6-8. The role of thrombophilic 
defects in the development of RVO is controversial except for elevated levels 
of homocysteine 9;10, although an association is not established for the C677T 
dimorphism in the gene of methylentetrahydrofolate reductase (MTHFR) 9;11. 
Two meta-analyses showed that the Factor V Leiden (FVL) mutation increases 
the risk of RVO by about 50 to 60% 9;12, whereas other prothrombotic defects, 
i.e. prothrombin G20210A and deficiencies of antithrombin, protein C and S are 
not associated with RVO9 . The role of lupus anticoagulant and anticardiolipin 
antibodies in RVO is uncertain 9;10;13. Elevated TAFI levels are a risk factor for 
venous thrombosis 14;15 but its role in idiopathic RVO has not been investigated. 
Likewise, the relation between fibrinolysis and RVO has not received much 
attention 10;16;17. Since RVO occurs at arterio-venous crossings where the blood 
flow is locally turbulent, changes in the platelet reactivity due to polymorphisms 
in platelet receptors may be important. The few available studies evaluating 
the role of platelets in RVO are of limited size making this association at best 
controversial 18-22.FVL (or activated protein C resistance) was found to be more 
prevalent in younger RVO patients 23;24, which has led to the hypothesis that risk 
factors other than hypertension and hyperlipidemia are of importance in RVO in 
young patients. We aimed to investigate the role of thrombophilia, fibrinolysis 
and platelet function in RVO by comparing their prevalence in RVO patients 
without known risk factors and in a control group.
Chapter 9
136
Materials and Methods
Study population and data collection
Cases were RVO patients, selected from fluorescein angiography databases of 
four academic ophthalmic centers in the Netherlands: Academic Medical Center 
Amsterdam, University Hospital Maastricht, University Hospital Groningen and 
Eye Hospital in Rotterdam, for whom the diagnosis was established between 
January 1st 1970 and May 1st 2000. We recruited these patients only if they did 
not have ocular diseases or risk factors predisposing to RVO, namely open-
angle glaucoma, optic nerve head drusen, hypermetropia, ocular inflammation 
or periphlebitis, hypertension, diabetes, hyperlipidemia, hematological disorders, 
renal insufficiency, hepatic disease and vasculitis. Controls were brought by the 
cases but if cases were unable to bring a volunteer, an appropriate healthy control 
was chosen from the hospital contact lens service that also services the same 
community. Controls were matched for age (± 3 years) to cases and were not 
genetically related to each other or to the cases. All participants provided written 
informed consent and the study was approved by the Medical Ethics Committee of 
Academic Medical Center Amsterdam, Medical Ethics Committee of University 
Hospital Maastricht, Medical Ethics Committee of University Hospital Groningen 
and Medical Ethics Committee of the Rotterdam Eye Hospital.
Patients and controls were subjected to a complete ocular examination 
including visual acuity measurement, biomicroscopy, intraocular pressure (IOP) 
measurement and a dilated fundus examination allowing confirmation of the RVO 
events in the cases, and excluding ocular abnormalities in the controls. Citrated 
blood was collected and centrifuged within 25 minutes after withdrawal at 4oC 
(3000 RPM for 10 minutes) and stored at -80oC until assayed. 
Endogenous thrombin potential and established thrombophilia 
The Endogenous Thrombin Potential (ETP) is derived from a global coagulation 
assay that measures tissue factor triggered thrombin generation in platelet-
poor plasma and provides an estimate of the clotting potential. Coagulation 
was triggered by recalcification in the presence of 5 pM recombinant human 
tissue factor (Innovin®, Siemens, Marburg, Germany), 4 μM phospholipids, 
and 417 μM fluorogenic substrate Z-Gly-Gly-Arg-AMC (Bachem, Bubendorf, 
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Switzerland). The ETP was determined with a calibrated automated thrombograph 
using a microtiter plate reading fluorometer (Fluoroskan Ascent, ThermoLab 
systems, Helsinki, Finland) and thrombinoscope software (Thrombinoscope BV, 
Maastricht, the Netherlands). 
Antithrombin activity was determined with the Berichrom Antithrombin assay 
(Siemens Healthcare Diagnostics, Marburg, Germany) on a Behring Coagulation 
System (Siemens Healthcare Diagnostics). Protein C activity (normal values 
≥ 70%) was assayed with the Coamatic protein C kit (Chromogenix, Mölndal, 
Sweden). Total protein S antigen (normal values ≥ 65%) was determined by 
ELISA (DAKO, Glostrup, Denmark). Free protein S (normal values ≥ 26%) was 
measured in the supernatant after precipitating the C4b-bound fraction of protein 
S with polyethylene glycol.
DNA was extracted from peripheral leukocytes. FVL and prothrombin 20210A 
polymorphisms were detected by routine PCR and restriction enzyme techniques. 
Factor (F) VIII levels were measured in a one-stage clotting assay with FVIII 
deficient plasma. The plasma levels were expressed as percentages of pooled 
normal plasma obtained from more than 150 hospital workers. Total homocysteine 
levels were measured using a high performance liquid chromatographic assay as 
reported previously 25.  Normal ranges for fasting and post-loading levels were 
6-15 and 18-51 mmol/L for premenopausal women and were 6-19, 25-69, 8-18 
and 25-54 mmol/L for postmenopausal women and men, respectively.
Two tests were performed to detect lupus anticoagulant: a diluted prothrombin 
time (dPT) using 200-fold diluted Innovin (Siemens Healthcare Diagnostics), 
and a diluted Russel’s Viper Venom test (dRVVT, LAC Screen, Gradipore, North 
Ryde, Australia). dPT and dRVVT were considered prolonged when the ratio 
of patient plasma to normal plasma was >1.2. In case of a prolonged dRVV 
screening test, a mixing test with normal plasma (1:1) was performed, and the 
sample was considered positive when the clotting time of the dRVV confirmation 
test was more than 20% reduced compared to the dRVV screening test. A patient 
sample was considered positive for lupus anticoagulant with either a prolonged 
dRVVT or dPT.  
The presence of anticardiolipin antibodies (ACA) IgG and IgM was tested by 
ELISA (IMTEC, Kordia, Leiden, The Netherlands). In case of anticoagulation 
therapy (n=2), protein C, S and lupus anticoagulant were not measured. 
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Using the Genome Variation Server (http://gvs.gs.washington.edu/GVS) common 
haplotypes were identified in the protein C receptor gene (PROCR) in the European 
Hapmap population. Three tagging single nucleotide polymorphisms (htSNPs; 
rs867186, rs2069952 and rs2069951) together tag four PROCR haplotypes. A 
htSNP is a polymorphism whose minor allele is specific to one haplotype (H). 
We used TaqMan SNP genotyping assays to determine the htSNPs. In this assay, 
fluorescent allele-specific oligonucleotide probes (Applied Biosystems, CA, 
USA) were used for PCR amplification and fluorescence endpoint reading for 
allelic discrimination was done on a ABI 7900 HT (Applied Biosystems).
Fibrinolysis parameters and TAFI polymorphisms
Lysis of a tissue-factor induced clot by exogenous tissue-type plasminogen 
activator was studied by monitoring changes in turbidity during clot formation 
and the subsequent lysis 26. The Clot Lysis Time (CLT) was defined as the time 
from the midpoint of the clear to maximum turbid transition, representing clot 
formation, to the midpoint of the maximum turbid to clear transition, representing 
the clot lysis.
Thrombin-Activable Fibrinolysis Inhibitor (TAFI) activity was measured in 
plasma as described 27, and TAFI antigen was detected in plasma by ELISA as 
described before 28. The measurements were done in duplicate. Plasma TAFI 
levels were expressed as percentage of pooled normal plasma. 
We determined four major TAFI haplotypes by identifying three htSNPs 
(rs2146881, rs3742264 and rs1926447) in the European population and 
subsequently performing TaqMan SNP genotyping assays.
Platelet receptors’ polymorphisms
Several SNPs were determined in glycoprotein (GP) IB (rs2243039 (Kozak 
polymorphism) and rs6065), GPVI (rs1613662), GPIa (rs1126643 and 
rs1062535), GPIIB (rs5911) and GPIIIA (rs5918) by TaqMan SNP genotyping 
assays or PCR and restriction enzyme technique (for GPIa rs1126643). 
Statistical analysis
Student’s t-test was used to evaluate the difference in the means of continuous 
variables between cases and controls. Odds ratios (OR) and 95% confidence 
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intervals (95%CI) were computed to assess the effect of discrete variables on RVO 
risk. Odds ratios were calculated to estimate RVO risk for the second and third 
tertiles of ETP, FVIII, CLT, TAFI activity and antigen level compared with the 
first tertile. The tertile stratification was done based on the levels in the controls. 
To investigate the effect of polymorphisms in platelet receptors and different 
haplotypes of PROCR and TAFI on the risk of RVO, we calculated odds ratios of 
RVO in heterozygous and homozygous subjects for the minor allele as compared 
to homozygous subjects for the common allele (reference group).
Results
Characteristics of the study population
We recruited 101 patients (56 men, 55.4%) with angiographically established 
RVO as cases and 94 (49 men, 52.1%) healthy subjects as controls. Mean age 
(±SD) was 48 (±11) and 46 (±10) in cases and controls respectively. The majority 
of the participants was younger than 60 years (84% of cases and 89% of controls) 
and of Caucasian origin (83% of cases and 88% of control). 
Endogenous thrombin potential and established thrombophilia 
Table 1 lists the results of ETP measurements and thrombophilia tests for both 
study groups. Mean ETP was 106% in both cases and controls and did not show 
an effect on the risk of RVO.
None of the cases or controls had antithrombin deficiency. Mean antithrombin, 
protein C activity and total protein S antigen level did not differ between cases 
and controls, but mean free protein S antigen level was higher in cases than in 
controls (mean difference: 6%, 95% CI: -10.4 to -2.5). Mildly decreased protein 
C levels, isolated low levels of free protein S and both total and free low protein S 
were observed in one case (protein C activity: 68%), two controls (free protein S: 
20, 21%) and one control (total protein S antigen: 50% and free protein S: 24%), 
respectively. These results were based on single measurements. The prevalence 
of FVL, prothrombin G20210A, hyperhomocysteinemia, lupus anticoagulant 
and anticardiolipin antibodies as well as the mean FVIII antigen level were 
not different between cases and controls. Similarly, the risk of RVO was not 
increased in subjects with higher level of FVIII or homocysteine as compared to 
those having lower levels. Tertile classification of homocysteine was performed 
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separately for fasting and post-loading measurements and stratified for sex (data 
not shown) and showed no association. 
In Table 2, the RVO risk associated with each PROCR haplotype is shown. 
Carriers of one or two alleles of H1 or H4 had an increased risk of RVO (OR: 
1.5, 95% CI: 0.8 to 2.8 and 1.8, 0.6 to 5.5), although these estimates did not reach 
statistical significance. 
Fibrinolysis parameters and TAFI polymorphisms
Table 3 describes CLT measurements and TAFI antigen and activity levels in cases 
and controls. Mean CLT was shorter in cases than in controls (mean difference: 
-7 %, 95% CI: -12.6 to -0.1). Since the distribution of CLT was slightly skewed, 
we also compared the medians and did not observe a difference between the 
two groups (71 (range: 40 to 127) in cases and 71 (45 to 150) in controls). No 
difference in the mean levels of TAFI antigen and activity between cases and 
controls was detected. However, subjects with TAFI activity in the highest tertile 
had a 1.5-fold (95% CI: 0.7 to 3.3) increased risk of developing RVO as compared 
to those in the lowest tertile.
Table 4 lists RVO risks associated with each TAFI haplotype. We were not able to 
assign a haplotype to 10 subjects (eight cases and two controls). Subjects carrying 
one or two H1 alleles had a slightly higher RVO risk (OR: 1.4, 95% CI: 0.8 to 2.7) 
than subjects without a H1 allele, although this was not statistically significant. 
H1 appeared to be associated with increased TAFI activity level. 
Platelet receptor polymorphisms
Table 5 presents the association of six SNPs in four platelet receptor genes with 
the risk of RVO. Carriers of the rs5918 (in GPIIIa gene) minor allele appeared to 
have an increased risk of RVO in a dose-dependent manner (OR in heterozygotes: 
1.7, 95% CI: 0.8 to 3.3, OR in homozygotes: 2.8, 0.5 to 15.9). Homozygotes for 
the minor alleles of the tested SNPs in GPIa (i.e. rs1062535 and rs1126643) 
showed a higher RVO risk (OR: 1.7, 95% CI: 0.7 to 4.1 and 1.8, 0.8 to 4.2 
respectively). These SNPs were in strong linkage disequilibrium (r2=0.82). In a 
recessive model (i.e. the risk in homozygotes for the minor allele compared with 
others), the odds ratios were 1.8 (95% CI: 0.8 to 3.9) for rs1062535 and 1.9 (95% 
CI: 0.9 to 4.1) for rs1126643. 
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Table 1. Endogenous thrombin potential and various established thrombophilic 
risk factors in RVO patients and controls
Patients
N= 101
Controls
N= 94
Mean difference/ 
OR
95%CI
ETP, mean levels (%) 106 106 0  -5.9 to 6.3
     <99 N (%) 26 (38) 28 (33) 1* -
     99-112 N (%) 18 (26) 29 (34) 0.7 0.3 to 1.5
     >112 N (%) 25 (36) 28 (33) 1.0 0.5 to 2.1
Antithrombin, mean levels (%) 103 105 -2 -1.7 to 4.7
Antithrombin deficiency N 0 0 - -
Protein C, mean levels (%) 109 106 3 -8.9 to 2.1
     Protein C deficiency N (%) 1 (1) 0 - -
Total protein S, mean levels (%) 103 102 1 -6.8 to 3.6
Free protein S, mean levels (%) 50 44 6 -10.4 to -2.5
     Protein S deficiency N (%) 0 1 (1) - -
FVL N (%) 5 (5) 4 (4) 1.2 0.3 to 4.5
Prothrombin G20210A N (%) 2 (2) 0 - -
FVIII, mean levels (%) 103 100 3 -9.9 to 5.3
     <91 N (%) 27 (31) 32 (34) 1* -
     91-108 N (%) 34 (40) 31 (33) 1.3 0.6 to 2.6
     >108 N (%) 25 (30) 31 (33) 0.5 0.5 to 1.9
Hyperhomocysteinemia N (%) 15 (16) 18 (19) 0.8 0.4 to 1.7
LAC N (%) 3 (3) 0 - -
IgG ACA N (%) 1 (1) 1 (1) 0.9 0.1 to 15.1
IgM ACA N (%) 4 (4) 2 (2) 1.9 0.3 to 10.6
LAC or ACA N (%) 7 (7) 3 (3) 2.3 0.6 to 9.1
Abbreviations: endogenous thrombin potential (ETP), factor V Leiden (FVL), factor VIII (FVIII), 
lupus anticoagulant (LAC) and anticardiolipin antibody (ACA).
Missing measurements: 31 patients and 9 controls for ETP, 2 patients and 2 controls for FVL, 1 
patient for prothrombin G20210A, 15 patients for FVIII, 6 patients for homocysteine, 5 patients and 
1 control for protein C, 2 patients and 2 cases for total protein S, 23 patients for free protein S and 
7 patients for antithrombin. * Reference category.
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Table 2. Common haplotypes of the PROCR gene in RVO patients and controls 
Haplotype
(htSNP)
Patients (%)
N= 77
Controls (%)
N= 90
OR 95% CI
H1 (rs2069952)
HxHx 28 (36) 41 (46) 1* -
H1Hx 41 (53) 40 (44) 1.5 0.8 to 2.9
H1H1 8 (11) 9 (10) 1.3 0.5 to 3.8
H1Hx/ H1H1 49 (64) 49 (54) 1.5 0.8 to 2.8
Frequency H1 37.0 32.2
H2 (all common)
HxHx 22 (29) 20 (22) 1* -
H2Hx 37 (48) 47 (52) 0.7 0.3 to 1.5
H2H2 18 (23) 23 (26) 0.7 0.3 to 1.7
H2Hx/ H2H2 55 (71) 70 (88) 0.7 0.3 to 1.4
Frequency H2 47.4 51.7
H3 (rs867186)
HxHx 63 (82) 68 (76) 1* -
H3Hx 14 (18) 21 (23) 0.7 0.3 to 1.5
H3H3 0 (0) 1 (1) - -
H3Hx/ H3H3 14 (18) 22 (24) 0.7 0.3 to 1.5
Frequency H3 9.1 12.8
H4 (rs2069951)
HxHx 68 (88) 84 (93) 1* -
H4Hx 8 (11) 6 (7) 1.6 0.5 to 4.9
H4H4 1 (1) 0 (0) - -
H4Hx/ H4H4 9 (12) 6 (7) 1.8 0.6 to 5.5
Frequency H4 6.5 3.3
* Reference category, Hx: all haplotypes except the one given, htSNP: haplotype tagging SNP, OR: 
odds ratio, 95% CI: 95% confidence interval
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Table 3. Fibrinolysis parameters and TAFI polymorphisms in RVO patients and 
controls 
Patients
N= 101
Controls
N= 94
Mean difference/ OR 95%CI
CLT, mean 70 77 -7 -12.6 to -0.1
    <93 N (%) 29 (40) 31 (34) 1* -
    93-103 N (%) 23 (32) 31 (34) 0.8 0.4 to 1.6
    >103 N (%) 20 (28) 30 (32) 0.7 0.3 to 1.5
TAFI antigen, mean 106 110 6 -0.3 to 8.0
    <103 N (%) 35 (51) 33 (36) 1* -
    103-115 N (%) 12 (18) 28 (31) 0.4 0.2 to 0.9
    >115 N (%) 21 (31) 30 (33) 0.7 0.3 to 1.7
TAFI activity, mean 102 101 2 -7.4 to 3.8
    <93 N (%) 21 (31) 32 (36) 1* -
    93-103 N (%) 19 (28) 28 (32) 1.0 0.5 to 2.3
    >103 N (%) 28 (41) 28 (32) 1.5 0.7 to 3.3
Abbreviations: clot lysis time (CLT) and thrombin activatable fibrinolysis inhibitor (TAFI).
Missing measurements: 28 patients and 2 controls for CLT, 32 patients and 3 controls for TAFI 
antigen, 33 patients and 6 controls for TAFI activity measurements. 
* Reference category.
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Table 4. Common haplotypes of the TAFI gene in RVO patients and controls 
Haplotype
(htSNP) 
Patients (%)
N= 69
Control (%)
N= 88
OR 95% CI Mean TAFI  
(95% CI)**
H1 (rs3742264)
HxHx 29 (42) 45 (51) 1* - 97.8 (94.1 to 101.5)
H1Hx 33 (48) 30 (34) 1.5 0.4 to 4.9 100.1 (94.9 to 105.3)
H1H1 7 (10) 13 (15) 0.7 0.1 to 7.3 114.6 (99.7 to 129.5)
H1Hx/ H1H1 40 (58) 43 (49) 1.4 0.8 to 2.7 104.5 (98.5 to 110.5)
Frequency H1 34.1 31.8
H2 (rs2146881and rs1926447)
HxHx 39 (57) 51 (58) 1* - 103.8 (98.3 to 109.4)
H2Hx 27 (39) 33 (38) 0.9 0.3 to 2.8 98.0 (93.4 to 102.6)
H2H2 3 (4) 4 (4) 1.0 0.1 to 13.5 96.5 (89.2 to 103.7)
H2Hx/ H2H2 30 (43) 37 (42) 1.1 0.6 to 2.0 97.8 (93.7 to 102.0)
Frequency H2 23.9 23.3
H3 (all common)
HxHx 25 (36) 33 (38) 1* - 105.1 (98.2 to 112.1)
H3Hx 37 (54) 39 (44) 1.1 0.3 to 4.3 99.4 (94.4 to 104.5)
H3H3 7 (10) 16 (18) 0.6 0.1 to 5.8 96.9 (91.8 to 101.9)
H3Hx/ H3H3 44 (64) 55 (62) 1.1 0.5 to 2.0 98.7 (94.8 to 102.6)
Frequency H3 36.9 40.3
H4 (rs1926447)
HxHx 62 (90) 80 (91) 1* - 101.0 (97.2 to 104.9)
H4Hx 7 (10) 8 (9) 1.1 0.4 to 3.3 104.2 (95.2 to 113.2)
H4H4 0 0 - - -
H4Hx/ H4H4 7 (10) 8 (9) 1.1 0.4 to 3.3 104.2 (95.2 to 113.2)
Frequency H4 5.1 4.6
** Mean TAFI activity level and 95% confidence interval in the controls, * Reference category, Hx: 
all haplotypes except the one given, htSNP: haplotype tagging SNP, OR: odds ratio, 95% CI: 95% 
confidence interval
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Table 5. RVO risk for different genotypes of polymorphisms in four platelet 
receptors
Gene 
SNP
Genotype Patients 
N=77(%)
Control 
N= 90 (%)
OR 95% CI
GPIba 
rs6065 CC 66 (86) 72 (80) 1* -
CT 11 (14) 18 (20) 0.7 0.3 to 1.5
TT 0 0 - -
CT/ TT 11 (14) 18 (20) 0.7 0.3 to 1.5
rs2243093
    (Kozak)
TT 59 (77) 65 (72) 1* -
CT 18 (23) 25 (28) 0.8 0.4 to 1.6
CC 0 0 - -
CT/ CC 18 (23) 25 (72) 0.8 0.4 to 1.6
GPIa
rs1062535 GG 27 (35) 33 (37) 1* -
AG 32 (42) 44 (49) 0.9 0.5 to 1.8
AA 18 (23) 13 (14) 1.7 0.7 to 4.1
AG/ AA 50 (65) 57 (63) 1.1 0.6 to 2.0
rs1126643 CC 27 (35) 34 (38) 1* -
CT 30 (39) 42 (47) 0.9 0.5 to 1.8
TT 20 (26) 14 (15) 1.8 0.8 to 4.2
CT/ TT 50 (65) 56 (62) 1.1 0.6 to 2.1
GPIIIa
rs5911 AA 30 (39) 25 (28) 1* -
AC 34 (44) 45 (50) 0.6 0.3 to 1.3
CC 13 (17) 20 (22) 0.5 0.2 to 1.3
AC/ CC 47 (61) 65 (72) 0.6 0.3 to 1.2
rs5918 TT 48 (62) 67 (74) 1* -
TC 25 (33) 21 (23) 1.7 0.8 to 3.3
CC 4 (5) 2 (2) 2.8 0.5 to 15.9
TC/ CC 29 (38) 23 (25) 1.8 0.9 to 3.4
GPVI
rs1613662 AA 51 (66) 62 (69) 1* -
AG 25 (33) 25 (28) 1.2 0.6 to 2.4
GG 1 (1) 3 (3) 0.4 0.0 to 4.0
AG/ GG 26 (34) 28 (31) 1.1 0.6 to 2.2
* Reference category, OR: odds ratio, 95% CI: 95% confidence interval
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Discussion
In this relatively large study on idiopathic RVO, we were unable to detect a 
significant association between established thrombophilia factors, fibrinolysis 
parameters or platelet receptor polymorphisms and idiopathic RVO. However, 
we observed non-significant risk increases for two haplotypes of PROCR (H1 
and H4), for higher TAFI activity, for TAFI H1 and for several platelet receptor 
polymorphisms.
The endothelial protein C receptor (EPCR) has a crucial role in the protein C 
anticoagulant system by reinforcing protein C activation by thrombin 29. In 
one study, higher circulating levels of this receptor (soluble EPCR, sEPCR) 
were associated with the risk of RVO in general 13.  Accordingly, we expected 
H3 PROCR carriers to have higher risk of RVO since H3 PROCR carriers are 
reported to have higher sEPCR levels than other haplotypes 30. Since our data 
did not support this hypothesis and also the effect of PROCR haplotypes on VTE 
risk is not clear 30;31, we suggest further investigations before drawing a definite 
conclusion. 
Two small-sized studies did not show an association between TAFI activity and 
RVO in general 10;17. We observed that TAFI H1, possibly through higher TAFI 
activity 32, showed a trend toward higher risk of idiopathic RVO. However, CLT 
did not differ between cases and controls, suggesting that impaired fibrinolysis 
is not a major contributor in the pathogenesis of idiopathic RVO. Moreover, as 
higher CLT and ETP, both established risk factors for venous thrombosis 33;34, did 
not differ between patients and controls, coagulation and fibrinolysis are probably 
balanced in idiopathic RVO. In contrast to our observation in idiopathic RVO 
patients, two small studies have reported significant P-values for the association 
of high Euglobulin Clot Lysis Time and the risk of RVO in general 16;17. 
Interestingly, we observed an association between some SNPs in platelet receptor 
genes and the risk of developing RVO. Functional studies have demonstrated that 
polymorphisms (rs1062535, rs1126643) in the GPIa component of the GPIa/IIb 
complex - the receptor for collagen on platelets - lead to a higher density of the 
complex and subsequently to enhanced adhesiveness to collagen 35. However, 
their role in RVO is uncertain; several studies have shown no effect of rs1126643 
19;21;22 while in one study both SNPs were correlated with RVO 20. Also several 
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studies have indicated that rs5918 in GPIIIa component of the GPIIb/IIIa complex 
- the receptor for fibrinogen and von Willebrand factor and the most abundant 
receptor on platelets - is not associated with RVO 18;19;22.
A limitation of our study is that despite a relative large number of idiopathic 
RVO patients, there was not sufficient power to detect modest risk increases. 
For instance the power to detect the observed 1.8 point estimate with our sample 
size for rs5918 was approximately 50%. For the same reason, we were unable to 
stratify our analysis for the types of RVO. Also, we did not adjust for multiple 
testing, which may lead to finding false positive associations.
In conclusion, our data suggest an association between PROCR H1 and H4, 
elevated TAFI activity, TAFI H1 and platelet receptor polymorphisms (rs5918, 
rs1062535 and rs1126643) and idiopathic RVO. We did not observe a role for 
established thrombophilia factors and CLT, although these results should be 
interpreted with caution due to the limited power to detect small effects.
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F5 R506Q (Factor V Leiden) and F2 G20210A (prothrombin G20210A) are risk 
factors for venous thrombosis.1 The results of studies as to whether these mutations 
also increase the risk of cardiovascular disease (CVD) are inconsistent. A meta-
analysis of 191 studies (N>150.000) calculated a 30% increased risk of CVD 
among single heterozygous F5 R506Q  or F2 G20210A carriers compared to non-
carriers.2 Despite its large size, this study included too few double heterozygous 
and homozygous carriers to estimate the risk of CVD in individuals with these 
genetic traits. Therefore, we performed a post hoc analysis in a retrospective 
family cohort that contained a fairly large number of relatives who were double 
heterozygous or homozygous for F5 R506Q  and F2 G20210A (n=52).
Details of our study have been published previously.3-5 Briefly, 1641 first-
degree relatives, aged 15 years or older, of consecutive patients (probands) 
with documented venous thrombosis or CVD before the age of 50 years and 
F2 G20210A, high FVIII or hyperhomocysteinaemia, were enrolled after 
informed consent was obtained. Information on CVD and exposure to classical 
cardiovascular risk factors was collected by using a standardized questionnaire 
and reviewing medical records. All patients were screened for F5 R506Q  and F2 
G20210A. Information was obtained without knowledge of the genetic status. 
Observation years were defined as the years from the age of 15 until the date 
of inclusion or until the date of the first thrombotic event. Incidences and 95% 
confidence intervals (95% CIs) were calculated under the Poisson distribution 
assumption. Relative risks and 95% CIs of cardiovascular disease were calculated 
in the double heterozygous/homozygous group, using single heterozygous carriers 
as a reference group. As we studied a thrombophilic cohort, we only compared 
single heterozygous F5 R506Q  or F2 G20210A carriers to double heterozygous 
and homozygous carriers. The a-priori CVD risk for other relatives was deemed 
too high for them to be included as a reference group. To avoid bias, we excluded 
probands from the analysis.
To prevent the risk of CVD being based on relatives with cardiovascular risk 
factors, we intended to repeat the analysis after excluding all relatives with 
overweight/obesity, smoking, hypertension, dyslipidemia or diabetes mellitus. 
Unfortunately, as all relatives had at least one of these risk factors at the time 
of CVD, we were unable to do this. For similar reasons, another analysis was 
performed after excluding all relatives with concomitant thrombophilias.
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The pedigrees of 500 probands (373 patients with objectively documented venous 
thrombosis, 107 patients with CVD, and 20 patients with both venous thrombosis 
and CVD) disclosed 1641 first-degree relatives aged 15 years or older. Of these 
relatives, 45 were not evaluable because of missing laboratory data and 1149 
were found to be non-carriers of F5 R506Q  or F2 G20210A (8% of whom 
had a cardiovascular event). The remaining 447 relatives were analyzed: 175 
were single heterozygous for F5 R506Q , 220 were single heterozygous for F2 
G20210A, 37 were double heterozygous for F5 R506Q  and F2 G20210A, 8 
were homozygous for F5 R506Q  and 7 were homozygous for F2 G20210A. 
The clinical characteristics are summarized in Table 1. Males and females were 
distributed equally. The median age at inclusion was 47 years (range, 15-91). 
Concomitant thrombophilias were found in approximately 60% of all relatives.
During the observation period a total of 33 arterial thrombotic events occurred: 
7% in single heterozygous F5 R506Q  or F2 G20210A carriers and 12% in double 
heterozygous and homozygous carriers. The median age at onset was similar in 
both groups (53 years; range, 26-78). The annual incidence of CVD was 0.23% 
(95% CI, 0.13-0.79) in single heterozygous F5 R506Q  or F2 G20210A carriers 
and 0.36% (95% CI, 0.13-0.79) in double heterozygous and homozygous carriers; 
relative risk 1.6 (95% CI 0.7-3.9) (Table 2). After exclusion of relatives with 
concomitant thrombophilias, the relative risk of CVD increased to 5.1 (95% CI, 
1.3-22.9) in double heterozygous or homozygous F5 R506Q  and F2 G20210A 
carriers compared to single F5 R506Q  or F2 G20210A carriers.
In our study, double heterozygous and homozygous F5 R506Q  and F2 G20210A 
carriers had a 1.6 fold (95% CI, 0.7-3.9) increased risk of CVD compared to 
single F5 R506Q  or F2 G20210A carriers. These results did not reach statistical 
significance, however, they further the findings of two previous studies that found 
a modest association between single heterozygous F5 R506Q  or F2 G20210A 
and CVD 2;6, but included too few subjects to calculate, as we did, a risk in 
homozygous and double heterzogygous carriers. 
It is unknown why, in F5 R506Q  and F2 G20210A carriers, the risk of CVD 
appears to be more than 10 times weaker than the risk of venous thrombosis. 
A plausible explanation is that atherosclerosis plays a major role in CVD and a 
smaller role in venous thrombosis.7 Atherosclerosis is known to be associated with 
increased endothelial damage (of which hyperhomocysteinaemia is a marker), 
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procoagulant changes (such as high levels of FVIII)8 and natural anticoagulant 
deficiencies.9  This could explain the observed increased relative risk of 5.1 (95% 
CI, 1.2-22.9) found after exclusion of relatives with concomitant thrombophilias. 
However, as we did not investigate whether atherosclerosis was actually less 
common in these relatives (e.g with intima media thickness), these results should 
be treated with caution.
Some aspects of our study warrant comment. A strength of our study is that, due 
to the large cohort of thrombophilic families, it was possible to estimate the effect 
of double heterozygosity or homozygosity for F5 R506Q  and F2 G20210A on 
CVD for the first time. A weakness is the retrospective design and that, despite 
its fairly large size, the number of double heterozygous or homozygous F5 
R506Q  and F2 G20210A carriers was too low to provide risk estimates with 
narrow confidence intervals. The number was also too low to make a subdivision 
of arterial thrombotic event types for additional sensitivity analyses. Another 
potential limitation of our study is referral bias, as this study was performed in 3 
university hospitals. However, as we tested consecutive patients (probands), we 
probably reduced such a bias. 
In conclusion, it is likely that double heterozygous or homozygous carriers of F5 
R506Q  and F2 G20210A have a higher risk of CVD than single F5 R506Q  or F2 
G20210A carriers. However, due to  small numbers, further research is required 
to verify our findings.
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Table 1. Clinical characterist
Heterozygous FVL-
Ptmut or Homozygous 
FVL or Ptmut
Single 
heterozygous FVL 
or Ptmut carriers
Total
 
Number 52 (12) 395 (88) 447
Male 21 (40) 185 (47) 206 (46)
Age at enrollment  (years) 51 (16-85) 47 (15-91) 47 (15-91)
Arterial thrombosis 6 (12) 27 (7) 33 
Age at onset 54 (41-78) 53 (26-78) 53 (26-78)
Classification
Myocardial infarction 2 (4) 12 (3) 14 (3)
Ischemic stroke 1 (2) 8 (2) 9 (1)
Transient ischemic attack 2 (4) 5 (1) 7 (1)
Peripheral arterial thrombotic event 1 (2) 2 (0.5) 3 (2)
Relatives with no other thrombophilic defects*
 21 (40) 153 (39) 174(39)
* No antIthrombin, protein C or protein S deficiency, hyperhomocysteinemia or high factor VIII 
levels.
FVL denotes factor V Leiden; Ptmut, prothrombin mutation.
Continous variables denoted as median (range), categorical variables as number (%).
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Table 2. Risk of cardiovascular disease in relatives of probands with a 
thrombophilic defect
 Observation 
years
Relatives 
with  
event
Annual incidence
% (95% CI)
Crude relative 
risk (95% CI)
All evaluable relatives
Single heterozygous F5 R506Q 
or F2 G20210A carriers
11854
 
27 0.23 (0.15-0.33) Reference
Double heterozygous or 
homozygous F5 R506Q or F2 
G20210A
1646
 
6 0.36 (0.13-0.79) 1.60 (0.66-3.88)
Relatives with concomitant 
thrombophilias excluded
Single heterozygous F5 R506Q 
or F2 G20210A carriers
4199
 
4 0.10 (0.03-0.24)  Reference
Double heterozygous or 
homozygous F5 R506Q or F2 
G20210A
614
 
3 0.49 (0.10-1.43) 5.13 (1.15-2.92)
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This chapter summarizes the results of the investigations presented in this thesis.
Part I
In part I, the aim was to search for new risk factors of venous thrombosis by 
analyzing the genetic linkage signals for venous thrombosis and for intermediate 
phenotypes that were observed in the GENES study (chapters 2, 3 and 4). 
Furthermore, we aimed to evaluate the implications of the findings for diagnosis 
and prevention of venous thrombosis (chapters 5 and 6).
Novel risk factors of venous thrombosis
Venous thrombosis is a multifactorial disease that demands individually tailored 
prognostic and diagnostic procedures. The tailoring is impeded by the fact that 
almost half of the genetic risk factors are unknown. Progress in DNA technology 
in the last decades is enabling the identification of new genetic risk factors by 
genome-wide linkage studies and genome-wide association studies, methods 
that each has their own limitations. Genome-wide linkage studies are hampered 
by the heterogeneity in genetic variations predisposing to a single disease, 
meaning that findings in one family might not have validity for other families 
or for the general population. Furthermore, the statistical power of this type of 
study is dictated by the number of affected individuals in a family which is not 
always large. Population-based genome-wide association studies do not have 
this limitation, as individuals of the study group are not related to each other. 
However, confounding by population admixture, false positive associations and 
inability to study rare genetic variations are among its disadvantages. 
Following the result of a previously conducted genome-wide linkage study, in 
chapter 2 we evaluated the effect of genetic variations in three genes (PROCR, 
THBD and FOXA2) on the levels of protein C (PC) in a large pedigree and also 
in the control population of LETS (Leiden Thrombophilia Study). Haplotype 3 
(H3) of PROCR was associated with higher levels of PC in the pedigree and also 
in the LETS controls. This finding is in line with the result of a recently published 
genome-wide association study 1. Increased levels of sEPCR, as reported before 
in H3 carriers 2, could not explain the higher levels of PC because, although 
the affinity of PC to bind to circulating EPCR is the same as the affinity for 
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endothelial EPCR, the PC levels in H3 carriers are much higher than that of 
sEPCR. We hypothesized that the amount of endothelial EPCR in H3 haplotype 
carriers was decreased and consequently the pool of PC bound to this fraction 
decreased, leaving more PC to circulate in the blood. An analysis of blood-
originated endothelial cells of PROCR H3 carriers and non-carriers with flow 
cytometry did not confirm this hypothesis as we observed no difference in the 
expression of EPCR between cells from H3 carriers and non-carriers. Hence, 
higher levels of PC in H3 carriers remain to be explained from a biochemical 
viewpoint. Interestingly, opposite to our expectation, H3 carriership with its 
inherent high PC levels does not protect against venous thrombosis 2.
In chapter 3, the effect of different haplotypes of NQO1 on the levels of factor 
(F) V and FII was investigated. We observed a negative association between FV 
and H4 in the pedigree, but we did not find such an association in the controls 
of the LETS, indicating the presence of other genetic variations on chr16 to be 
responsible for the linkage peaks that were first observed in the GENES study 
3. In the LETS controls, H4 carriers had lower levels of vitamine K dependent 
coagulation factors, especially FII  and total protein S, which is plausible knowing 
that H4 carriers have lower or undetectable activity of the NQO1 enzyme. 
We studied the risk of venous thrombosis and the levels of vitamin K dependent 
coagulation factors for different haplotypes of the enzymes (VKORC1, GGCX and 
NQO1) involved in the vitamine K cycle in chapter 4. Similar to other studies, 
we noticed no association between haplotypes of VKORC1 and the risk of venous 
thrombosis in LETS 4-6. No association existed either with haplotypes of GGCX 
and NQO1. The levels of a panel of coagulation factors (protein C, protein S, 
protein Z, FII, FVII, FIX and FX ) were reduced in carriers of the VKORC1*2B 
haplotype which is probably due to lower expression of VKORC1 in the liver of 
the carriers. The strongest effect was on FIX levels; each copy of VKORC1*2B 
haplotype was associated with a reduction of 3.26 U/dl. 
Clinical aspects of thrombophilia
In chapter 5, we reviewed hereditary and acquired thrombophilia and the 
indications for thrombophilia testing. These were discussed in relation to the 
impact of test results on primary and secondary prevention settings or as a family 
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screening tool. Routine thrombophilia screening does not seem to be justified 
as most individuals with thrombophilia will not develop venous thrombosis. 
The usefulness of thrombophilia testing for secondary prevention of venous 
thrombosis depends on its impact on clinical management regarding dosis or 
duration of anticoagulation treatment and the risk-benefit balance of prophylaxis 
in high-risk situations. Although some authors suggest thrombophilia testing for 
patients with thrombosis before 50 years of age, recurrent events, family history 
of venous thrombosis and thrombosis in unusual sites 7;8 a recent evidence-based 
guideline recommends against thrombophilia testing 9. Family screening remains 
also questionable because, although the risk of thrombosis in first degree relatives 
of patients with thrombophilia is two- to ten-fold increased, the absolute risk of 
venous thrombosis is low, even in high-risk situations 10-12. 
Pregnancy is associated with a 5-fold increased risk of venous thrombosis, and the 
risk is even higher postpartum (±20-fold) 13; a quarter of these events is a recurrence. 
Since a significant decrease in recurrence rate is observed with prophylaxis, 
14;15 pregnant women with a history of thrombosis are generally advised to use 
of anticoagulation. Thrombophilia is not an indication for prophylaxis during 
pregnancy or postpartum in women without a history of venous thrombosis 
with the possible exception of antithrombin deficiency, homozygosity for factor 
V Leiden or prothrombin G20210A mutations, or combined heterozygosity for 
both mutations 12;16. The optimal doses of LMWH in pregnancy with respect to 
thrombosis recurrence risk and the risk of postpartum bleeding is not clear. The 
increasing number of reports of the failure of low dose prophylaxis 17-19 indicates 
the need for randomized clinical trials to demonstrate the safety of high doses of 
LMWH for prophylactic measures in pregnancy. 
In chapter 6, we observed that postpartum hemorrhage (PPH) did not occur more 
often in women who were given therapeutic doses of LMWH (RR: 0.8, 95% CI: 
0.5-1.4). For women who delivered vaginally, this risk estimate of no increase 
was firm (RR: 0.5, 95%CI: 0.3-1.1), whereas for those women who delivered by 
cesarean section the risk of PPH (for cesarion section a priori defined as more than 
1000 mL blood loss) appeared increased but due to the low number of women 
the confidence interval is very wide (RR: 2.5, 95% CI: 0.3-18.9). The median 
blood loss was found to be similar in treated and untreated women, except for the 
subgroup of normal vaginal deliveries where it was lower in the LMWH users 
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(median difference: -100, 95% CI: -156 to -44). A likely explanation for this 
observation is differential use of oxcytocics in LMWH users. 
Part II
In part II we addressed the relationship between venous and arterial thrombosis. 
We aimed to test the hypothesis that the two conditions are related by the presence 
of shared risk (chapters 7, 9 and 10). In chapter 8, inflammatory markers were 
studied as risk factors for recurrence of venous thrombosis, since several lines 
of evidence have indicated that inflammation promotes the development of 
atherosclerosis and cardiovascular disease 20;21.  
Several previous studies have questioned the distinction between venous 
and arterial thrombosis. An increased risk of arterial thrombosis 22-25 among 
individuals who have had previous venous thrombosis was established in three 
cohort studies 26-28. Whether this association was based on “shared risk factors” 
is unlikely since the corresponding risk did not differ by adjusting for age and 
established cardiovascular risk factors 26. In an analysis of the Beethoven study, 
a large cohort study of thrombophilic families in chapter 7, the same modestly 
increased risk of arterial thrombosis in individuals with previous venous 
thrombosis was observed, although it did not reach statistical significance. 
The risk did not change by adjusting for “shared risk factors” separately and 
simultaneously by using a propensity score considering age, cardiovascular risk 
factors and presence of one ore more thrombophilic defects conditional to venous 
thrombosis history. Therefore we concluded that “shared risk factors” alone can 
not explain this association. 
Generally speaking, conventional cardiovascular risk factors have, if any, 
a mild effect on the development of venous thrombosis 29. It should be noted 
that atherosclerosis also does not raise the risk of future venous thrombotic 
events 30;31. Likewise, the role of thrombophilia in pathogenesis of arterial 
thrombosis remains obscure, especially for the rare thrombophilic defects such as 
antithrombin deficiency 32;33, protein C deficiency 34;35 or protein S deficiency 34;35. 
A borderline effect on myocardial infarction though has been attributed to FVL and 
prothrombin G20210A 36. The effect of double heterozygosity or homozygosity 
for FVL or prothrombin mutations was not studied because of the low prevalence 
of these mutations. In a post-hoc analysis of the Beethoven study (chapter 8), we 
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observed that relatives who were double heterozygous or homozygous for FVL 
or the prothrombin mutation were at a nonstatistically significant 1.6 times higher 
risk of arterial thrombosis as compared to heterozygotes for either mutation. The 
risk after excluding relatives with concomitant thrombophilia was 5.1 (95% CI: 
1.2-22.9). In conclusion, double heterozygosity or homozygosity for FVL or the 
prothrombin mutation seemed to increase the risk of arterial thrombosis. 
In the context of the relation of venous and arterial thrombosis, retinal vein 
occlusion (RVO) is an interesting disease, since risk factors for this venous 
occlusion mainly are established arterial risk factors, such as hypertension, 
hyperlipidemia and diabetes, whereas the relationship with thrombophilia is 
controversial 37. In chapter 10, we evaluated the role of established thrombophilic 
defects, of assays indicating procoagulant state as well as of platelet receptor 
polymorphisms that are known to increase the thrombosis tendency 38-40, in 
patients with idiopathic RVO.  The only suggestive association was found for 
platelet receptor polymorphism rs5918 with a dose-dependent effect on the risk of 
idiopathic RVO (OR for heterozygotes: 1.7, 95% CI: 0.8-3.3 and for homozygotes: 
2.8, 0.5-15.9). No association was observed for established thrombophilia and 
clot lysis time.
Inflammation initiated by thrombosis in the veins can possibly contribute to 
higher risk of arterial thrombosis after venous thrombotic events. The formed 
thrombin triggers inflammation in the endothelium by activating neutrophils and 
inducing the production of selectins, cytokines and cellular adhesion molecules 
41;42. Dysfunctional endothelium not only lacks its normal antithrombotic and 
fibrinolytic activity but also becomes more thrombogenic by expressing higher 
amounts of von Willebrand factor, tissue factor, plasminogen activator inhibitor 
and factor V 43. Chronically increased CRP and IL6, however, do not seem to 
influence the development of new venous thrombosis 44;45. On the contrary, acute 
inflammatory diseases are known to increase the risk of venous and arterial 
thrombosis for a short period 46;47.  
In chapter 9, the association between high levels of inflammatory biomarkers 
and D-dimer and the risk of recurrent venous thrombosis was evaluated in the 
case population of the LETS. The risk of recurrence, adjusted for age, sex and 
BMI was about 2.2 times higher during ongoing inflammation, indicated by 
CRP levels above 3 mg/L (95% CI: 1.3-3.8).  No association was noted between 
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cytokine levels and the risk of recurrence, probably because of the higher 
detection limit of beads assays compared to ELISA assays which could have led 
to fewer individuals with detectable levels. As previously shown, higher D-dimer 
levels were associated with a higher risk of recurrence (HR: 1.7, 95% CI: 0.9-
3.4). Furthermore, we observed an additive effect between D-dimer and CRP. 
Therefore, individuals with either elevated D-dimer or CRP and those with both 
elevated CRP and D-dimer had a higher recurrence risk compared to patients 
with low CRP and D-dimer levels (HR 1.9; 95% CI 1.1-3.5 and 3.1; 1.4-7.2 
respectively).
Future perspectives
Despite advances in prediction of venous thrombosis, its incidence has not 
been changed which indicates the need to identify new risk factors for first and 
recurrent venous thrombosis. In this context, genome wide association studies 
seem promising in finding new candidate genetic risk factors especially for 
particular types of thrombosis such as retinal vein thrombosis where there are 
still ambiguities surrounding risk factors. Interestingly, sometimes the results of 
these studies are in line with genome wide linkage studies, like the one mentioned 
about the role of variations in chromosome 20 and the levels of protein C. 
The risk of arterial thrombosis rises modestly after an episode of venous 
thrombosis. Whether shared risk factors or chronic inflammation triggered by 
venous thrombosis explains this risk remains unclear. There are indications, 
though not strong enough, that traditional cardiovascular risk factors can not 
solely justify this association.
At last, as mentioned above, a randomized clinical trial study between high and 
prophylactic doses of LMWH will answer which dose in pregnancy is optimal 
with respect to efficacy and bleeding risk during pregnancy and postpartum. 
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Dit hoofdstuk vat het onderzoek beschreven in dit proefschrift samen. 
Deel I
In deel I hebben we gezocht naar nieuwe risicofactoren voor veneuze trombose 
door analyse van de genetische linkage signalen voor veneuze trombose en voor 
intermediaire fenotypen die waargenomen zijn in de GENES studie (hoofdstuk 2, 
3 en 4). Verder worden de implicaties van trombofilieonderzoek voor de diagnose 
en de preventie van veneuze trombose besproken (hoofdstukken 5 en 6).
Nieuwe risicofactoren voor veneuze trombose
veneuze trombose is een multifactoriële ziekte die een geïndividualiseerde 
prognostische en diagnostische aanpak nodig heeft. Dit wordt bemoeilijkt door 
het feit dat nog lang niet alle genetische risicofactoren bekend zijn. Vooruitgang 
in DNA-technologie in de laatste decennia heeft de identificatie van nieuwe 
genetische risicofactoren door genoom-wijde linkage studies en genoom-wijde 
associatie studies vergemakkelijkt, alhoewel elk van deze onderzoeksvormen 
zijn eigen beperkingen heeft. Genoom-wijde linkage studies worden belemmerd 
wanneer er veel heterogeniteit is in de genetische variaties die tot ziekte 
predisponeren. Dit betekent dat de bevindingen in de ene familie misschien 
niet toepasbaar zijn in andere families, laat staan in de algemene bevolking. 
Bovendien wordt de statistische power van dit soort onderzoeken mede bepaald 
door het aantal aangedane personen in een familie, en dit aantal is vaak niet groot. 
Populatie-gebaseerde genoom-wijde associatie studies hebben deze beperkingen 
niet doordat studie deelnemers geen bloedverwanten van elkaar zijn. Echter, 
confounding door een ongelijke verdeling van etniciteiten over patiënten en 
controles, vals-positieve associaties, en het onvermogen om zeldzame genetische 
variaties te bestuderen, behoren tot de beperkingen van genoom-wijde associatie 
studies.
Naar aanleiding van het resultaat van een eerder uitgevoerd genoom-wijd linkage 
onderzoek, wordt in hoofdstuk 2 het effect van genetische variaties in drie genen 
(PROCR, THBD en FOXA2) op de plasmaspiegel van proteïne C (PC) in een 
grote stamboom, en ook in de controlepopulatie van LETS (Leiden Trombofilie 
Studie) ,bestudeerd. Er werd een verband gevonden tussen haplotype 3 (H3) 
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van PROCR en hogere spiegels van PC in leden van de stamboom en ook in 
de LETS controles. Deze bevinding is in overeenstemming met het resultaat 
van een recent verschenen genoom-wijde associatie studie. Hogere circulerende 
EPCR spiegels bij H3 dragers, iets dat ook eerder beschreven is, kunnen de 
hogere PC spiegels niet verklaren. Hoewel de affiniteit van PC om te binden aan 
circulerende EPCR hetzelfde is als de affiniteit voor endotheel-gebonden EPCR, 
is de absolute PC spiegel in molairen in H3 dragers veel hoger dan de sEPCR 
spiegel. We veronderstelden dat de hoeveelheid endotheel-gebonden EPCR in 
H3 dragers misschien laag is en als gevolg hiervan de hoeveelheid PC gebonden 
aan deze fractie kleiner is, zodat er meer PC voor de circulatie beschikbaar is 
Flowcytometrie van uit bloed gekweekte endotheelcellen bevestigde deze 
hypothese niet. We zagen geen verschil in de expressie van EPCR tussen de 
cellen van de H3 dragers en niet-dragers. Kortom, een hogere PC spiegel in H3 
dragers moet nog vanuit biochemisch oogpunt verklaard worden. In tegenstelling 
tot onze verwachtingen biedt H3 dragerschap met zijn inherente hoge PC spiegel 
geen bescherming tegen veneuze trombose.
In hoofdstuk 3 is het effect van verschillende haplotypes van NQO1 op de spiegel 
van factor (F) V en FII onderzocht. We zagen een negatieve associatie tussen FV 
en NQO1 H4 in de stamboom maar niet in controles van de LETS,  hetgeen wijst 
in de richting van een andere genetische variatie op chr16 die verantwoordelijk 
is voor de linkage signalen in de GENES studie. In de LETS controles hadden 
H4 dragers een lagere spiegel van vitamine K afhankelijke stollingsfactoren, in 
het bijzonder trombine en totaal proteïne S, wat aannemelijk is wetende dat H4 
dragers een lagere of niet detecteerbare activiteit van het enzym NQO1 hebben.
In hoofdstuk 4 is de relatie bestudeerd tussen het risico op veneuze trombose 
of de spiegel van vitamine K-afhankelijke stollingsfactoren met verschillende 
haplotypes van de genen die coderen voor enzymen die betrokken zijn bij de 
vitamine K-cyclus (VKORC1, GGCX en NQO1). In overeenstemming met 
eerdere observaties vonden wij geen verband tussen haplotypes van VKORC1 
en het risico op veneuze trombose in LETS. Tevens was er geen verband 
met haplotypes van GGCX en NQO1. De plasmaspiegel van een panel van 
stollingsfactoren (proteïne C, proteïne S, proteïne Z, FII, FVII, FIX en FX) was 
lager in dragers van het VKORC1*2B haplotype, hetgeen waarschijnlijk te wijten 
is aan de lagere expressie van VKORC1 in de lever van de dragers. Het sterkste 
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effect betrof de FIX spiegel met een daling van 3.26 U / dl voor elk allel van 
VKORC1*2B.
Klinische aspecten van trombofilie
In hoofdstuk 5 worden erfelijke en verworven vormen van trombofilie en 
de indicaties voor trombofilie onderzoek besproken. Het accent lag daarbij 
op de invloed van de testresultaten op primaire en secundaire preventie van 
trombose en op familie screening. Routinematige trombofilie screening is niet 
gerechtvaardigd, aangezien de meeste mensen met trombofilie geen veneuze 
trombose zullen ontwikkelen. Het nut van trombofilie onderzoek bij secundaire 
preventie van veneuze trombose is deels afhankelijk van de invloed van de 
uitslagen op het klinische management wat betreft dosis en duur van behandeling 
met anticoagulantia, en deels afhankelijk van de afweging tussen risico en baten 
van profylaxe in risicovolle situaties. Sommige auteurs hebben voorgesteld om 
trombofilie onderzoek alleen te verrichten bij patiënten met trombose voor hun 
vijftigste levensjaar, bij recidiverende trombose, bij een positieve trombose 
familiegeschiedenis of bij trombose op ongebruikelijke plaatsen. Een recente 
‘evidence-based’ richtlijn   adviseert om geen trombofilie onderzoek te verrichten 
in bovengenoemde situaties. Familie onderzoek is omstreden omdat het risico op 
trombose in eerste graads familieleden van patiënten met trombofilie weliswaar 
twee tot tien keer verhoogd is, maar het absolute risico op veneuze trombose laag 
blijft, zelfs in hoog-risico situaties.
Zwangerschap is geassocieerd met een vijfmaal verhoogd risico op veneuze 
trombose. Het risico is nog sterker verhoogd (± 20-maal) in de 6 tot 12 weken 
postpartum. Een kwart van de gevallen betreft recidief trombose. Omdat het 
recidief risico sterk daalt door profylaxe met anticoagulantia, wordt aan zwangere 
vrouwen met een voorgeschiedenis van trombose geadviseerd profylaxe te 
gebruiken in de postpartum periode. Trombofilie op zichzelf is geen indicatie 
voor profylaxe tijdens de zwangerschap of postpartum bij vrouwen zonder 
een voorgeschiedenis van veneuze trombose, met als mogelijke uitzondering, 
patiënten met een positieve familiegeschiedenis voor trombose die homozygoot 
zijn voor factor V Leiden of protrombine G20210A mutaties of gecombineerde 
heterozygositeit voor beide mutaties. De optimale dosering van LMWH tijdens de 
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zwangerschap ter vermijding van recidief trombose, gebalanceerd tegen het risico 
van postpartum bloeding is niet duidelijk. Het toenemende aantal meldingen van 
falen van lage dosering profylaxe onderstreept de noodzaak van gerandomiseerde 
klinische studies om de effectiviteit en veiligheid van een hoge dosis LMWH als 
profylaxe tijdens zwangerschap aan te tonen.
Hoofdstuk 6 toont aan dat postpartum bloeding (PPH) niet vaker voorkomt bij 
vrouwen die worden behandeld met therapeutische doses LMWH dan bij vrouwen 
die niet met LMWH werden behandeld (RR: 0.8, 95% CI: 0.5 tot 1.4). Het mediane 
bloedverlies bleek vergelijkbaar te zijn tussen behandelde en onbehandelde 
vrouwen behalve in de subgroep met een normale vaginale bevalling waar de 
hoeveelheid bloedverlies iets lager was in de LMWH gebruikers (mediaan 
verschil: -100, 95% CI: -156 tot -44). Een mogelijke verklaring hiervoor is het 
preferentiële gebruik van oxytocine in LMWH gebruikers.
Deel II
In deel II hebben we de relatie tussen veneuze en arteriële trombose bestudeerd. 
We hebben getracht om de “shared risk factors” hypothese te testen en dit komt 
aan bod in hoofdstukken 7, 9 en 10. Verschillende studies hebben aangetoond dat 
ontsteking de ontwikkeling van atherosclerose en hart- en vaatziekten bevordert. 
In hoofdstuk 8 werden inflammatoire markers bestudeerd als risicofactor voor 
recidief veneuze trombose. 
Mensen die veneuze trombose hebben gehad hebben een verhoogd risico op 
arteriële trombose. Of deze associatie uitsluitend gebaseerd is op ‘shared risk 
factors’ is onwaarschijnlijk, omdat het bijbehorende risico niet afhankelijk is 
van leeftijd of aanwezige cardiovasculaire risicofactoren. Een analyse in de 
Beethoven studie, een grote cohort studie van families met trombofilie (hoofdstuk 
7), toonde eenzelfde verhoogd risico voor arteriële trombose bij mensen met 
eerdere veneuze trombose laten zien, hoewel het effect niet statistisch significant 
was. Wij onderzochten of gemeenschappelijke risicofactoren dit verband konden 
verklaren, door het berekenen van een zogenaamde propensity score gebaseerd op 
leeftijd, de aanwezigheid van cardiovasculaire risicofactoren en de aanwezigheid 
van één of meer trombofilie afwijkingen. Op grond van dit onderzoek kwamen 
wij tot de conclusie dat ‘shared risk factors’ het verband tussen veneuze trombose 
en arteriële hart- en vaatziekten niet voldoende kunnen verklaren.
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In het algemeen hebben conventionele cardiovasculaire risicofactoren een gering 
effect op de ontwikkeling van veneuze trombose. Ook atherosclerose verhoogt het 
risico op toekomstige veneuze trombose niet. Tevens blijft de rol van trombofilie 
in de pathogenese van arteriële trombose klein. Dit geldt vooral voor de rol van 
zeldzame trombofilie afwijkingen zoals antitrombine deficiëntie, proteïne C 
deficiëntie of proteïne S deficiëntie. Echter, een klein effect op myocardinfarct is 
toegeschreven aan FVL en protrombine G20210A. Het effect van gecombineerde 
heterozygositeit of homozygositeit voor FVL of protrombine G20210A was 
vanwege de lage prevalentie van deze mutaties niet bekend. In een post-hoc 
analyse van de Beethoven studie (hoofdstuk 8) zagen we dat familieleden die 
dubbel heterozygoot of homozygoot voor FVL of protrombine mutatie G20210A 
waren een 1.6 maal hoger risico (niet significant) op arteriële trombose hadden 
in vergelijking met heterozygoten voor de afzonderlijke mutaties. Na uitsluiting 
van familieleden met andere trombofilie factoren bedroeg het relatieve risico 
voor dubbel heterozygoten of homozygoten zelfs 5.1 (95% CI: 1.2 tot 22.9) ten 
opzichte van heterozygoten voor iedere mutatie afzonderlijk. 
Wat de relatie tussen veneuze en arteriële trombose betreft, is veneuze 
occlusie in het netvlies (Retinal Vein Occlusion: RVO) een interessante ziekte. 
Risicofactoren voor RVO betreffen voornamelijk dezelfde als voor arteriële 
hart- en vaatziekten zoals hypertensie, hyperlipidemie en diabetes mellitus, 
terwijl de rol van trombofilie omstreden is. In hoofdstuk 10 hebben we de rol 
van trombofilie afwijkingen, bloedplaatjes receptor polymorfismen en fibrinolyse 
bij RVO bestudeerd in een patiënt-controle onderzoek van 101 patiënten met 
idiopathische RVO en gezonde controle personen. De enige suggestieve associatie 
die gevonden werd was voor polymorfisme rs5918 in een bloedplaatjes receptor 
met een dosisafhankelijk effect op het risico van idiopathische RVO (OR voor 
heterozygoten: 1.7, 95% CI: 0.8 tot 3.3 en voor de homozygoten: 2.8, 0.5-15.9). 
Er werd geen verband waargenomen tussen RVO en trombofilie of clot lysis tijd.
Ontsteking, geïnitieerd door veneuze trombose, kan mogelijk bijdragen aan het 
risico op arteriële trombose. Het gevormde trombine induceert ontsteking van het 
endotheel door het activeren van neutrofielen en het induceren van de productie 
van selectines, cytokines en cellulaire adhesiemoleculen. Ontstoken endotheel 
heeft verminderde antitrombotische en fibrinolytische eigenschappen en het 
wordt nog meer trombogeen door de uitscheiding  van Von Willebrand-factor, 
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tissue factor, plasminogeen activator inhibitor en factor V. Het lijkt er niet op 
dat chronisch verhoogde spiegels van CRP of IL6 het risico op eerste veneuze 
trombose beïnvloeden. In hoofdstuk 9 is het verband tussen inflammatoire 
biomarkers en D-dimeer en het risico op recidief veneuze trombose in de LETS 
geëvalueerd. Het risico op recidief trombose, gecorrigeerd voor leeftijd, geslacht 
en BMI, was 2.2 (95% CI: 1.3 tot 3.8) keer toegenomen bij een CRP spiegel 
hoger dan 3 mg/L. Er kon geen verband vastgesteld worden tussen cytokine 
spiegels en het risico op recidief trombose. De reden hiervoor is mogelijk de 
hogere detectielimiet van beads assays ten opzichte van ELISA assays wat heeft 
geleid tot een lager aantal mensen met een detecteerbare spiegel. Zoals eerder 
aangetoond hangt een D-dimeer spiegel boven 250 ng/ml samen met een hoger 
risico op recidief trombose (HR: 1.7, 95% CI: 0.9 tot 3.4). Verder was er een 
additief effect tussen de spiegels van D-dimeer en CRP. Dus mensen met een 
hoge D-dimeer of CRP en mensen met zowel hoge CRP als D-dimeer hadden een 
hoger recidief risico in vergelijking met patiënten met een lage CRP en D-dimeer 
spiegels (HR 1.9, 95% CI 1.1 tot 3.5 en 3.1, 1.4 tot7.2 respectievelijk).
Toekomstperspectieven
Ondanks de vooruitgang in de kennis van de etiologie en predictie van veneuze 
trombose is de incidentie onveranderd gebleven wat wijst op de noodzaak om 
nieuwe risicofactoren te identificeren voor zowel het eerste event als het recidief 
van veneuze trombose. In deze context lijken de genoom-wijde associatie studies 
bij het vinden van nieuwe genetische risicofactoren veelbelovend te zijn. Dit geldt 
in het bijzonder voor sommige vormen van trombose zoals veneuze trombose in 
het netvlies waar nog steeds veel onduidelijkheden zijn omtrent de risicofactoren. 
Interessant is dat soms de resultaten van dergelijke onderzoeken overeen komen 
met genoom-wijde linkage studies, zoals de studie die eerder genoemd is over het 
effect van variaties op chromosoom 20 op de spiegel van proteïne C.
Na een episode van veneuze trombose stijgt het risico van arteriële trombose. 
Het is onduidelijk of het “shared risk factors” of chronische ontsteking zijn, die 
hieraan ten grondslag liggen. 
Samenvatting 

Chapter 11
11
181
Dankwoord
Chapter 11
182
Aan het eind van mijn proefschrift wil ik graag iedereen bedanken die mij aan het 
begin van mijn wetenschappelijke carrière geholpen heeft.
Allereerst wil ik mijn hooggeleerde promotores, prof. dr. P. Reitsma en prof. dr. 
S. Middeldorp bedanken. Beste Pieter en Saskia, ik heb jullie begeleiding en 
steun ontzettend gewaardeerd. Ook jullie duidelijke interesse in andere aspecten 
van mijn leven heb ik altijd op prijs gesteld.  
Hooggeleerde prof. dr. H. Büller, beste Harry, zonder jou was dit werk niet 
mogelijk geweest. 
Hooggeleerde prof. dr. F.R. Rosendaal, bedankt dat u mij de gelegenheid 
heeft gegeven om op de afdeling Klinisch Epidemiologie van het LUMC als 
gastmedewerker te werken. Ik heb veel op deze afdeling geleerd.
Hooggeleerde prof. dr. J.P. Vandenbroucke, het was een eer om te kunnen 
deelnemen aan het methodenuur. Door deze vorm van onderwijs heb ik veel van 
u geleerd.
Beste kamergenoten, lieve Irene, Renée, Linda en Gürbey, bedankt voor de 
gezellige sfeer en ondersteuning. Sorry dat ik de mooie plantjes die jullie mij 
gegeven hebben niet goed kon onderhouden. Lieve Renée, ik ben vereerd dat je 
mijn paranimf wilt zijn, bedankt. 
Alle andere medepromovendi, Karin, Kirsten, Carolina, Bob, Jiongwei en Begum, 
het was een plezier om met jullie samen te werken.
Beste dr. Suzanne Cannegieter en dr. Saskia le Cessie, bedankt dat jullie mij zo 
graag geholpen hebben met lastige statistische en methodologische vragen.
Beste dr. Marieke de Visser, dr. Willem Lijfering en dr. Carla Vossen, bedankt dat 
ik ondanks jullie beperkte tijd, altijd bij jullie terecht kon. Ik heb ontzettend veel 
van jullie geleerd en van onze samenwerking genoten.
 
Chapter 11
11
183
Beste Yvonne Souverein, Brechje Kock, Marianna Veendorp, Henriëtte Bekkers-
den Haan en Tamara Groen, bedankt voor jullie goede zorg en secretariële 
ondersteuning.
Beste Beethoven studie voorgangers, Ivan Bank en Michiel Coppens, veel dank 
voor de moeite die jullie hebben genomen om mij met de Beethoven database te 
leren werken.
Beste Iris Wicher en Michael Tanck, bedankt voor jullie snelle reacties op mijn 
e-mails en alle brainstorm sessies over de GENES studie. 
Beste Danny Cohn, ik vond het bijzonder leuk met jou samen te werken.
Beste Nadine Gibson, bedankt voor alle gezelligheid en de vele avondetentjes 
samen met je lieve dochter. 
Beste Joep Defesche, Claartje Koch, Kamran Bakhtiari, bedankt voor alle hulp 
bij het verzamelen van de lab monsters.
 
Beste Ingeborg de Jonge en Petra Noordijk, bedankt dat ik op elke moment bij 
jullie terecht kon voor vragen over databases of lab materiaal. 
Beste Aat van Wijngaarden, mijn dank voor je geduld, tijd en je hulp bij allerlei 
lab proeven.  
Dear Anthony Weaver, I am very glad that you gave me the permission to use the 
photo of your beautiful modern painting “Divers cohesion” for the cover of my 
thesis. Thank you.
Papa en mama, de gedachte dat jullie altijd aan mij en mijn ontwikkeling denken 
geeft mij motivatie en kracht om door te gaan. Mijn respect en dank voor jullie 
kan ik niet onder woorden brengen. Ik hoop dat ik jullie vertrouwen waard ben. 
Lieve broer, Hossain en schoonzus Rozita, ontzettend dank voor jullie 
onvoorwaardelijke steun en gezelligheid. Hossain, ik bewonder je om de persoon 
die je bent. Ik wil je bedanken dat je altijd voor mij klaar staat. 
Dankwoord
Chapter 11
184
Lieve zus, Ajda, een speciaal dank  voor jou omdat je mij begeleid hebt op weg 
naar dit onderzoek.
Lieve zus, Bahereh, veel dank voor je interesse en de afleiding buiten werktijd.
Mevrouw en mijnheer Navabi, lieve schoonouders Shahla en Jawad, bedankt 
voor jullie liefde en zorg. Ik voel me bij jullie echt thuis. Lieve Kaweh en Azadeh, 
bedankt voor jullie interesse en hulp.
Mijn lieve man, Arash, jij vangt mij als ik val, je inspireert mij en je bent er altijd 
als ik je nodig heb. Ik hou van je!
Chapter 11
11
185
Curriculum vitae and publications 
Chapter 11
186
Sare Roshani werd geboren op 16 september 1979 in Mashhad (Iran). Na drie 
jaar profiel wiskunde op de middelbare school gehad te hebben, raakte ze 
geïnteresseerd in de biologie en uiteindelijk is ze met profiel biologie in 1997 
van de Saadi middelbare school in Mashhad cum laude afgestudeerd. In 2004 
behaalde zij cum laude haar artsexamen aan het Mashhad University of Medical 
Science (1998-2004). Na haar afstuderen heeft ze 19 maanden als basis arts op 
spoedeisende hulp gewerkt. In deze periode besloot ze om ervaring op te doen 
in het wetenschappelijke aspect van de geneeskunde. Om die reden kwam ze in 
2006 naar Nederland en begon aan haar promotieonderzoek over de associatie 
van arteriële en veneuze trombose waarvan de resultaten in dit proefschrift 
beschreven staan. Ze begon haar onderzoek eerst aan het Academisch Medisch 
Centrum in Amsterdam. Na een periode van 6 maanden, verhuisde ze naar het 
Leids Universitair Medisch Centrum en zette haar project op de afdeling Klinische 
Epidemiologie verder onder leiding van prof. S.Middeldorp en prof. P.H.Reitsma. 
Ondertussen leerde ze de Nederlandse taal en behaalde ze de Nederlandse 
taaldiploma (programma II). Tevens nam ze deel aan een assessment om haar 
artsendiploma te laten valideren en zich kunnen inschrijven in het BIG-register. 
Gedurende haar promotie-onderzoek, volgde ze verschillende cursussen over 
statistiek en epidemiologie, zoals klinische epidemiologie op Schiermonnikoog 
en lezingen van Kenneth Rothman. Ook heeft zij verschillende (inter)nationale 
congressen en symposia bezocht waar zij een poster heeft gepresenteerd of 
een mondelinge presentatie heeft gehouden. Zij zal in februari 2012 aan het 
Leids Universitair Medisch Centrum als basisarts afstuderen en zich verder 
specialiseren. 
Chapter 11
11
187
Roshani S, Cohn DM, Stehouwer AC , Wolf H , van der Post JAM, Büller 
HR, Kamphuisen PW, Middeldorp S. Incidence of postpartum hemorrhage in 
women receiving therapeutic doses of low-molecular-weight heparin: results of a 
retrospective cohort study. BMJ Open. 2011 Nov 14;1(2):e000257.
de Visser MC, Roshani S, Rutten JW, van Hylckama Vlieg A, Vos HL, 
Rosendaal FR, Reitsma PH. Haplotypes of VKORC1, NQO1 and GGCX, their 
effect on activity levels of vitamin K-dependent coagulation factors, and the risk 
of venous thrombosis. Thromb Haemost. 2011 Sep; 106(3):563-5. 
Roshani S, Pintao MC, de Visser MC, Tieken C, Tanck MW, Wichers IM, 
Meijers JC, Rosendaal FR, Middeldorp S, Reitsma PH. High levels of protein 
C are determined by PROCR haplotype 3. J Thromb Haemost. 2011 May; 
9(5):969-76. 
Roshani S, Lijfering WM, Coppens M, Hamulyák K, Prins MH, Büller HR, 
Middeldorp S. Risk factors of arterial cardiovascular complications in patients 
with prior venous thromboembolism. Neth J Med. 2011 Jan; 69(1):27-30.
Roach RE, Roshani S, Meijer K, Hamulyák K, Lijfering WM, Prins MH, Büller 
HR, Middeldorp S. Risk of cardiovascular disease in double heterozygous 
carriers and homozygous carriers of F5 R506Q (factor V Leiden) and F2 
(prothrombin) G20210A: a retrospective family cohort study. Br J Haematol. 
2011 Apr; 153(1):134-6. 
Roshani S, Cohn DM, Middeldorp S. Thrombophilia and venous 
thromboembolism: implications for testing. Semin Thromb Hemost. 2007 Sep; 
33(6):573-81.
Curriculum vitae and publications 
